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Association of cardiovascular and musculoskeletal biomarkers with clinical outcomes
in chronic obstructive pulmonary disease.
Jilles M. Fermont
Background Chronic obstructive pulmonary disease (COPD) is one of the leading
causes of death in the world. In addition to premature mortality, the consequent
socio-economic burden is high, causing reduced quality of life, loss of productivity,
and hospital admission. Diagnosis of COPD relies on lung function tests, which are
inadequate and often leave the condition undiagnosed and thus untreated. There
is a growing interest in the extra-pulmonary manifestations of COPD and assess-
ing the predictive value of cardiovascular abnormalities, musculoskeletal weakness
and plasma biomarkers for acute exacerbation of COPD, hospital admission and
mortality, as there is currently no individual biomarker able to reliably identify or
predict these common clinical outcomes. The aim of this research was to identify
and evaluate the predictive value of existing and novel biomarkers for COPD, and
determine if and how these biomarkers can predict the longer-term clinical outcomes
using electronic health record data.
Methods Electronic databases were systematically searched and identified 61 stud-
ies, which were synthesised, including meta-analyses to estimate pooled hazard ratios
of the associations between selected biomarkers and common clinical outcomes. Data
derived from the Evaluating the Role of Inflammation in Chronic Airways disease
(ERICA) study were linked to electronic health record data (i.e. hospital admis-
sions) and survival data. Predictive models for mortality and cardiovascular related
hospital admission were developed using stratified multivariable Cox regression, and
assessed by C-indices with 10-fold cross-validation. Negative binomial regression was
used to model the event rate of acute exacerbation of COPD and determine the risk
of hospitalisation due to acute exacerbation of COPD, and the associated length of
stay. Data from the UK Biobank were used to explore cause-specific deaths in COPD.
Sex-specific all-cause and cause-specific mortality rates were age-standardised using
the 2013 European Standard Population. Hazard ratios were estimated using Cox
proportional hazards regression, adjusted for age and sex.
Findings Systematic review indicated that shorter six-minute walk distance, ele-
vated heart rate, fibrinogen, C-reactive protein, and white cell count were associated
with a higher risk of mortality. Shorter six-minute walk distance and elevated fibrino-
gen and C-reactive protein were associated with COPD exacerbation, and shorter six-
minute walk distance and higher heart rate, C-reactive protein and interleukin-6 were
associated with hospitalisation. Data from the ERICA cohort indicated no signifi-
cant difference between the discriminative ability of a BODE Index with six-minute
walk and BODE Index with short physical performance battery when predicting mor-
tality. For most musculoskeletal measures, poorer performance was associated with
higher rate or longer duration of hospitalised acute exacerbation of COPD. Measures
of arterial stiffness and carotid intima-media thickness were not associated with car-
diovascular events. Measures of exercise capacity were significantly associated with
cardiovascular disease and improved the discriminative ability when added to Fram-
ingham risk factors. Data from the UK Biobank indicated COPD was associated
with a higher risk of all-cause mortality, and cardiovascular death. In both men and
women, COPD had an associated threefold higher risk of early mortality, including
a fourfold higher risk of cardiovascular-related death in women, and threefold higher
risk of cardiovascular-related death in men.
Conclusions Epidemiological evidence indicates that musculoskeletal measures have
the potential to replace the six-minute walk in the BODE Index for predicting mor-
tality in COPD. In addition, physical capacity should be considered as an important
treatable trait in reducing risk of hospitalisations for acute exacerbation of COPD.
Data from the ERICA cohort does not support the use of objective measures of arte-
rial stiffness and carotid intima-media thickness in addition to Framingham risk fac-
tors for predicting cardiovascular events within COPD. Findings in the UK Biobank
indicated that COPD is associated with a higher risk of cardiovascular death but
cancer and respiratory disease to be the leading causes.
Preface
The aim of this dissertation was to explore the relationships between existing and
novel biomarkers, questionnaire data, and electronic health record data and deter-
mine if and how these biomarkers can predict common clinical outcomes (i.e. acute
exacerbation of chronic obstructive pulmonary disease (COPD), hospitalisation, mor-
tality) within a COPD population. To conduct the analyses I used clinical data from
the Evaluation of the Role of Inflammation in Chronic Airways disease (ERICA) co-
hort – a unique and well-defined dataset containing numerous biomarkers including
musculoskeletal and cardiovascular markers, and demographic data of individuals
diagnosed with COPD – and linked these to mortality data and electronic health
record data obtained from the UK Office for National Statistics and National Health
Services (NHS) Digital (England), NHS Wales and NHS Scotland, respectively. To
explore how some of the findings in the ERICA cohort present in a different cohort,
I have analysed data from the UK Biobank.
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“One of the challenges for biomedicine in the digital age is how to
move from data to knowledge and from knowledge to action to
enhance the lives of patients in real-world contexts.”
Gibbons
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Chronic obstructive pulmonary disease is a lung dis-
ease characterized by chronic obstruction of lung air-
flow that interferes with normal breathing and is not
fully reversible
World Health Organisation
1
Introduction
Chapter summary
This chapter describes the definition, underlying biology and disease manifestation of chronic
obstructive pulmonary disease (COPD). Incidence and prevalence of COPD are reported in ad-
dition to how COPD is diagnosed, and common clinical outcomes including COPD exacerbation,
hospital admission and mortality. There is a great incentive to identify high risk individuals in
an early stage of disease with a focus on extra-pulmonary manifestations of COPD (i.e. systemic
disease). Biomarkers currently used in diagnosing and staging COPD are described, in addition
to novel biomarkers that can potentially capture systemic disease that traditional lung func-
tion measures fail to capture. A specific focus is placed on cardiovascular and musculoskeletal
measures. Several clinical studies are exploring the potential use of measuring extra-pulmonary
manifestations of COPD, including the Evaluating the Role of Inflammation in Chronic Airways
disease (ERICA) study and are briefly introduced. This chapter concludes with an outline of
the thesis.
1
1.1 Background
1.1.1 Definition
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) – an independent body
working with health care professionals aimed at increasing the awareness and promoting evidence-
based practice for lung disease – characterises chronic obstructive pulmonary disease (COPD)
by a “persistent air flow limitation that is usually progressive” and by the association with “an
enhanced chronic inflammatory response in the airways and the lung to noxious particles or
gases”.107 It is characterised by acute exacerbations, also known as flare ups, and comorbidities
with both contributing to disease severity. Previously differentiation was made between chronic
bronchitis and lung emphysema, with bronchitis being characterised by productive sputum (i.e.
phlegm) and emphysema by air trapping in the lungs due to breakage of the alveoli (i.e. air
sacs). As most individuals have a combination of the two conditions, often just the term COPD
is used (Figure 1.1, page 2). Chronic bronchitis, however, is still seen as a separate disorder
and may exist in individuals even with normal spirometry.
Figure 1.1: Chronic inflammation of the small airways. In addition to narrowing of the airways, lung
tissue is damaged due to inflammation of the airway lining removing the elastic recoil. Image taken
from the British Lung Foundation. “COPD: Living with chronic obstructive pulmonary disease”.
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1.1.2 Biology of COPD and manifestations
Chronic inflammation is present throughout the airways, parenchyma – functional lung tissue
–, and in the pulmonary vasculature. Pathological changes include structural changes in the
airway epithelial, smooth muscle and connective tissue with destruction of capillaries and the
development of pulmonary hypertension and abnormal enlargement of the heart.165 In addition
to the lungs, COPD is also believed to lead to systemic problems such as impaired systemic
muscle function and reduced exercise intolerance resulting from an increase in inflammatory
markers such as macrophages, eosinophil count and neutrophils in various parts of the lung.43
Cardiovascular disease is believed to be a common comorbidity in COPD. Even in mild cases of
COPD, individuals may experience a reduced maximum heart rate and oxygen uptake.34 Car-
diovascular disease is believed to be a common comorbidity in COPD. Evidence suggest the two
diseases go hand-in-hand193,253 and can be explained by a so-called spill-over effect of inflam-
matory response (Figure 1.2, page 4).272 As a result of chronic inflammation in the pulmonary
vasculature, the walls gradually thicken starting with the intima, followed by an increase in
smooth muscle, proteoglycans and collagen, and the infiltration of inflammatory cells into the
vessel walls that in turn could lead to arterial stiffness.229 The evidence of a spill-over effect,
however, is inconclusive with some studies being unable to measure a relationship between pro-
ductive cough and blood.3 The statistical power of these studies is low, however, due to small
sample sizes (n <50). Also, even in the absence of COPD, smoking itself may lead to systemic
inflammation241 and has been found to continue in former smokers.126 In addition, ageing itself
is accompanied with low-grade inflammation.69 An alternative view is to see systemic inflam-
mation as a multi-organ inflammation.17 In the Evaluation of COPD Longitudinally to Identify
Predictive Surrogate End-points (ECLIPSE) cohort, an association between common diseases
such as heart disease and diabetes, and systemic inflammation was found.180 Considering low-
grade inflammation continues after smoking cessation, and ageing being an unmodifiable factor
there is growing interest in targeting systematic inflammation therapeutically (i.e. secondary
prevention).294 Some evidence suggests that alongside smoking cessation, frequent exercise and
3
administering anti-inflammatory medication such as statins in those with systemic disease to
lower the risk of COPD (i.e. primary prevention).293
Figure 1.2: Inflammatory spill-over effect. “Mechanisms by which arterial stiffness is increased in
chronic obstructive pulmonary disease”.272 With permission.
It takes several years for COPD to develop, with the airways gradually becoming narrower
making it harder to breathe, causing chronic air trapping within the lungs. The usual onset of
COPD is after the age of forty and most individuals will have a smoking history of at least ten
pack years. Classical disease manifestations include chronic coughing, sputum production, dys-
pnoea (i.e. breathlessness), and an overall decline in lung function measured through spirometry
(Figure 1.3, page 6). Systemic manifestations on the other hand include pulmonary hyperten-
sion, impaired systemic muscle function, unintended weight loss. Due to the various systemic
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manifestations, it is suggested that COPD should be considered a systemic disease and research
should focus on the metabolic and musculoskeletal manifestations.218
1.1.3 Incidence and prevalence of COPD
Globally, COPD is highly prevalent and positioned within the top ten of diseases with highest
disease burden, measured by disability-adjusted life years, and increases with advancing age.106
In particular in the developing world, the global burden of disease is expected to increase,
primarily due to ageing populations and an increasing number of smokers.239 In the United
Kingdom (UK), approximately 1.2 million individuals are diagnosed with COPD with more
than 100.000 newly diagnosed each year according to the British Lung Foundation. Diagnosis of
COPD under the age of forty is uncommon but nearly 5% of people >40 have diagnosed COPD.
Although COPD is dominated by men, within the UK there has been an increasing number of
women with physician-based diagnosis of COPD. This particularly has been the case for socio-
economically deprived areas and the northern-east part of the UK, affected by a threefold higher
risk of COPD compared to more affluent areas. In terms of overall incidence of COPD in the
UK, however, there has not been a significant change in recent years.239 Incidence rates for men
were 2.1/1000 people and 1.8/1000 for women in 2012.
1.1.4 Clinical outcomes
Common clinical outcomes in COPD include premature mortality, acute exacerbation of COPD,
and hospital admission. Globally, the number of deaths related to COPD is highest in Bulgaria
followed by North Korea and Greece with the UK positioned twelfth.134 These high number of
deaths reflect past smoking patterns, levels of air pollution, occupational exposures, and poorly
ventilated indoor cooking fires. In the UK, premature mortality from COPD is almost twice as
high compared the European average.290 Hence, the Department of Health introduced a strate-
gic agenda aimed at preventing, identifying, and treating COPD in earlier stages of disease
hoping to improve life expectancy and quality of life.205 The increasing number of governmental
5
Figure 1.3: Signs and symptoms of chronic obstructive pulmonary disease. Netter image modified.
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publications, initiatives, and allocation of research funding emphasises the importance of ad-
dressing COPD and its consequences. In 2017, pollution has been the central topic of the Chief
Medical Officer′s annual report, including recommendations targeted at improving the quality
of air we breathe.68 In 2018, to address the impact of common clinical outcomes, the National
Health Services (NHS) England published the COPD RightCare Pathway report with a focus
on early identification and accurate diagnosis to improve long-term care and management.196
Other initiatives include funding allocation to the NHS Trust supporting the development of
a self-management system for those affected, a National COPD Audit Programme aimed at
improving provided care, and the NHS Business Services Authority Respiratory Dashboard that
focuses on COPD exacerbations and inform best practice for drug prescription.
1.1.5 Diagnosing COPD
Diagnosing COPD relies heavily on spirometry results and is the most widely used marker for
diagnosis and grading disease severity. An individual is required to exhale air completely from
their lungs as quickly as possible after inhalation, expressed as the forced expiratory volume in
one second (FEV1). The volume of air exhaled after maximum inhalation indicates the forced
vital capacity (FVC). Both measures are generally reduced with a lower score indicating worse
lung function. Airflow limitation that is not fully reversible is confirmed by the presence of a
post-bronchodilator FEV1 <80% of predicted value in combination with an FEV1/FVC <70%
(Figure 1.4, page 8). These values have also been used by GOLD to categorise patients accord-
ing to disease severity.107 Initial categorisation was based on stages, according to lung function
performance only, but have been replaced with groups based on COPD assessment test (CAT) or
Medical Research Council (MRC) dyspnoea score and exacerbation history leading to hospital
admission or not, in addition to airflow limitation. More recently, a system to classify COPD
patients, primarily to address under-diagnosis, and assessment and management of COPD, was
suggested by Agusti et al. where all smokers′ regardless of cough, dyspnoea or sputum should
undergo spirometry. Agusti suggested differentiating between ‘Simple COPD′ – referring to
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those who are younger than 65 years of age with only mild/moderate airflow limitations and
few symptoms and would be categorised as GOLD A, and ‘Complex COPD′ – referring to all
other patients who are more symptomatic and should be referred to specialist care, categorised
as GOLD B, C and D.4
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Figure 1.4: Spirometry results indicating lung obstruction. Image taken from the Global Initiative for
Chronic Obstructive Lung Disease 2016 report.107
1.1.6 Established risk factors
Smoking is in most cases what causes COPD related death, followed by air pollution and particu-
lates in household and occupation.106 One of the most important and cost-effective interventions
considered that could prevent COPD and improve lung function and survival, is smoking cessa-
tion.29,261 However, especially amongst those with lower socio-economic status, there has been
no significant reduction.244 An increasing importance is placed on minimising risk factors and
disease progression through prevention other than smoking cessation, as COPD is still largely
underdiagnosed and therefore undertreated due to the current diagnosis that primarily relies on
lung function measurements failing to capture the heterogeneity of the disease.48,59,75,122,226
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1.1.7 Predicting clinical outcomes
It was believed that over time patients would worsen with increasing airflow limitation. However,
clinicians have come to realise the disease is much more heterogeneous than initially thought
and existing measures such as FEV1 might not be appropriate as they fail to capture systemic
disease. Replacing GOLD stages with groups based on symptoms and history of exacerbation
in addition to airflow limitation, however, has not led to a significant difference being measured
in terms of their ability to predict hospital admission and mortality.141 Identifying individuals
at high risk for common clinical outcomes has remained difficult. There is a growing interest in
systemic manifestations. Assessing the predictive value of cardiovascular (CV) abnormalities,
skeletal muscle weakness and plasma biomarkers for clinical outcomes are recognised to be
of increasing clinical importance. In particular manifestations that can easily be measured in
clinical practice and that support early stage detection. For example, inflammatory markers such
as C-reactive protein (CRP) and fibrinogen have been assessed for their association between
COPD and systemic inflammation and higher levels are often found in those diagnosed with
COPD compared to those without. Other biomarkers such as reduced walking distance or
lower limb muscle strength (i.e. muscle weakness) may well be predictors of clinical outcomes.
Exercise testing such as six-minute walk (6MW) distance and cardiopulmonary exercise testing
have already been recommended in the European Respiratory Society211 and American Thoracic
Society11 guidelines.
1.1.8 Prognostic model development
Assessing the predictive value of biomarkers can be evaluated through the development of a
multivariable prediction model. Transparent Reporting of a multivariable prediction model for
Individual Prognosis Or Diagnosis (TRIPOD) guidelines inform about the development, valida-
tion and updating of prediction models.52 When combining prognostic factors that have been
identified as important predictors for a particular outcome such as mortality or AECOPD into
a multidimensional index, they indicate disease severity or levels of risk and can be used in
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clinical practice by healthcare providers supporting in their decision making (Figure 1.5, page
11). Alternatively, they can help stratify patients for clinical trials and interventions (e.g. drug
treatment, smoking cessation, or physical rehabilitation) aimed at modifying disease outcomes
(e.g. AECOPD, mortality or hospital admission). The performance (i.e. discriminative ability)
of such models is commonly expressed as the area under the receiver operating characteristic
curve,177 Somers′ D-statistic,202 or Harrell′s C-statistic.10 A model with a discriminative abil-
ity of 0.5 equates to random chance, whereas a performance of 1.0 is perfect prediction. As a
rule of thumb, a C-statistic of 0.5-0.7 is considered weak, 0.7-0.8 good, and >0.8 very good.129
However, there are no clear guidelines on the minimum level of model accuracy required. A per-
sistent problem with risk prediction in lung disease, however, is the poor discriminative ability
of predictive models. In addition, some models are based on too small datasets, lack statistical
validation, fail to address missing data, are badly calibrated, or over-fit the data.27,155 Simulta-
neously, typically little attention is given to the clinical practicalities such as cost, complexity,
patient burden and time required, limiting the impact (i.e. improving patient outcomes) and
widespread adoption of prediction models in clinical practice. Using electronic health record
(EHR) data has been suggested as a potential solution to improve the uptake of prediction
models.108 Improvement of the presentation of models and the inclusion of provider and patient
preferences are alternative examples that have been suggested to improve uptake.144
1.1.9 Multidimensional scoring systems
With the increased attention for extra-pulmonary manifestations in COPD, numerous scoring
systems have been suggested and introduced aiming to improve prediction in clinical practice.
For example, Celli and colleagues developed and validated a weighted multidimensional grading
system based on body mass index, the degree of airflow obstruction, dyspnoea, and exercise
capacity measured by the 6MW test (BODE). The BODE Index is better than FEV1 to assess
disease severity and predicting risk of death,40 and found to be superior in predicting hospital
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Figure 1.5: Prognostic multivariable modelling study. Abbreviations: T, moment of prediction. Y,
time of the event. Image taken from the transparent reporting of a multivariable prediction model for
individual prognosis or diagnosis (TRIPOD) statement.52
admission when compared to the GOLD classifications.208 Both GOLD and the BODE Index,
however, appear to perform poorly at predicting mortality.45 In addition, Puhan et al. concluded
that the original BODE Index failed to accurately predict mortality and introduced an updated
index (U-BODE) by re-assigning the number of points given to the variables included, in addition
to developing a simplified ADO index based on age, dyspnoea and obstruction.225
Fisk et al. (2016, unpublished) compared three of these classification systems: GOLD stage,
GOLD group, and BODE whilst assessing the relationship between COPD severity and the two
most clinically important extra-pulmonary manifestations: CV disease and muscle weakness.
The authors found that the cut-off points used in GOLD groups are incorrect and suggest the
use of BODE Index quartiles in the evaluation of vascular and musculoskeletal phenotypes, in
particular arterial stiffness and quadriceps weakness.
Considering COPD is irreversible, and treatments are still lacking, the focus of managing
COPD is shifting towards prevention. Evaluating these systemic manifestations in COPD are
considered to be a key unmet need, with some clinicians arguing to move away from disease
labels such as COPD and focus on so-called ′treatable traits′ such as improving quadriceps
muscle strength, addressing disease complexity and overlap of symptoms amongst diseases.4
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1.1.10 Novel biomarkers
1.1.10.1 Inflammatory markers
Biomarkers of interest that are believed to be of predictive value include multiple inflammatory
markers and CV and musculoskeletal measures. See Appendix C for detailed descriptions.
For example, fibrinogen, white cell count (WCC), interleukins 6 (IL-6) and 8 (IL-8), tumour
necrosis factor-alpha (TNF-α), and CRP are measures of inflammation and may be related to
muscle or CV problems in COPD patients. Both CRP and fibrinogen are acute phase reactants
and considered key regulators of inflammation. Levels increase with the presence of acute sys-
tematic inflammation. In 2015, the Food and Drug Administration approved fibrinogen as a
prognostic marker for mortality and COPD exacerbations.179 White cell count (i.e. leukocytes)
are essential part of the immune system with elevated levels indicating inflammation. Persistent
systemic inflammation is linked to poor clinical outcomes.6 Interleukins 6 and 8, with IL-8 being
a leukocyte chemotactic cytokine – low molecular weight proteins that stimulate recruitment of
leukocytes – produced by various cells, are also inflammatory markers and play a key role in
immune responses and production is activated by inflammatory stimuli.
1.1.10.2 Cardiovascular markers
Cardiovascular markers of interest include pulse wave velocity (PWV), augmentation index
(AIx), and carotid intima-media thickness (CIMT). For example, elevated PWV has been re-
ported in patients with COPD but the predictive value is not yet known. Similarly, these markers
are predictors in other populations and have the potential of clinically predicting CV disease in
COPD. In addition, despite the lack of widespread assessment, these markers are already known
to a majority of respiratory and CV physicians. The PWV indicates the velocity of circulating
blood flow and is a measure of vessel stiffness. Augmentation index reflects the pressure from the
ascending aortic (i.e. central wave) and influences central blood pressure. Both can be measured
using pulse wave analysis, a simple and reliable method.286 Higher values reflect increasing pres-
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sure on the arterial system. It is suggested that those with systemic inflammation and vascular
dysfunction may be more likely to suffer from CV disease and mortality.120,181 Findings in the
Anglo-Cardiff Collaborative Trial (ACCT), a large cohort of healthy normotensive individuals,
suggest AIx to be an appropriate measure for those aged <50, and PWV to be an appropriate
measure for individuals aged >50.173 Systematic analysis of PWV in predicting CV disease sug-
gested model improvement to identify high-risk populations.19 Carotid intima-media thickness
is a non-invasive measure of atherosclerotic burden but also reflects arterial remodelling, and
is used as a proxy measure for CV disease. Albeit a weak predictor in fully adjusted models,
evidence suggest increased CIMT to be linked with a higher risk of future cerebrovascular and
CV events.25,26 In the ARIC (Atherosclerosis Risk In Communities) Study195 with nearly 16.000
individuals recruited from the general population, and The Multi-Ethnic Study of Atheroscle-
rosis (MESA) study with nearly 7000 adults with absence of clinically diagnosed CV disease,95
CIMT was found to improve the predictive ability for coronary heart disease. Despite the sug-
gestion of CIMT being an important risk factor for determining CV outcomes such as stroke
and myocardial infarction, conclusive evidence for its usefulness in COPD is lacking.262
1.1.10.3 Musculoskeletal markers
In recent years there has also been an increasing interest in examining the predictive value of
functional activities of the musculoskeletal system. Exercise limitation (i.e. impaired exercise
tolerance) including musculoskeletal weakness is common within a COPD population, especially
during and after acute exacerbation of COPD (AECOPD).221 Level of impairment is thought
to correspond with lung function but is prevalent in all stages of COPD.77 Determinants of
exercise capacity include 6MW distance and quadriceps strength.109 The 6MW test is a well-
known test to assess exercise intolerance and can evaluate an individual′s functional exercise
capacity. It is primarily used in chronic respiratory disease and heart failure. The goal of the
6MW is to walk as far as possible in six minutes. The test has been evaluated for its ability to
predict mortality, hospitalisation and exacerbation in a variety of diseases including chronic heart
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failure, peripheral arterial occlusive disease,187 and COPD allowing stratification of patients
for clinical trials.38 Alternative measures include resting heart rate (i.e. measure of cardiac
efficiency) and musculoskeletal measures short physical performance battery (SPPB), quadriceps
maximum voluntary contraction (QMVC), and sniff nasal inspiratory pressure (SNIP). The
SPPB is a battery of tests (i.e. four-metre gait speed, balance, chair stand) used to evaluate
the physical performance of the lower extremities.116 Quadriceps muscle weakness is a surrogate
marker of functional activity (i.e. quadriceps muscle strength) and found in 30-40% of COPD
patients, regardless of breathlessness or the level of airflow limitation.237,292 Quadriceps muscle
weakness is an indicator of declining muscle function and can be estimated through, for example,
predicted quadriceps strength – a regression equation incorporating age, gender, height and fat-
free mass.237 Sniff nasal inspiratory pressure is a surrogate marker of respiratory muscle function
(i.e. inspiratory muscle strength) and can be used to identify respiratory muscle weakness. On
the contrary to lung function, musculoskeletal functioning can be trained and improved with
exercise training. Also, efforts are made in developing new medications to target musculoskeletal
dysfunction. Not only does preventing or limiting declining exercise tolerance and physical
training improve mortality, it also improves quality of life.171
Current evidence on the association between these selected CV and musculoskeletal biomark-
ers and the occurrence of clinical outcomes within a COPD population, however, is limited.
1.1.11 Clinical studies
Multiple cohort studies aimed at improving outcomes in COPD of which several are address-
ing the need for novel biomarkers in predicting common clinical outcomes exist. Examples
include US-based “Exercise in Health and Chronic Obstructive Pulmonary Disease” study that
aimed to assess oxidative stress in relation to peripheral muscle dysfunction (NCT02300064), the
French “Role of Systemic Inflammation in Increase of Cardio-vascular Risk in Chronic Obstruc-
tive Pulmonary Disease (BPCO)” study (NCT02888886) that assessed the relationship between
inflammatory markers and CV mortality, and the Belgium-based “Systemic Consequences and
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Comorbidities in Mild/Moderate Chronic Obstructive Pulmonary Disease (COPD), Time for Ac-
tion!” study (NCT01314807) that evaluates skeletal muscle dysfunction and physical inactivity
in COPD. UK-based studies, which are part of a partnership between multiple medical centres
with an interest in COPD, and Innovate UK and GlaxoSmithKline include the ECLIPSE,270
Assessment of Risk in Chronic Airways Disease Evaluation (ARCADE),101 and Evaluating the
Role of Inflammation in Chronic Airways disease (ERICA) studies.184 All three form part of
a consortium that has the overarching aim to fill the biomarker gap and support stratified
medicine. The ERICA study, however, is rather unique and differs from all other cohort studies
through capturing multiple musculoskeletal and CV measures in addition to lung performance
and questionnaire data. In addition, the cohort allows linkage with EHR data and survival data.
1.2 Thesis outline
Spirometry has limitations, COPD is more complex and heterogeneous than initially thought,
and effective treatments are lacking. In particular due to the absence of treatment and the
frequency of adverse outcomes, early diagnosis and identifying high risk individuals in an early
stage of disease is crucial. The availability of EHR data has sparked the hope of being able
to capture the heterogeneity of COPD, and assess the relationship between new potential risk
factors and common clinical outcomes. Key scientific questions include which phenotypic traits
(i.e. CV and musculoskeletal) influence treatment and clinical outcomes? Do EHR data enable
to capture the various disease manifestations of COPD? Can COPD management be improved
to better identify high risk individuals in an early stage of disease, allowing timely intervention,
and treating the right patients?
The overall aim of my doctoral research is to identify and evaluate the relationships between
existing and novel biomarkers, and questionnaire data, and EHR data and determine if and how
these biomarkers can predict common clinical outcomes (i.e. AECOPD, hospitalisation, mor-
tality) within a COPD population. Chapter 2 describes systematically synthesised published
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evidence on the associations between selected CV and musculoskeletal biomarkers that are not
yet widely used in clinical practice but may potentially better capture systemic problems in
COPD than conventional measures, and the occurrence of clinical outcomes including exacer-
bations, hospitalisation, and mortality within a COPD population. Chapter 3 describes the
ERICA cohort, baseline values of key variables captured, and differences between recruitment
sites and sex, and examined the presence of missing data and relationships between variables of
interest. Chapter 4 evaluates the association between the measures of skeletal muscle function
and all-cause mortality in stable COPD patients, and with the assumption that a relation-
ship would be found to investigate whether a BODE Index in which the 6MW component was
replaced by alternative musculoskeletal measures retained predictive ability when predicting
death. Chapter 5 describes cause of death in a COPD defined population identified in the
UK Biobank, and compares survival risk with a non-COPD defined population. Comparisons
between findings in the UK Biobank and the ERICA cohort are made. Chapter 6 evaluates
the relationship between musculoskeletal measures and the risk of hospital admissions due to
AECOPD, and determined a relationship between musculoskeletal measures and length of hos-
pital stay for initial AECOPD using routinely collected hospital electronic health records and
clinical data from the ERICA cohort. Chapter 7 describes incidence of fatal- and non-fatal CV
disease within COPD, and evaluated the association of classical Framingham risk factors with
subsequent fatal and non-fatal CV events in stable COPD patients using clinical data from the
ERICA cohort and EHR data, and determined the association of measures of arterial stiffness
and incident CV disease and their added value above and beyond Framingham risk factors. In
addition, it describes the association of alternative measures including musculoskeletal function,
thought to better capture systemic problems, and CV disease, and their added value above and
beyond Framingham risk factors. Chapter 8 summarises and discusses the evidence available
before this dissertation, the added value of the work presented in this doctoral research, and
discusses the implications of all the available evidence. In addition, analysis for future research
are proposed. Appendix A provides a list of research items I authored during the PhD. Ap-
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pendix B includes a data dictionary I created providing descriptions and ranges of values of
the variables (i.e. baseline and follow-up questionnaire data) captured in the ERICA study.
Appendix C includes the ERICA study protocol. Appendix D includes the data completion
form I created to collect data for the meta-analysis. Appendix E includes a table with cause
of death descriptions.
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Biomarkers and clinical outcomes in COPD – a
systematic review & meta-analysis
Chapter summary
Background Conventional measures to evaluate chronic obstructive pulmonary disease (COPD)
may fail to capture systemic problems particularly musculoskeletal weakness and cardiovascular
disease. Identifying these manifestations and assessing their association with clinical outcomes
(i.e. mortality, exacerbation, and COPD hospital admission) is of increasing clinical importance.
Objective To assess associations between six-minute walk distance, heart rate, fibrinogen, C-
reactive protein, white cell count, interleukins 6 and 8, tumour necrosis factor-alpha, quadriceps
maximum voluntary contraction, sniff nasal inspiratory pressure, short physical performance
battery, pulse wave velocity, carotid intima-media thickness and augmentation index, and clinical
outcomes in patients with stable COPD.
Methods We systematically searched electronic databases (August 2018) and identified 61
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studies, which were synthesised, including Meta-Analyses and Systematic Reviews of Observa-
tional Studies (MOOSE) guidelines and reported in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Findings Shorter six-minute walk distance and elevated heart rate, fibrinogen, C-reactive
protein and white cell count were associated with higher risk of mortality. Pooled hazard ratios
were 0.80 (95% CI 0.73 to 0.89) per 50 m longer six-minute walk distance, 1.10 (95% CI 1.02
to 1.18) per 10 bpm higher heart rate, 3.13 (95% CI 2.14 to 4.57) per twofold increase in
fibrinogen, 1.17 (95% CI 1.06 to 1.28) per twofold increase in C-reactive protein and 2.07 (95%
CI 1.29 to 3.31) per twofold increase in white cell count. Shorter six-minute walk distance and
elevated fibrinogen and C-reactive protein were associated with exacerbation, and shorter six-
minute walk distance, higher heart rate, C-reactive protein and interleukin-6 were associated
with hospitalisation. Few studies examined associations with musculoskeletal measures.
Conclusion Findings suggest six-minute walk distance, heart rate, C-reactive protein, fib-
rinogen, and white cell count are associated with clinical outcomes in stable COPD patients. Use
of musculoskeletal measures to assess outcomes in COPD patients requires further investigation.
2.1 Background
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide,
with prevalence of 5.6% (3.2 million) in 2015 projected to increase to 7.8% by 2030.172 The
consequent socio-economic burden of COPD is high, causing reduced quality of life, loss of
productivity, increased hospital admissions and premature mortality.206,289 One important and
cost-effective intervention is smoking cessation.29,261 However, increasing importance is placed
on improving risk factors and slowing down disease progression by addressing non-pulmonary
aspects of the condition.48,59,75,122,226
Spirometry is the most widely used marker of disease severity and progression. No longer is it
believed that all patients will worsen over time with increasing airflow limitation. Clinicians have
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now identified that COPD is more heterogeneous than initially thought and existing measures
such as forced expiratory volume in one second (FEV1) may fail to capture systemic disease5
and have divergent trajectories.154
Chronic obstructive pulmonary disease also leads to systemic problems, such as skeletal
muscle weakness and cardiovascular (CV) disease, the latter accounting for a third of deaths
in COPD.174 While multiple studies have shown that quadriceps involvement in COPD is as-
sociated with worse outcomes,171,215,259 it has also been postulated that these features result
from an increase in inflammatory markers like C-reactive protein (CRP) and fibrinogen,43 with
a spill-over effect of inflammatory response proposed as the underling mechanism.272 Thus cap-
turing systemic manifestations such as exercise intolerance, CV abnormalities, skeletal muscle
weakness, and plasma biomarkers are recognised to be of increasing clinical importance.17
We aim to systematically synthesise the published evidence on the associations between
selected CV and musculoskeletal biomarkers that are not yet widely used in clinical practice but
may potentially better capture systemic problems in COPD than conventional measures, and the
occurrence of clinical outcomes including exacerbations, hospitalisation, and mortality within a
COPD population. Individual studies and a limited number of reviews47,151,158 have assessed
the association between selected biomarkers and clinical outcomes, however, to our knowledge
no published study has systematically synthesised this evidence.
2.2 Methods
2.2.1 Search strategy
The review protocol was registered with PROSPERO (CRD 42016052075). The systematic re-
view includes electronic searches in the Ovid versions of MEDLINE, Embase, Cochrane Library,
CINAHL, and Web of Science. Search terms related to pulmonary disease were combined with
terms related to CV and musculoskeletal measure, clinical outcome, and study design (Table
2.1, page 23). A meta-analysis was carried out following meta-analysis of observational studies
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in epidemiology (MOOSE) guidelines and reported in accordance with the preferred reporting
items for systematic reviews and meta-analyses (PRISMA) guidelines to identify prospective
studies assessing the relationship between CV or musculoskeletal measures and the occurrence
of clinical outcomes in COPD.185,254
2.2.2 Biomarkers and outcomes
Biomarkers that may capture systemic problems in COPD and are not yet widely used in
clinical practice were included: six-minute walk (6MW) distance, resting heart rate, quadri-
ceps maximum voluntary contraction (QMVC), sniff nasal inspiratory pressure (SNIP), short
physical performance battery (SPPB), pulse wave velocity (PWV), carotid intima-media thick-
ness (CIMT), and augmentation index (AIx). Data relevant to inflammation were fibrinogen,
CRP, white cell count (WCC), interleukin-6, (IL-6) -8 (IL-8), and tumour necrosis factor-alpha
(TNF-α). Clinical outcomes of interest included: mortality, exacerbation, and hospitalisation.
Mortality was defined as all-cause mortality. Exacerbation was defined as patients who either
had a change in medication, which required increase or initiation of steroids or antibiotics, or
were admitted to hospital due to COPD. Hospitalisation, a subset of COPD exacerbation by
definition, was limited to only exacerbations that resulted in admissions related to COPD.
Two reviewers independently completed the selection and review of articles. Full-text papers
and reviews found in the initial search were cross-referenced. Studies that satisfied the full-text
paper selection criteria included: (i) primary research; (ii) had a sample size ≥ 50 with COPD;
(iii) assessing a relevant biomarker; (iv) full-text paper in English; (v) a general population
(e.g. not a single gender); (vi) did not include unstable COPD patients (e.g. currently in acute
exacerbation, currently hospitalised or recruited on discharge); and (vii) were prospective studies
with a follow-up period ≥ 6 months.
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Table 2.1: Search strategies
Terms related to pul-
monary disease
Terms related to selected
CV and musculoskeletal
biomarker
Terms related to clinical
adverse outcomes
Terms related to study
design
1. exp Pulmonary Dis-
ease, Chronic Obstruc-
tive/
9. biological marker.tw. 36. exp Cardiovascular
Diseases/
52. exp Cohort Studies/
2. chronic obstructive
pulmonary disease.tw.
10. systemic inflamma-
tion.tw.
37. cardiovascular dis-
ease.tw.
53. cohort stud$.tw.
3. COPD.tw. 11. exp Leukocytes/ 38. exp Hospitalization/ 54. exp Prospective
Studies/
4. pulmonary emphy-
sema.tw.
12. exp Interleukin-6/ 39. hospitali$.tw. 55. prospective.tw.
5. chronic bronchitis.tw. 13. exp Interleukin-8/ 40. patient admission.tw. 56. longitudinal
stud$.tw.
6. exp Forced Expiratory
Volume/
14. exp Fibrinogen/ 41. exp Death/ 57. exp Case-Control
Studies/
7. exp Vital Capacity/ 15. exp Tumor Necrosis
Factor-alpha/
42. death.tw. 58. case-control
stud$.tw.
8. or/1-7 16. exp C-Reactive Pro-
tein/
43. exp Mortality/ 59. exp Randomized
Controlled Trials as
Topic/
17. exp Carotid Intima-
Media Thickness/
44. mortality.tw. 60. rct.tw.
18. CIMT.tw. 45. outcome.tw. 61. or/52-60
19. exp Pulse Wave Anal-
ysis/
46. exp Prognosis/ 62. 8 and 35 and 51 and
61
20. pulse wave veloc-
ity.tw.
47. prognos$.tw.
21. PWV.tw. 48. exp Survival Analy-
sis/
22. augmentation in-
dex.tw.
49. survival.tw.
23. AIx.tw. 50. exacerbation.tw.
24. exp Heart Rate/ 51. or/36-50
25. 6 minute walk$.tw.
26. 6mwt.tw.
27. 6mwd.tw.
28. exp Quadriceps Mus-
cle/
29. quadriceps max$ vol-
untary contraction.tw.
30. qmvc.tw.
31. sniff nasal inspiratory
pressure.tw.
32. snip.tw.
33. short physical perfor-
mance battery.tw.
34. sppb.tw.
35. or/9-34
*Terms related to pulmonary disease were combined with terms related to cardiovascular and
musculoskeletal biomarker, clinical outcome and study design. Search strategy was used with Medline
(Ovid) and modified as necessary for use with the other databases. For medical subject headings
(MeSH) terms, all subheadings selected. Abbreviations: exp, exploded MeSH term. tw, text word.
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2.2.3 Data extraction and quality assessment
Where possible, adjusted (i.e. age, sex, body mass index (BMI), and smoking status) and unad-
justed hazard ratios (HR) for mortality were collected, as well as model performance measures
(e.g. C-statistic). Sample sizes, mean values, and standard deviations of the biomarkers for
individuals with and without the event (i.e. mortality, exacerbation, or hospitalisation) were
extracted from published studies to estimate standardised mean differences (SMD). Where data
were not published, the corresponding authors were contacted and asked to provide data by
completing a data collection form (Appendix B). Three reminders were sent over a period of
four months. For studies reporting the same cohort, data from the study with the most com-
pleted outcome data, largest sample size, or with the longest follow-up were used. The quality
of each study was based on QUADAS-2 quality assessment criteria.285 Scoring was based on the
follow-up period, sample size, reporting of adjustment factors, method of defining COPD, age of
study participants, and study type (Table 2.2, page 27). Scores range from 0-15, where fifteen
is considered of highest quality.
2.2.4 Statistical analysis
To synthesize and analyse quantitative data, while accounting for heterogeneity by incorporating
between study variability of effect sizes, results from the studies were assessed with random
effects meta-analysis. Data were graphically displayed using forest plots. Where necessary
and possible, HRs were converted to the selected unit effect measure. Hazard ratios for log-
transformed biomarkers represent a twofold increase in the biomarker. To address uncertainty,
we excluded studies with a quality score in the bottom QUADAS-2 score tertile (1st, 15-12/ 2nd,
11-9/ 3rd, 8-0). Funnel plots – scatterplots of observed outcome against the standard error – were
generated to assess potential publication bias. Asymmetry in the plots may indicate publication
bias. Galbraith plots – radial plots of the ratio of observed outcome to standard error against
reciprocal of standard error – were generated to assess heterogeneity in effect sizes.124 Results
from a fixed-effects meta-analysis were compared against those from a random-effects meta-
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analysis. Finally, meta-regression was conducted where possible to analyse the impact of length
of follow-up, year of publication, and the mean age of the cohort. Trend analysis was performed
using ANOVA.
2.3 Findings
The systematic review yielded 2852 unique references from five electronic databases. After
screening the abstracts, 61 articles met the selection criteria (Figure 2.1, page 26 and Table
2.3, page 29). The age of participants of the included studies ranged from 40-80 years of age,
with an approximate median age of 65 years. The sample sizes ranged from 53-20192 subjects,
with a median size of 237. The follow-up period ranged between six and 423 months, with
an approximate median time of 36 months. The evaluation of COPD longitudinally to identify
predictive surrogate end-points (ECLIPSE) and BMI, airflow obstruction, dyspnoea and exercise
(BODE) cohorts were the most studied cohorts.
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Records identified through
database searching (n = 3736)
Additional records identified
through other sources (n = 6)
Records after duplicates re-
moved (n = 2852)
Records screened (n = 2852) Records excluded (n = 2637)
Full-text articles assessed for
eligibility (n = 215)
Full-text articles excluded, with
reasons (n = 154) ¶
Studies included in qualitative
synthesis (n = 61)
Studies included in quantitative
synthesis (meta-analysis) (n =
32)
Identification
Screening
Eligibility
Included
Figure 2.1: Flow diagram of studies included in the review, based on the Preferred Reporting Items
for Systematic Review and Meta-Analysis Protocols.185 Records identified: MEDLINE, n = 1175;
Embase, n = 1597; Cochrane, n = 56; CINAHL, n = 143; Web of Science, n = 765. Abbreviations:
COPD, chronic obstructive pulmonary disease.
¶Reasons for exclusion: only conference abstracts available (n = 41); cross-sectional i.e. there was no
follow-up (n = 29); sample size of <50 with COPD (n = 18); follow-up period of <6 months (n = 21);
other reasons e.g. single gender assessment (n = 17); assessed unstable COPD patients i.e. acute
exacerbation or hospitalised (n = 13); not primary research e.g. review papers (n = 7); no assessment
of relationship between COPD and relevant outcome (n = 6); full text unavailable in the English
language (n = 2)
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2.3.1 Included biomarkers
The most frequently reported biomarkers in the studies were: 6MW distance (56%), CRP (39%),
fibrinogen (28%), IL-6 (25%), IL-8 (16%), WCC (16%), TNF-α (11%), and resting heart rate
(8%), with few assessing CIMT, PWV, and AIx. With the exception of the 6MW distance,
very few musculoskeletal biomarkers (i.e. QMVC, SNIP, and SPPB) were reported for their
association with clinical outcomes within COPD. The majority of studies (n = 34) included
mortality as an outcome measure, followed by exacerbation (n = 25) and hospitalisation (n =
15). Of these, eleven studies investigated two outcomes, and only one investigated all three
outcomes.
2.3.2 Data synthesis
All 61 studies were included in the qualitative review, with 32 studies included in the quantitative
data synthesis (Figures 2.2 2.6 2.10, pages 34-42; Figures 2.3 2.7 2.11, pages 35-43) and the
sensitivity analyses (Figures 2.4 2.5 2.8 2.9 2.12 2.13, pages 36-45). Twenty (69%) studies
reported data on mortality, nine (28%) reported data on COPD exacerbations, and eight (25%)
reported data on COPD hospitalisation. Data from Faganello et al.89 except for IL-8 were
excluded as the same cohort but with a longer follow-up period was examined by Ferrari et
al.92 Data from Spruit et al.248 were also excluded as the ECLIPSE cohort was examined in a
more recent publication by Mullerova et al.192 Additionally, data from Agusti et al. (ECLIPSE
cohort)7 and Durheim et al. (INSPIRE-II cohort)82 were not included as more data were made
available through Celli et al.42 and Blumenthal et al.,23 respectively. Results of the 6MWD
reported by de Torres et al.72 (BODE cohort, n = 218) were not included because these were
covered by Cote et al. using a larger study sample (n = 365) and longer follow-up time.57
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2.3.3 Association between cardiovascular and musculoskeletal measures, and clini-
cal outcomes
2.3.3.1 Six-minute walk distance
Multiple studies, including ECLIPSE (n = 2138), BODE (n = 1379) and INSPIRE (investigating
new standards for prophylaxis in reducing exacerbations)-II (n = 326), reported that COPD
patients with a shorter 6MW distance at baseline have a higher number of clinical events over a
follow-up period of at least six months. A 6MW distance of less than 350 metres was associated
with higher risk of early mortality, according to Cote and colleagues,55 while only Dajczman et al.
found a significant difference in mortality with a cut-off point of 6MW distance ≤150 metres.66
The 6MW-based model, authored by Cote et al. had a C-statistic of 0.75, similar to Waschki et
al. (C-statistic = 0.77)281 and higher than Casanova et al. (C-statistic = 0.70),36 and Spruit et
al. (C-statistic = 0.67) for a 6MW distance threshold of 334 metres.248 The remaining studies,
with relatively small sample sizes, indicated no statistical significant difference in 6MW distance
between those with and without exacerbation.56,80,93 Meta-analysis indicated that longer walking
distances at baseline were associated with early mortality (HR 0.80 per 50 metres increase, 95%
CI 0.73 to 0.89, p <0.01, I2 = 99.4%, COPD exacerbation (SMD -0.27, 95% CI -0.41 to -0.13, p
<0.01, I2 = 53.0% and hospitalisation (SMD -0.48, 95% CI -0.66 to -0.30, p <0.01, I2 = 61.3%).
Galbraith plots showed several studies outside the 95% confidence intervals, indicating Ozgur et
al.,210 Marino et al.,169 Monninkhof et al.,186 and Dreyse et al.80 to be the least consistent with
the overall results, potentially causing bias (Figure 2.14, page 46). Removal of these studies did
not alter findings. After removing studies with a quality score in the bottom tertile (≤8), SMDs
for exacerbation (SMD -0.27 to -0.15) and hospitalisation (SMD -0.48 to -0.35) had a substantial
change, resulting from the removal of studies with small sample sizes and short follow-up times.
Meta-regression indicated no differences in HRs for studies with longer follow-up time or those
more recently published, but suggests higher HRs for studies with older participants (p = 0.027;
Figure 2.15, page 47).
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Biomarker
Six−minute walk distance (per 50m increase)
Resting heart rate (per 10 bpm increase)
Fibrinogen (per 100 g/dL)
Fibrinogen (per twofold increase)
C−reactive protein (per twofold increase)
White cell count (per twofold increase)
Interleukin 6 (per twofold increase)
Tumour necrosis factor (per twofold increase)
No. of studies
12
8
3
4
10
6
5
3
No. of individuals
4181
5285
28813
2243
4078
3165
2594
2324
No. of cases
778
2385
6302
231
791
584
276
241
Pooled HRs [95% CI]
0.80 [0.73, 0.89]
1.10 [1.02, 1.18]
1.24 [1.11, 1.39]
3.13 [2.14, 4.57]
1.17 [1.06, 1.28]
2.07 [1.29, 3.31]
1.10 [0.92, 1.32]
0.94 [0.88, 1.01]
0.50 1.0 2.0 5.0
Lower risk
mortality
Higher risk
mortality
Hazard ratio
Figure 2.2: Pooled hazard ratios for the risk of mortality with 95% confidence intervals, by
biomarker. Studies included: Ferrari et al., 2013,92 Celli et al., 2012,42 Blumenthal et al., 2016,23 de
Torres et al., 2008,72 Cote et al., 2007,57 Dajczman et al., 2015,66 Waschki et al., 2011,281 Dreyse et
al., 2015,80 Ozgur et al., 2012,210 Mannino et al., 2012,169 Jensen et al., 2013,139 Valvi et al., 2012,265
Liu et al., 2011,159 Grolimund et al., 2015,112 Budweiser et al., 2007,31 Husebo et al., 2014,133
Antonelli-Incalzi et al., 2006,13 Cano et al., 2004,33 Lacasse et al., 2005,152 and Warnier et al., 2014.280
See Figure 2.3, page 35 for full study details. Bars, 95% confidence intervals.
2.3.3.2 Resting heart rate
Jensen et al. estimated that having a resting heart below 65 beats per minute (bpm) compared
to above 85 bpm (C-statistic = 0.59), was associated with increased survival of approximately
ten years in Global initiative for chronic Obstructive Lung Disease (GOLD)107 stage I, ∼7 years
for GOLD stage II, and ∼6 years in GOLD stages III-IV.139 Meta-analysis indicated that higher
resting heart rates at baseline were associated with early mortality (HR 1.10 per 10 bpm, 95%
CI 1.02 to 1.18, p = 0.01, I2 = 99.4%), exacerbation (SMD 0.09 bpm, 95% CI 0.00 to 0.17, p
= 0.05, I2 = 0.0%), and hospitalisation (SMD bpm 0.21, 95% CI 0.15 to 0.28, p <0.01, I2 =
10.0%). After removing studies with a quality score in the bottom tertile, HRs for mortality
increased (1.10 to 1.15), and SMD (0.09 to 0.08) lost significance for exacerbation.
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Figure 2.3: Adjusted hazard ratios for the risk of mortality with 95% confidence intervals, by
biomarker. Values in grey are unadjusted and not included in the pooling of results. ****Adjusted for
age, sex, body mass index, and smoking status, unless otherwise indicated. ∧Adjusted for additional
confounders; Blumenthal et al. adjusted for age, Charlson index, duration of COPD, GOLD, and coping
skills training; Cote et al. adjusted for body mass index and Charlson score; Dajzman et al. adjusted
for age, sex, and FEV1; Ozgur et al. adjusted for body mass index, IC/TLC, FEV1, dyspnoea index,
PaO2, and PaCO2; Mannino et al. adjusted for age, sex, body mass index, smoking status, ethnicity,
diabetes, cardiovascular disease, education level, and poverty income ratio; Valvi et al. adjusted for
age, sex, body mass index, smoking status, ethnicity, education level, diabetes mellitus, cardiovascular
disease, and GOLD stage; de Torres et al. adjusted for age, sex, pack-year history, cardiovascular risk
factors or disease, and treatment with inhaled corticosteroids. Bars, 95% confidence intervals.
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Figure 2.4: Hazard ratios for mortality using fixed-effect modelling, sensitivity analysis.
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Figure 2.5: Hazard ratios for mortality, sensitivity analysis. Lower quartile QUADAS-2 scores
removed.
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Biomarker
Six−minute walk distance (meter)
Resting heart rate (bpm)
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Standardised mean difference
Figure 2.6: Pooled standardised mean differences with 95% confidence intervals for the risk of
exacerbation, by biomarker. Studies included: Faganello et al., 2010,89 Cote et al., 2007,57 Dreyse et
al., 2015,80 Ferrari et al., 2011,93 Monninkhof et al., 2003,186 Hurst et al., 2010,132 Husebo et al.,
2014,133 Wedzicha et al., 2000,282 Jennings et al., 2009,137 and Marino et al., 2014.170 See Figure 2.7,
page 39 for full study details. Bars, 95% confidence intervals.
2.3.3.3 Fibrinogen
Within the Copenhagen City Heart Study and Copenhagen General Population Study (n =
8020), Thomsen et al. reported a higher risk of exacerbation with elevated fibrinogen levels,
however, only in combination with elevated levels of CRP and WCC at baseline (C-statistic =
0.73).260 Celli et al. reported a similar C-statistic of 0.70 when including fibrinogen together
with WCC, CRP, and other inflammatory markers to their predictive model.42 Meta-analysis
indicated that for mortality, there was a positive association with fibrinogen (HR 3.13 per twofold
increase, 95% CI 2.14 to 4.57, p <0.01, I2 = 0.0%, and HR 1.24 per 100 g/dL, 95% CI 1.11
to 1.39, p <0.01, I2 = 83.5%).159,169,265 Higher levels of fibrinogen were also associated with
exacerbation (SMD 0.23 g/dL, 95% CI 0.14 to 0.33, p <0.01, I2 = 0.0%).
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Figure 2.7: Standardised mean differences with 95% confidence intervals for the risk of exacerbation,
by biomarker. Bars, 95% confidence intervals.
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Figure 2.8: Standardised mean differences for exacerbation using fixed-effect modelling, sensitivity
analysis.
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Figure 2.9: Standardised mean differences for exacerbation, sensitivity analysis. Lower quartile
QUADAS-2 scores removed.
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Figure 2.10: Pooled standardised mean differences with 95% confidence intervals for the risk of
hospitalisation, by biomarker. Studies included: Ferrari et al., 2013,92 Mullerova et al., 2015,192 Dreyse
et al., 2015,80 Monninkhof et al., 2003,186 Jensen et al., 2013,139 Groenewegen et al., 2008,111 Husebo
et al., 2014,133 Cano et al., 2004,33 Jennings et al., 2009,137 and Dahl et al., 2011.65 See Figure 2.11,
page 43 for full study details. Bars, 95% confidence intervals.
2.3.3.4 C-reactive protein
Moy et al. suggested that combining CRP with step count is a good predictor of acute exacerba-
tions (C-statistic = 0.59) and hospital admission (C-statistic = 0.69).189 However, de Torres et
al. (BODE cohort, n = 218), reported no statistically significant associations between baseline
CRP levels and mortality,72 along with Grolimund et al. (ProHOSP, n = 469),112 Ferrari et
al.,92 and Waschki et al.281 There was also no difference in CRP levels at baseline for COPD
exacerbation in the COSMIC study.111 Meta-analysis indicated that individuals with higher
levels of CRP measured at baseline had a higher risk of early mortality (HR 1.17 per twofold
increase, 95% CI 1.06 to 1.28, p <0.01, I2 = 81.5%). Higher levels of CRP were also associated
with COPD exacerbations (SMD 0.12 mg/L, 95% CI 0.04 to 0.21, p <0.01, I2 = 0.0%), and
hospitalisation (SMD 0.33 mg/L, 95% CI 0.13 to 0.53, p <0.01, I2 = 92.8%). After removing
studies with a quality score in the bottom tertile, HRs for mortality increased (1.25 to 1.31),
and decreased for hospitalisation (0.20 to 0.13). Meta-regression indicated no statistical signifi-
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Figure 2.11: Standardised mean differences with 95% confidence intervals for the risk of
hospitalisation, by biomarker. Bars, 95% confidence intervals.
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Figure 2.12: Standardised mean differences for hospitalisation using fixed-effect modelling, sensitivity
analysis.
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Figure 2.13: Standardised mean differences for hospitalisation, sensitivity analysis. Lower quartile
QUADAS-2 scores removed.
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Figure 2.14: Galbraith plots for mortality.
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cant difference for studies with longer follow-up time, with older participants and more recently
published (Figure 2.15, page 47).
2.3.3.5 White cell count
Only a few studies compared baseline measures with clinical outcomes over time (≥6 months).
Several studies reported COPD patients with higher WCC levels at baseline at higher risk of
clinical outcomes.31,42,132,192,260 However, Husebo et al. did not find higher baseline measures
to be associated with a higher number of exacerbations during three years of follow-up.133
Additionally, Grolimund et al. (ProHOSP, n = 469) did not find a statistically significant
difference between WCC levels and mortality.112 Meta-analysis indicated an association between
higher levels of WCC at baseline and a higher risk of earlier death (HR 2.07 per twofold increase,
95% CI 1.29 to 3.31, p <0.01, I2 = 75.3%). However, WCC levels were not associated with
exacerbation (SMD 0.05, 95% CI -0.06 to 0.17, p = 0.38, I2 = 18.7%) or hospitalisation (SMD
0.20, 95% CI -0.05 to 0.44, p = 0.12, I2 = 72.5%). After removing studies with a quality score
in the bottom tertile, HRs for mortality increased for fibrinogen (5.18 to 5.99; Figure 2.5, page
37).
2.3.3.6 Interleukin 6
Hurst et al. (ECLIPSE, n = 2138) did not find higher baseline measures to be associated with
a higher number of exacerbations.132 Additionally, Waschki et al.281 and Wedzicha et al.282 did
not find higher IL-6 baseline levels to be associated with a higher risk of mortality. Meta-analysis
indicated no association between IL-6 and earlier mortality (HR 1.10 per twofold increase, 95%
CI 0.92 to 1.32, p = 0.28, I2 = 66.1%). Neither was there an association with exacerbation (SMD
0.06, 95% CI -0.02 to 0.15, p = 0.16, I2 = 0.0%). Increased levels were, however, associated with
hospitalisation (SMD 0.12, 95% CI 0.04 to 0.20, p = 0.01, I2 = 0.0%).
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2.3.3.7 Interleukin 8
Interleukin 8 levels and its relation with clinical outcomes in COPD is not well reported. Within
the ECLIPSE study (n = 2138), Hurst et al., found that IL-8 levels at baseline was not a
statistically significant predictor for exacerbations after one year of follow-up.132 However, Celli
et al., who also used data from ECLIPSE (n = 1843), did find increased levels at baseline to
be associated with a higher risk of mortality after three years of follow-up.42 Meta-analysis
indicated no association between IL-8 and exacerbation (SMD 0.19, 95% CI -0.40 to 0.79, p =
0.52, I2 = 83.5%).
2.3.3.8 Tumour necrosis factor-alpha
Celli et al. (ECLIPSE, n = 1843) did not find a statistically significant difference between those
who died after three years of follow-up and those still alive.42 Hurst et al. (ECLIPSE, n =
2138) reported similar findings for exacerbations after one year of follow-up.132 Additionally,
Groenewegen et al. reported no statistically significant difference between the baseline TNF-α
measure and clinical outcomes in the COSMIC cohort (n = 277), after one year of follow-
up.111 Meta-analysis indicated no associations between elevated levels of TNF-α and the risk of
earlier death (HR 0.94 per twofold increase, 95% CI 0.88 to 1.01, p = 0.07, I2 = 0.0%), nor for
exacerbation (SMD 0.04, 95% CI -0.17 to 0.25, p = 0.71, I2 = 62.4%), or hospitalisation (SMD
-0.01, 95% CI -0.09 to 0.07, p = 0.88, I2 = 0.0%).
2.3.3.9 Quadriceps maximum voluntary contraction
In recent years there has been an increasing interest in examining the predictive value of func-
tional activities of the musculoskeletal system. The quadriceps muscle is of particular interest,
being assessed using QMVC as a surrogate marker. However, only two studies assessing the
same cohort of patients have assessed QMVC in relation to clinical outcomes, where quadriceps
muscle function of 184 COPD patients using QMVC was found to be a good predictor of mor-
tality after four years of follow-up (HR 0.88, 95% CI 0.77 to 1.00) with higher levels reducing
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risk.188,259
2.3.3.10 Sniff nasal inspiratory pressure
Moore et al. reported a statistically significant association between baseline SNIP and mortality
(HR 0.73 per 10 cmH2O, 95% CI 0.63 to 0.84, C = 0.68) and suggest that, compared to pul-
monary plethysmographs, a test commonly performed to measure functional residual capacity,
SNIP is recommended because of its low cost and efficiency.188
No studies included in our systematic review reported associations with SPPB, PWV, CIMT,
and AIx.
2.3.4 Publication bias
Publication bias was present in most biomarkers for all outcome measures, indicated through
asymmetrical funnel plots (Figure 2.16, page 51). Larger studies appear in the top of the
graphs with outliers near the bottom. Bias seemed to primarily occur due to the poor quality
of small studies, which deviated most from the other studies. As indicated, the smaller studies
have the tendency to show larger differences between those with the event compared to those
without. Removal of studies that fell outside of the funnel plot did not alter findings.
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Figure 2.16: Funnel plots for mortality. A = six-minute walk distance. B = resting heart rate. C =
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2.4 Discussion
This study systematically summarises and examines the association between multiple outcomes
and biomarkers that may potentially better capture systemic problems in COPD patients and
are not yet widely utilised in clinical practice. Our main findings indicate that stable COPD
patients had higher risks of premature death if they had a shorter walking distance, and higher
resting heart rate, fibrinogen, CRP and WCC at baseline, when followed-up over a period of
at least six months. Only a shorter walking distance, and higher fibrinogen and CRP levels
indicated a higher risk of COPD exacerbation. The risk for COPD-related hospital admission
was higher with a shorter walking distance, and higher resting heart rate and CRP and IL-6
levels.
No studies evaluating SPPB, CIMT, PWV, and AIx were included in our systematic review.
However, a small number of publications have assessed these in relation to clinical outcomes
in COPD (which did not meet our selection criteria). Based on a meta-analysis of seventeen
studies, mainly in the general population, a SPPB score <10 (range 0-12) was found to be pre-
dictive of all-cause mortality.216 The gait speed, one of SPPBs components, was also found to
predict hospital readmission in elderly COPD patients.148 The non-invasive CIMT and its role
in clinical outcomes in COPD patients has not been largely investigated. However, it has been
shown that patients with COPD, in particular smokers, are at higher risk of an elevated CIMT
due to atherosclerotic plaque formation and developing arterial stiffness as a result of hypox-
aemia.49,94,135 Other studies found associations with PWV213 and AIx.181 We have identified
gaps in the literature that need to be examined in order to address these research questions,
and while the recommendation for clinical utility differs slightly, the evidence across the studies
suggest that the use of musculoskeletal measures to assess outcomes in COPD patients are worth
further investigation.
This review has some potential limitations. By focussing on stable (i.e. non-hospitalised)
patients, our results may not be generalisable to unstable COPD patients. Additionally, study
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heterogeneity exists due to differences between studies in definitions of stable COPD, the du-
ration of stability prior to study enrolment, patient selection criteria, length of follow-up, and
outcome definitions. We aimed to address this by using random effects modelling, using SMDs
(which are robust to varying lengths of follow-up114), and sensitivity analysis. We did not have
access to individual patient data, which would allow us to model time-to-event data, adjust for
a common set of confounders and estimate the discriminative ability of the biomarkers. Where
possible, HRs are presented with adjustment for age, sex, BMI, and smoking status. Ideally
studies should be adjusted for disease severity (i.e. FEV1) and comorbidities like hypertension
and diabetes.180 And even so, continuous variables such as FEV1 might not have been linear
in the included studies and should have been transformed appropriately. Fitting a linear model
to nonlinear data may result in biased estimates. Other potential sources of bias include e.g.
history of sleep apnoea, number of previous hospital admissions prior study enrolment, and years
of COPD. Also, most studies included had short follow-up times of about six months. Selecting
a longer follow-up period, for example of a year, as a cut-off point would result in too few studies
being included. Simultaneously, while over a too long time period or time, the predictive value
of a biomarker would diminish.
Future investigation should focus on evaluating and validating the predictive ability of COPD
biomarkers, preferably in large studies with longer follow-up time. Emphasis should be placed
on ensuring biomarkers are generalisable (i.e. more diversity in ethnicity and comorbidities) and
practical for clinical use. Tests such as the 6MW distance are not well adopted for clinical prac-
tice as they require time and space.23 Future research could focus on the validation of fast and
simple tests such as the SPPB or its components. These are easier and faster to conduct, require
less space, and patients are less likely to require oxygen. Newly developed risk models could help
monitor clinically diagnosed COPD patients in an early stage of disease to identify patients at
high risk for mortality, exacerbation, and hospitalisation. Some work is already underway, with
the SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD) study group
developing a debility score aiming to identify COPD patients with debility, i.e. extreme breath-
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lessness, decreased exercise capacity, and poor health status.54 Additionally, the Evaluation of
the Role of Inflammation in Chronic Airways disease (ERICA) study cohort could help provide
answers to these questions aiming to fill the biomarker gap.
2.5 Conclusions
These findings suggest that 6MW distance, resting heart rate, fibrinogen, CRP, WCC, and IL-6
are associated with clinical outcomes in COPD. The review process elicited very few studies
that examined the association between musculoskeletal measures (e.g. SPPB and QMVC) and
COPD. While the recommendation for clinical utility differs slightly, the evidence across the
studies suggest these are worth further investigation.
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Evaluating the Role of Inflammation in Chronic
Airways disease (ERICA) study
Chapter summary This chapter describes the Evaluating the Role of Inflammation in
Chronic Airways disease (ERICA) study, a multi-centre non-interventional epidemiological ob-
servational study of individuals clinically diagnosed with chronic obstructive pulmonary disease
(COPD). Baseline values of key variables are compared by recruitment site and sex using stan-
dard non-parametric statistics. Missing data are described. Partial correlations are used to
examine the relationships between variables. Hospital episode statistics and causes of death are
briefly described. In total, 714 individuals were included in the analysis. Most individuals had
GOLD (Global initiative for chronic Obstructive Lung Disease) stage II. There were noticeable
differences in most baseline variables such as age, resting heart rate and walking distance be-
tween recruitment sites and sexes. Individuals at Cardiff had worse scores for most baseline
variables compared to other sites, for example, they scored lower on the musculoskeletal mea-
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sures, had worse arterial stiffness, and higher COPD impact scores. For most variables (e.g.
age, forced expiratory volume in one second, and walking distance) there were significant differ-
ences between sexes but not lung function, body mass index, and inflammatory markers. Most
primary hospital admissions related to pulmonary- and cardiac disease. A majority of deaths
were attributed to pulmonary disease. Compared to other COPD cohorts, the ERICA study
has a relatively small sample size but is unique in terms of data density, including measures of
cardiovascular and musculoskeletal function in addition to lung function, medical- and family
history, and biochemical measures.
3.1 Background
The Evaluating the Role of Inflammation in Chronic Airways disease (ERICA) study is a multi-
centre observational, non-interventional, epidemiological cohort study, with a sample size of 734
individuals diagnosed with chronic obstructive pulmonary disease (COPD), established to iden-
tify cardiovascular (CV) and musculoskeletal biomarkers that could be targeted to improve the
outcomes of COPD patients. It is a unique dataset that contains numerous biomarkers and de-
mographic data measured longitudinally on patients diagnosed with COPD. The data collection
is tied to capture events and changes related to respiratory, musculoskeletal and CV function
including changes in therapy allowing to investigate the prevalence and significance of CV and
musculoskeletal manifestations of COPD. Five UK centres with an interest in COPD undertook
this study: Cambridge (n = 90), Edinburgh (n = 102), Cardiff (n = 374), Nottingham (n = 107)
and London (n = 61). The ERICA study is part of a consortium based on a partnership between
academia and industry. The consortium includes additional cohort studies ECLIPSE (Evalu-
ation of COPD Longitudinally to Identify Predictive Surrogate End-points)270 and ARCADE
(Assessment of Risk in Chronic Airways Disease Evaluation).101
Key variables captured in the ERICA study relate to musculoskeletal and CV function. Mus-
culoskeletal measures of particular interest are the short physical performance battery (SPPB)
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and its components four-metre gait speed (4MGS), balance and chair stand. Others include
quadriceps maximum voluntary contraction (QMVC), six-minute walk (6MW) distance, and
sniff nasal inspiratory pressure (SNIP). Key CV function measures include arterial pulse wave
velocity (PWV), carotid-intima media thickness (CIMT), and augmentation index (AIx). These
measures are not yet widely used in clinical practice but may potentially better capture systemic
problems in COPD than conventional measures, and the occurrence of clinical outcomes (i.e.
COPD exacerbations, hospital admission, mortality) within a COPD population.
The aim of this chapter was to describe the ERICA cohort, baseline values of key variables
captured and differences between recruitment sites and sex, and to examine any missing data
and relationships between variables of interest.
3.2 Methods
3.2.1 Study details of the ERICA study
The patient population includes adults aged >40 years with a clinical diagnosis of COPD, post-
bronchodilator spirometry forced expiratory volume in one second (FEV1/ forced vital capacity
(FVC) ratio <0.7 and FEV1 ≤80% of predicted normal, current or ex-smoker with a smoking
history of at least ten pack years, and who were clinically stable for more than four weeks from
any exacerbation requiring treatment with oral steroids or antibiotics or hospitalisation were
eligible.184 Patients with the inability to provide written informed consent, a known diagnosis
of α1-anti-trypsin deficiency, known neurological or skeletal muscle disease, pregnancy, and
ongoing participation in a trial of an experimental drug were excluded from the ERICA study.
Individuals were prospectively recruited either from existing databases, through clinicians at
outpatient COPD clinics, or by advertisements at one of the study sites. In Cardiff, individuals
were selected from the ARCADE study – a CV screening cohort – who consented for the ERICA
study. At the other sites patients were recruited opportunistically from COPD clinics.
Clinical measures, blood samples, medical history, and questionnaire data were collected
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starting December 2011 and individuals were followed-up every six months for up to 30 months
via postal or telephone questionnaire, or until death. Standard operating procedures were de-
veloped to standardise measurements between the different study sites. For blood biomarkers,
up to 50 ml of blood was drawn and analysed at the local National Health Services biochemical
and haematological laboratory. Full details of the study protocol, including standardisation pro-
cedures, have been provided elsewhere,184 and are available on ericacopd.org (created by J.M.
Fermont). The study was registered with the UK Clinical Trials Gateway. See Appendix C for
the ERICA study protocol, and Appendix D for a detailed data dictionary (created by J.M.
Fermont).
Fibrinogen and neutrophil levels, amongst other parameters such as high-sensitivity C-
reactive protein (CRP) and lipid profiles, were measured for all ERICA study participants via
withdrawing up to 50 ml venous blood. Arterial stiffness was measured via aortic PWV, AIx, and
central blood pressure using the non-invasive SphygmoCor system.286 During each cardiac cycle
mean arterial pressure indicated average blood pressure. The highest pressure on the cardiac
system was indicated by the systolic blood pressure. The CIMT was measured on both sides of
the neck through imaging using ultrasound (triggered R-wave) with a linear probe 7-12 MHz and
three electrocardiogram electrodes. Patients lied down and rested five minutes before scanning
but were seated for examination. Quadriceps maximum voluntary contraction was measured
using the technique described by Edwards et al. where the best effort of six contractions was
recorded.85 The 6MW distance was recorded as the distance walked by the patient as quickly
as possible for six minutes.14 Body mass index (BMI) was estimated through bodyweight and
height, and categorised according to the World Health Organization.291 Exacerbation history,
one year preceding the study, was defined as self-reported antibiotics and/or steroids use in
the last twelve months. Disease severity was defined according to Global initiative for chronic
Obstructive Lung Disease (GOLD) classification.107 The SPPB has a range of 0-12 points and
its three subtests score 0-4. Total SPPB score is the sum of points of each component. Func-
tional limitation was defined by a SPPB cut-off score of <10.20,216 In addition, the SPPB was
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categorised in groups <3 vs. 3-11 vs. 12.214 The COPD assessment test (CAT) was categorised
in groups <10 (low), 10-20 (medium, 21-30 (high) and >30 (very high).105 Total St. George’s
Respiratory Questionnaire for COPD (SGRQ-C) score, consisting of a symptoms, activity, and
impact component, was estimated using the item-weighted algorithm provided by Jones.142 Both
questionnaires reflect on the impact of COPD on activities of daily living with higher scores in-
dicating increasing limitations. Self-reported comorbidities at baseline were elicited with, for
example, the questions “Have you ever required antibiotics for your chest?”, and “If yes, how
many courses of steroids have you required in the last 12 months?”.
3.2.2 Outcome measures
Clinical data from the ERICA study were linked with mortality data obtained from the UK Office
for National Statistics (ONS) and hospital episode statistics (HES) obtained from the National
Health Services (NHS) Digital, NHS Scotland and NHS Wales. Applications for data linkage
were prepared by J.M. Fermont and submitted March 2016. Data were received November 2017.
The following information was used for data linkage purposes only: NHS number, date of birth,
postcode, forename and surname. Causes of death were categorised by CV and respiratory
physicians according to descriptions provided on death certificates (Appendix E).
3.2.3 Missing values in baseline characteristics
Some individuals had missing values for various baseline characteristics (Table 3.1, page 65).
These were examined to assess the level and type of missing data, the missing data patterns and
other basic descriptive statistics. Extreme values were examined individually. Based on thresh-
olds determined by a clinician part of the ERICA consortium, unusual values were removed:
glucose (n = 20), glycated haemoglobin (HbA1c; n = 9), glomerular filtration rate (GFR; n =
27), fibrinogen (n = 4), white cell count (WCC; n = 1), haemoglobin (n = 2), neutrophils (n =
1), total cholesterol (n = 1), low-density lipoprotein (LDL; n = 18), and CIMT (n = 1).
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3.2.4 Statistical analysis
Demographics were described using number and percentage for categorical variables such as
Medical Research Council (MRC) dyspnoea score and GOLD stage,107 and the median with
interquartile range (IQR) for continuous variables such as age and BMI. Categorical data were
analysed using chi-square tests, unless e.g. the expected cell frequency condition fails, in which
case the Fisher′s exact test was used. Continuous and ordinal data were analysed using the
Wilcoxon-Mann-Whitney test and Kruskal-Wallis test. Associations between the clinical mea-
sures were quantified using partial Spearman’s rank correlations adjusted for age, sex, FEV1,
and recruitment site. Values <0.30 were considered weak, 0.30-0.50 as moderate, and >0.50
as strong.51 The maximum number of independent variables to be included in the models was
determined by the number of events. According to Van Belle’s statistical rules of thumb approx-
imately ten events per variable are required to obtain reliable regression coefficient estimates.266
All tests were two-sided and of statistical significance at an alpha level of 0.05. Analyses were
performed using STATA version 13.0 (College Station, Texas) and R (R Foundation). Patient
demographics and group comparisons are displayed in figures and tabular form.
3.2.5 Patients′ consent and permission to publish
Ethics approval and written informed patient consent was obtained in writing from all study
participants and permits the processing and publishing of all data included in this dissertation.
Each patient has been allocated a unique study number. Ethics approval was granted by the
National Research Ethics Service Committee East of England - Cambridge South and registered
under reference 11/EE/0357. The ERICA study was funded by the Technology Strategy Board
and the Medical Research Council.
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3.3 Findings
3.3.1 Missing data
In total, there was <10% missing values with most for CIMT, followed by PWV, 6MW distance,
QMVC and SNIP. The majority of missing values for CIMT were present in London, for PWV in
Nottingham, and for 6MW in Cambridge. Most of the missing values related to a single variable,
for example, 46 (6%) had missing values for CIMT only. These were likely to be missing due to
the difficulty of obtaining high quality images. Eleven individuals (2%) had missing values for
both CIMT and PWV. Only four individuals had missing values for CIMT, PWV, 6MW and
QMVC (Figures 3.1 3.2, pages 61-62).
Edinburgh London Nottingham
all Cambridge Cardiff
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Figure 3.1: Missing values displayed by total and recruitment site. CIMT = carotid intima-media
thickness. Abbreviations: PWV, pulse wave velocity. 6MW, six-minute walk. QMVC, quadriceps
maximum voluntary contraction. SNIP, sniff nasal inspiratory pressure. AIx, augmentation index.
SPPB, short physical performance battery. BMI, body mass index. MRC, Medical Research Council
dyspnoea. FEV1, forced expiratory volume in one second.
It is unlikely these values are missing completely at random. For example, plots suggest that
missing values in walking distances are not missing completely at random: walking distance
seemed to be missing for those with (A) lower QMVC, (B) higher BMI, (C) worse MRC dyspnoea
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Figure 3.2: Percentage and pattern of missing values in key baseline characteristics. Abbreviations:
QMVC, quadriceps maximum voluntary contraction. Abbreviations: 6MW, six-minute walk. PWV,
pulse wave velocity. CIMT, carotid-intima media thickness.
scores, and (D) worse FEV1 (Figure 3.3, page 63).
3.3.2 Descriptive statistics
Of the 734 individuals entered into the study, 729 met study inclusion criteria of whom 714
were able to be linked with NHS and ONS for hospital admission and survival status (Figure
3.4, page 64). Most individuals were recruited in Cardiff (n = 370). In total, 434 (61%) were
male with a median baseline age of 67 years (range 43-89 years), median (IQR) BMI of 26.6
kg/m2 (23.3 - 31.1) with two-thirds above normal bodyweight (Table 3.1, page 65, and Figures
3.5 3.6, pages 67-67). Cambridge and Nottingham had a significantly higher number of males
compared to other sites, with Cardiff the least (p <0.001). Overall, the median age was lowest in
London (p = 0.027) but with the largest difference in median age by sex (p = 0.019). Body mass
index was highest in London (23 kg/m2) and lowest in Cardiff (28 kg/m2; p <0.001), whereas
Nottingham had the highest difference in BMI between sexes (p = 0.018).
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Figure 3.3: Missing data patterns. Margin plots in blue indicate the distribution of observed data
given the other variable is observed. Red box plots indicate data distribution of the observed data
given the other variable is missing. Abbreviations: BMI, body mass index. 6MW, six-minute walk.
FEV1, forced expiratory volume in one second. QMVC, quadriceps maximum voluntary contraction.
SNIP, sniff nasal inspiratory pressure.
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Individuals screened (n = 746)
Did not meet inclusion criteria
(n = 12)
Individuals entered into study
(n = 734)
Missing FEV1/ FVC ratio (n =
5)
Individuals completed visit (n
= 729)
Individuals with ONS/ HES
status (n = 714)
Not followed-up by NHS (n =
15)
Individuals included in analysis
(n = 714)
Missing baseline data (n = 84)
¶
Study entry
Screening
Baseline visit
Follow-up
Analysis
Figure 3.4: Participant enrolment flow diagram. Abbreviations: FEV1 = forced expiratory volume
one second. FVC = forced vital capacity. ONS, Office for National Statistics. HES, hospital episode
statistics. NHS = National Health Services.
¶Missing baseline data: body mass index (n = 7), smoking status (n = 4), Medical Research Council
dyspnoea score (n = 5), six-minute walk distance (n = 34), short physical performance battery (n = 8),
quadriceps maximum voluntary contraction (n = 27), sniff nasal inspiratory pressure (n = 26).
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Figure 3.5: Histograms displaying the distribution of age, by sex and recruitment site. Dashed lines
indicate median values by sex. Where only one median line is visible, medians for both sexes are similar.
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Figure 3.6: Histograms displaying the distribution of body mass index, by sex and recruitment site.
Dashed lines indicate median values by sex. Where only one median line is visible, medians for both
sexes are similar.
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3.3.3 Lung function measures
All individuals were ex-smokers with at least ten pack years of smoking by default with 218
(31%) current smokers, and 406 (57%) were identified as GOLD stage II equating to a median
(IQR) FEV1 of 1.3 (0.9-1.7) litre. About 46% (n = 327) had self-reported productive cough –
mucus or phlegm – on most mornings. The median number of self-reported exacerbations of
COPD one year before study enrolment was 1 (0-3; Table 3.1, page 65, and Figures 3.7 3.8,
pages 68-69). Individuals from London had a significantly lower FEV1 % predicted compared
to the other sites (p <0.001). Edinburgh had a significant higher number of women with an
exacerbation history than men (p = 0.004).
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Figure 3.7: Histograms displaying the distribution of forced expiratory volume in one-second (FEV1)
percentage predicted, by sex and recruitment site. Dashed lines indicate median values by sex.
3.3.4 Biochemical measures
The median (IQR) levels of circulating inflammatory markers were 3.4 (2.9 - 3.9) g/dL for
fibrinogen and 3.4 (1.6 - 7.5) mg/L for C-reactive protein (CRP). Median white cell count
(WCC; i.e. leukocytes) was 7.1 (6.0 - 8.6) mcL. Neutrophils were 1.4 (1.2 - 1.7) mmol/L. There
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Figure 3.8: Histograms displaying the distribution of exacerbation history, one year before study
enrolment, by sex and recruitment site. Dashed lines indicate median values by sex.
was a significant difference in fibrinogen levels between sites with the lowest in Cambridge (3.1;
p = 0.001) but not for other inflammatory markers CRP (p = 0.470), WCC (p = 0.305), and
neutrophils (p = 0.136; Table 3.1, page 65, and Figures 3.9 3.10 3.11 3.12, pages 70-71).
Median haemoglobin levels were 14.3 (13.4 - 15.3) g/L, 41 (38 - 45) mmol/mol for HbA1c
and 4.9 (4.5 - 5.4) mmol/L for glucose. Haemoglobin levels were higher for men than for women
(p <0.001). Median GFR values were 87 (76 - 101) mL/min/1.73 m2. Glomerular filtration
rates decreased with advancing age (p <0.001; Table 3.1, page 65, and Figures 3.13 3.14
3.15, pages 72-73).
Individuals from Cardiff had the lowest high-density lipoprotein (HDL) levels (1.3; p <0.001).
Median HDL levels were 1.4 (1.2 - 1.7) mmol/L, with higher levels indicating a lower risk of
heart disease. Median total cholesterol levels were 5.0 (4.3 - 5.8) mmol/L (Table 3.1, page 65,
and Figures 3.16 3.17, pages 73-74).
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Figure 3.9: Histograms displaying the distribution of fibrinogen by sex and recruitment site. Dashed
lines indicate median values by sex.
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Figure 3.10: Histograms displaying the distribution of C-reactive protein by sex and recruitment site.
Dashed lines indicate median values by sex. Where only one median line is visible, medians for both
sexes are similar.
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Figure 3.11: Histograms displaying the distribution of white cell count by sex and recruitment site.
Dashed lines indicate median values by sex. Where only one median line is visible, medians for both
sexes are similar.
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Figure 3.12: Histograms displaying the distribution of neutrophil count by sex and recruitment site.
Dashed lines indicate median values by sex. Where only one median line is visible, medians for both
sexes are similar.
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Figure 3.13: Histograms displaying the distribution of glucose level by sex and recruitment site.
Dashed lines indicate median values by sex. Where only one median line is visible, medians for both
sexes are similar.
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Figure 3.14: Histograms displaying the distribution of haemoglobin by sex and recruitment site.
Dashed lines indicate median values by sex.
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Figure 3.15: Histograms displaying the distribution of glycated haemoglobin by sex and recruitment
site. Dashed lines indicate median values by sex. Where only one median line is visible, medians for
both sexes are similar.
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Figure 3.16: Histograms displaying the distribution of high-density lipoprotein levels by sex and
recruitment site. Dashed lines indicate median values by sex.
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Figure 3.17: Histograms displaying the distribution of total cholesterol levels by sex and recruitment
site. Dashed lines indicate median values by sex.
3.3.5 Musculoskeletal measures
The median (IQR) 6MW distance was 366 (255 - 440) metres, with shortest distances in Notting-
ham and longest in London (p <0.001). Men completed longer walking distances than women
(p <0.001). More than 40% (n = 292) had functional limitation with a median total SPPB score
of 10 (8 - 11), and SPPB components 4MGS 4 (3 - 4), balance 4 (4 - 4), and chair stand 3 (1
- 4) points. Men scored two median points higher than women (p <0.001; Table 3.1, page 65,
and Figures 3.18 3.19, pages 75-75).
Median values of peak quadriceps contraction were 30 (22 - 39) kg. Scores were the lowest
for those in Cardiff (28 kg) and highest in Nottingham (33 kg; p <0.001). Males had a me-
dian additional 13 kg of quadriceps strength compared to females (p <0.001). The sniff nasal
inspiratory pressure had a median score of 53 (38 - 70) cm H2O. Women, and generally those in
Cardiff had significantly lower median SNIP scores compared to men and other sites respectively
(p <0.001, p <0.001; Table 3.1, page 65, and Figures 3.20 3.21, pages 76-76).
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Figure 3.18: Histograms displaying the distribution of six-minute walk distance by sex and
recruitment site. Dashed lines indicate median values by sex. Where only one median line is visible,
medians for both sexes are similar.
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Figure 3.19: Histograms displaying the distribution of the short physical performance battery by sex
and recruitment site. Dashed lines indicate median values by sex. Where only one median line is
visible, medians for both sexes are similar.
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Figure 3.20: Histograms displaying the distribution of quadriceps maximum voluntary contraction by
sex and recruitment site. Dashed lines indicate median values by sex.
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Figure 3.21: Histograms displaying the distribution of sniff nasal inspiratory pressure by sex and
recruitment site. Dashed lines indicate median values by sex.
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3.3.6 Cardiovascular measures
The median (IQR) resting heart rate was 74 (66-82) beats per minute, with about a third (n
= 217) of the cohort a resting heart rate too high. Edinburgh (72 bpm) had the lowest resting
heart rate with London (79 bpm) the highest (p = 0.002). Women had slightly higher resting
heart rates than men (p = 0.006). Median value of the mean arterial pressure was 103 (95 -
111) mmHg. Median systolic blood pressure was 142 (131 - 154) mmHg, with 92% who had a
systolic blood pressure >120 mmHg (Table 3.1, page 65, and Figures 3.22 3.23 3.24, pages
77-78).
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Figure 3.22: Histograms displaying the distribution resting heart rate by sex and recruitment site.
Dashed lines indicate median values by sex.
Measures of arterial stiffness include CIMT, PWV, and AIx. Median CIMT was 0.81 (0.71 -
0.96) mm, with Cardiff (0.83) reporting the highest thickness followed by Edinburgh (0.82) and
Nottingham (0.82; p = 0.002). Augmentation index had median values of 28% (20 - 34%) with
Edinburgh (29%) and woman (31%) reporting highest values, p = 0.002 and p <0.001 respec-
tively. Median PWV was 9.8 (8.4 - 11.8) m/sec. with nearly half of the cohort (n = 310) had
an abnormally raised PWV. Cambridge (10.1), London (10.1) but also males (10.1) reported
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Figure 3.23: Histograms displaying the distribution of mean arterial pressure by sex and recruitment
site. Dashed lines indicate median values by sex. Where only one median line is visible, medians for
both sexes are similar.
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Figure 3.24: Histograms displaying the distribution of systolic blood pressure by sex and recruitment
site. Dashed lines indicate median values by sex. Where only one median line is visible, medians for
both sexes are similar.
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highest median values (p = 0.002, p = 0.011 respectively; Table 3.1, page 65, and Figures
3.25 3.26 3.27, pages 79-80).
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Figure 3.25: Histograms displaying the distribution of carotid intima-media thickness by sex and
recruitment site. Dashed lines indicate median values by sex. Where only one median line is visible,
medians for both sexes are similar.
3.3.7 Questionnaires
A proportion over 45% (n = 323) had high COPD Assessment Test (CAT) scores with a me-
dian (IQR) of 20 (13-26) points for the cohort, and median SGRQ-C points of 51 (34-66) with
Cambridge (SGRQ-C, 42 points; CAT 16 points) scoring the lowest scores for both measures
(p <0.001 and p <0.001, respectively). Most individuals (91%) were symptomatic with 40%
(n = 281) feeling at least “short of breath when hurrying on the level or walking up a slight
hill”, and 64 (9%) feeling “too breathless to leave the house or I am breathless when dressing”,
measured by the MRC dyspnoea scale indicating perceived impact of breathlessness on mobil-
ity (i.e. physical activity). Eighty-two (12%) individuals self-reported diabetes, and 402 (56%)
self-reported taking medications for treating CV disease. Cardiff (63%) and Edinburgh (61%)
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Figure 3.26: Histograms displaying the distribution of augmentation index by sex and recruitment
site. Dashed lines indicate median values by sex.
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Figure 3.27: Histograms displaying the distribution of pulse wave velocity by sex and recruitment
site. Dashed lines indicate median values by sex. Where only one median line is visible, medians for
both sexes are similar.
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had a significant higher number of individuals taking such medications with London the least
(37%; p <0.001; Table 3.1, page 65, and Figures 3.28 3.29, pages 81-82).
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Figure 3.28: Histograms displaying the distribution of COPD assessment test scores by sex and
recruitment site. Dashed lines indicate median values by sex. Where only one median line is visible,
medians for both sexes are similar.
3.3.8 Correlations
There was a strong positive correlation between COPD impact measures CAT, MRC, and SGRQ-
C; measures of physical functioning SPPB and its components (i.e. 4MGS, balance, and chair
stand), and 6MW; between sex and QMVC; and between inflammatory markers fibrinogen and
CRP. There was a strong negative correlation between MRC, SGRQ-C, CAT and 6MW. The
6MW distance and MRC dyspnoea score correlated strongly with most variables including CAT,
SGRQ-C, and SPPB (Figure 3.30, page 83).
After adjustment, correlations between FEV1 and age, and BMI, exacerbation history, and
FEV1 were weak: reducing lung capacity with advancing age, and higher BMI, and fewer exac-
erbations with higher FEV1 (Figure 3.31, page 84).
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Figure 3.29: Histograms displaying the distribution of St George’s respiratory questionnaire for
COPD, by sex and recruitment site. Dashed lines indicate median values by sex. Where only one
median line is visible, medians for both sexes are similar.
There was little evidence of correlation between inflammatory markers such as fibrinogen
and WCC, and FEV1. This was similar for other biochemical measures such as neutrophils and
HDL cholesterol (Figure 3.32, page 85).
Data indicated a moderate positive association between 6MW distance, QMVC, and FEV1
indicating longer walk distances and increasing quadriceps muscle strength with increasing lung
capacity. Correlations between resting heart rate and other musculoskeletal measures SPPB or
its components (4MGS r = 0.19, balance r = -0.01, and chair stand r = 0.11) and SNIP were
weak (Figure 3.33, page 86).
There was a strong positive correlation between SPPB (4MGS r = 0.57, balance r = 0.26, and
chair stand r = 0.57) and 6MW distance, indicating increasing physical functioning, except for
balance, with longer walking distance. Correlations between resting heart rate, QMVC, SNIP,
and FEV1 were weak (Figure 3.34, page 87).
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Figure 3.30: Correlation matrix of baseline variables. Abbreviations: GFR, Glomerular filtration rate.
SMOKE, smoking status. PHL, phlegm. EXAC, exacerbations. MRC, dyspnoea scale. SGRQ, St
George’s respiratory questionnaire for COPD. CAT, COPD assessment test. HR, heart rate. WCC,
white cell count. NEUT, neutrophils. FIB, fibrinogen. CRP, C-reactive protein. HDL, high-density
lipoprotein. CHOL, total cholesterol. AIx, augmentation index. SBP, systolic blood pressure. MAP,
mean arterial pressure. CIMT, carotid intima-media thickness. PWV, pulse wave velocity. BG,
glucose. HBA1c, glycated haemoglobin. DB, diabetes. BMI, body mass index. DRUG = use of
cardiovascular drugs. FEV1, forced expiratory volume in one-second. HB, haemoglobin. QMVC,
quadriceps maximum voluntary contraction. SNIP, sniff nasal inspiratory pressure. SPPB, short
physical performance battery. WD, six-minute walk distance. Correlation coefficients with a values
<0.30 were considered weak, 0.30 - 0.50 as moderate, and >0.50 as strong.51
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Figure 3.31: Scatter plots displaying the distribution of (A) age, (B) body mass index (BMI), (C)
exacerbation history, and (D) forced expiratory volume in one second (FEV1) percentage predicted,
over FEV1, by sex. Partial correlations (pr) are displayed in the top left corners.
Correlations between COPD symptom questionnaires and FEV1 were moderate, with higher
scores (i.e. increasingly symptomatic) associated with worse lung function (Figure 3.35, page
87).
There was an absence of correlation between arterial stiffness measures CIMT, PWV, AIx,
and FEV1 (Figure 3.36, page 88).
Increasing CIMT and PWV, but not AIx, were moderately associated with advancing age.
Pulse wave velocity correlated moderately with higher systolic blood pressure. Higher AIx was
strongly correlated with increasing resting heart rate (Figure 3.37, page 89).
3.3.9 Time to event outcomes
Survival data and electronic hospital records were available for 714 individuals, as fifteen indi-
viduals were not followed by the NHS. During 75 months of follow-up, a total of 149 deaths
(21%) occurred. There was a higher proportion of deaths in Cardiff (49%) compared to the
other sites (Figure 3.38, page 90). A majority of deaths were due to pulmonary causes (55%),
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Figure 3.32: Scatter plots displaying the distribution of (A) fibrinogen, (B) high-density lipoprotein
(HDL) cholesterol, (C) white cell count (WCC), (D) glomerular filtration rate (GFR), (E) glycated
haemoglobin (HbA1c), and (F) neutrophils over forced expiratory volume in one second (FEV1), by
sex. Partial correlations (pr) are displayed in the top left corners.
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Figure 3.33: Scatter plots displaying the distribution of (A) resting heart rate (HR), (B) six-minute
walk (6MW) distance, (C) short physical performance battery (SPPB), (D) quadriceps maximum
voluntary contraction (QMVC), and (E) sniff nasal inspiratory pressure (SNIP) over forced expiratory
volume in one second (FEV1), by sex. Partial correlations (pr) are displayed in the top left corners.
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Figure 3.34: Scatter plots displaying the distribution of (A) resting heart rate (HR), (B) short
physical performance battery (SPPB), (C) quadriceps maximum voluntary contraction (QMVC), and
(D) sniff nasal inspiratory pressure over six-minute walk distance, by sex. Partial correlations (pr) are
displayed in the top left corners.
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Figure 3.35: Scatter plots displaying the distribution of (A) St. George respiratory questionnaire for
COPD (SGRQ-C), (B) COPD assessment test (CAT), and (C) Medical Research Council (MRC)
dyspnoea score over forced expiratory volume in one-second (FEV1), by sex. Partial correlations (pr)
are displayed in the top left corners.
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Figure 3.36: Scatter plots displaying the distribution of (A) carotid intima-media thickness (CMIT),
(B) augmentation index (AIx), and (C) pulse wave velocity (PWV) over forced expiratory volume in
one-second (FEV1), by sex. Partial correlations (pr) are displayed in the top left corners.
followed by cancer (24%) with 12% a cardiac cause of death. Pulmonary-related cause of death
increased with advancing disease severity (i.e. GOLD; Figure 3.39, page 90). Most deaths
occurred amongst those aged 65-74 years (Figure 3.40, page 91).
Most hospital ICD-10 (10th revision of the international statistical classification of diseases
and related health problems) diagnoses were recorded at the secondary position during hospital
admission (Figure 3.41, page 91). Diseases of the respiratory and circulatory system were
amongst the most common diagnosis, with “chronic lower respiratory diseases” (J40-J47) and
“ischaemic heart diseases” (I20-I25) as one of the most frequently reported primary diagnosis
(Figure 3.42, page 92).
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Figure 3.37: Scatter plots displaying the distribution of age, systolic blood pressure, and resting heart
rate (HR) under (A-C) carotid intima-media thickness (CIMT), (D-F) augmentation index (AIx), and
(G-I) pulse wave velocity (PWV), by sex. Partial correlations (pr) are displayed in the top left corners.
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Figure 3.38: Cause of death (n = 149) during study period, by recruitment site. Mortality data were
obtained from the Office for National Statistics. Deaths were categorised by cardiac and respiratory
physicians.
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Figure 3.39: Deaths in the ERICA cohort, by cause and GOLD stage.
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Figure 3.40: Deaths in the ERICA cohort, by age band.
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Figure 3.41: Hospital admissions extracted from electronic health record data using ICD-10 chapter
coding, by primary and secondary position.
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Figure 3.42: Primary hospital admissions extracted from electronic health record data, by ICD-10
chapter coding. J95-J99, Other diseases of the respiratory system. J40-J47, Chronic lower respiratory
diseases. J09-J18, Influenza and pneumonia. I70-I79, Diseases of arteries, arterioles and capillaries.
I60-I69, Cerebrovascular diseases. I30-I52, Other forms of heart disease. I26-I28, Pulmonary heart
disease and diseases of pulmonary circulation. I20-I25, Ischaemic heart diseases. D10-D36, Benign
neoplasms. C81-C96, Malignant neoplasms, stated or presumed to be primary, of lymphoid,
haematopoietic and related tissue. C76-C80, Malignant neoplasms of ill-defined, secondary and
unspecified sites. C51-C58, Malignant neoplasms of female genital organs. C43-C44, Melanoma and
other malignant neoplasms of skin. C30-C39, Malignant neoplasms of respiratory and intrathoracic
organs. C15-C26, Malignant neoplasms of digestive organs. XXI, Factors influencing health status and
contact with health services. XIX, Injury, poisoning and certain other consequences of external causes.
XVIII, Congenital malformations, deformations and chromosomal abnormalities. XIV, Diseases of the
genitourinary system. XIII, Diseases of the musculoskeletal system and connective tissue. XI, Diseases
of the digestive system. VII, Diseases of the eye and adnexa. III, Diseases of the blood and
blood-forming organs and certain disorders involving the immune mechanism.
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3.4 Discussion
This chapter describes the ERICA cohort including selection criteria, definitions used, outcomes
measures captured, presence of missing values, and differences in key variables between sexes
and recruitment sites, and the association between baseline characteristics. In addition, clinical
outcomes are briefly described. Most individuals had GOLD stage II, indicating moderate lung
disease. Noticeable were the differences between sexes. The cohort consisted predominantly
of men, and women were about two years younger. Compared to men, women had higher
number of previous exacerbations, cholesterol levels, resting heart rate and AIx, and were more
symptomatic, measured by CAT, SGRQ-C, and MRC. Women had lower levels of neutrophils
and haemoglobin, shorter walk distance, lower SPPB, QMVC, and SNIP scores, and CIMT and
PWV scores. There were no differences in FEV1%, BMI, and inflammatory markers between
sexes. There was a strong correlation between 6MW distance and chair stand component of the
SPPB, which requires quadriceps muscle strength, yet correlation between 6MW and QMVC was
weak. Overall, there was a moderate correlation between measures of function and symptoms,
and FEV1. Correlations between spirometry and blood tests were weak. The SPPB scores
were skewed negative with a longer left tail, in particular for men. Especially for the balance
component, many individuals scored the highest possible score, indicating that the balance
component may not be sensitive enough to capture performance differences in this population.
The study was originally designed and powered on the basis of a tertile analysis of variables
PWV and QMVC, based on an estimated sample size of 800 individuals with COPD.184 However,
not all individuals could be included due to study ineligibility. In addition, the NHS and ONS did
not follow (i.e. flag) all individuals for survival status and hospital admission, further reducing
the sample size for analysis and therefore also statistical power. The overall sample size was
relatively small, limiting e.g. subgroup analysis.
Patient questionnaires included self-reported questions such as history of exacerbations and
use of steroids and CV drugs. Recall bias is common when collecting self-reported data with
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increasing bias as time passes. For example, Frei et al. reported that patients were unable to
accurately recall the number of COPD exacerbations.96 The authors assessed >400 patients over
a 6-month period and found inaccuracies in reporting. Quint et al. reported on the other hand
that using daily diary cards can reliably recall the number of exacerbations in the first year.227
No diary cards were used in the ERICA study.
In terms of generalisability, individuals were recruited throughout the UK. For each centre,
baseline measures of ten volunteers were compared with those of the other sites.184 Inter- and
intra-user reliability was assessed through intra-class correlation coefficients. All sites required
individual site training as well as centralised training in addition to standardisation visits. Only
when sites were considered competent, sites could start with the recruitment. In addition to
recruitment pamphlets, which might have led to self-selection bias, potential study participants
were identified by local principle investigators and clinical care teams. Also, individuals with
systemic inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease were
excluded and may therefore limit generalisability.
Assessments were anticipated to take place over two visits but had to be completed within
three months. Some individuals had already undergone assessments in previous studies within
the consortium such as either ARCADE, the ECLIPSE Extension study, PROACTIVE, MRC
WP4 Consortium or Skeletal Muscle dysfunction study but these measures were only used if
captured within the last three months of recruitment. More importantly, post-bronchodilator
spirometry, one of the selection criteria, had to be performed before or on the first visit. Spirom-
etry is the gold standard to diagnose COPD.
Despite the training and standardisation there was variation between recruitment sites for
most variables. Populations at the different sites were not comparable on several measures.
The centre in London had slightly healthier individuals, whereas individuals from Cardiff had
more severe disease. For example, individuals from Cardiff scored lower on the musculoskeletal
measures, had worse arterial stiffness and higher COPD impact scores compared to the other
sites. Although, according to the ONS life expectancy is the worst in Scotland and Wales.207
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There was, however, some evidence that data such as the 6MW distance were not missing
completely at random. A possible cause could be that measurements such as QMVC and 6MW
were either novel to most sites or required verbal encouragement and instructions. Along with
PWV and CIMT, these measures were considered most likely to result variability between sites
due to differences in equipment and measurements (i.e. expertise). Also, missing values for the
6MW could have resulted from the contraindications for conducting a 6MW test. Myocardial
infarction during the previous month and unstable angina were absolute contraindications. A
resting heart rate >120 bpm, a systolic blood pressure >180 mmHg, or a diastolic blood pressure
>100 mmHg were relative contraindications.
The mean age in the ERICA cohort (67 years) was well above the usual age of COPD
diagnosis and comparable to other cohorts including the Investigational Study of Psychological
Intervention in Recipients of Lung Transplant (INSPIRE)-II cohort (66 years) and Body mass
index, airflow Obstruction, Dyspnoea and Exercise (BODE) cohort (67 years) with the exception
of the ECLIPSE study, one of the largest COPD cohorts. ERICA participants were slightly older
compared to ECLIPSE participants (64 years). In terms of disease severity, ERICA participants
were comparable to the other cohorts.
In contrast to many other cohort studies,151,158 all individuals were clinically stable. The
clinical pathway differs between stable and unstable COPD. The focus of disease management
for individuals with stable COPD is on health education, disease coping strategy, treatment
regulation, and prevention. Disease management for individuals with unstable COPD, however,
is primarily focussed on medical intervention including non-invasive positive pressure ventila-
tion and antibiotic treatment. When assessing the predictive performance of novel biomarkers,
aimed at identifying high risk individuals in an early stage of disease allowing for preventative
intervention such as exercise training, it is crucial to assess biomarkers that are clinically stable.
Most deaths were related to pulmonary disease followed by cancer, of which a large proportion
had hospital visits (primary visits) related to chronic lower respiratory disease and lung cancer,
as expected within a COPD population.
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The ERICA study was designed as a multi-centre observational, non-interventional, epidemi-
ological cohort study with prospective data collection. Strengths of observational cohort studies,
in particular prospective ones, include the ability of evaluating the association between disease
or baseline measures and multiple outcomes (e.g. acute exacerbation of COPD, hospital admis-
sion, and mortality) and allows for the calculation of disease rates. One of the disadvantages
of prospective cohort studies is the associated cost. For example, follow-up data were collected
every six months via postal or telephone questionnaire but for cost reasons there were no re-
peated measurements of CV and musculoskeletal measures taken, limiting the assessment of
the predictive value of these biomarkers at different time points. Attrition (i.e. systematic loss
to follow-up) is a potential bias in observational studies. However, the use of electronic health
records prevented this, as the NHS collects every hospital visit, and the ONS reports any deaths.
Linked electronic health record data therefore is one of the major strengths of this dissertation.
It not only avoids recall bias, which is often the case with self-reported data, but also prevents
lost to follow-up and therefore improves the reliability of findings.
In conclusion, the ERICA cohort is unique in terms of the density of the data captured
in a COPD population. Other and larger cohort studies, such as ECLIPSE270 and NHANES
(National Health and Nutritional Examination Survey)-III,168 do exist but none have captured
musculoskeletal and CV function measures in addition to lung performance, biochemical markers,
medical history, et cetera. ERICA is the first prospective observational cohort study that has
enabled the examination of the relationship between inflammatory markers, musculoskeletal and
CV measures within a COPD population, and evaluate their association with common clinical
outcomes.
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Can simpler measures substitute for the six-minute
walk component of the BODE Index in predicting
death in COPD in the ERICA cohort?
Chapter summary
Background The BODE (Body mass index, airflow Obstruction, Dyspnoea and Exercise) In-
dex predicts mortality in chronic obstructive pulmonary disease but includes a six-minute walk
component; the test would be simpler if the six-minute walk was replaced.
Objective We investigated whether a modified BODE Index in which six-minute walk was
replaced by alternative measures of skeletal muscle performance, the short physical performance
battery or components (i.e. four-metre gait speed, balance, and chair stand), quadriceps and
nasal inspiratory muscle strength, retained predictive ability.
Methods We analysed 630 individuals with stable chronic obstructive pulmonary disease at
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baseline from the Evaluation of the Role of Inflammation in Chronic Airways disease (ERICA)
cohort study and in whom UK Office for National Statistics verified mortality data was available.
Variables tested at baseline included short physical performance battery, quadriceps maximum
voluntary contraction, and sniff nasal inspiratory pressure. Predictive models were developed
using stratified multivariable Cox regression, and assessed by C-indices and calibration plots
with 10-fold cross-validation and replication.
Findings During median two years of follow up, 60 (10%) individuals died. There was
no significant difference between the discriminative ability of BODE based on six-minute walk
(C-index 0.709, 95% CI, 0.680 to 0.737), BODE based on short physical performance battery
(C-index 0.683, 95% CI, 0.647 to 0.712), BODE based on four-metre gait speed (C-index 0.676,
95% CI, 0.643 to 0.700), BODE based on balance (C-index 0.686, 95% CI, 0.651 to 0.713), and
BODE based on nasal inspiratory muscle strength (C-index 0.676 (95% CI, 0.637 to 0.703) when
predicting mortality. Quadriceps muscle voluntary contraction was not able to substitute the
six-minute walk in the BODE Index without loss in discriminative ability.
Conclusion Short physical performance battery, its four-metre gait speed and balance com-
ponents, and sniff nasal inspiratory pressure have the potential to replace the six-minute walk
in the BODE Index without significant loss of predictive ability.
4.1 Background
4.1.1 Introduction
Chronic obstructive pulmonary disease (COPD) was responsible for 3.2 million deaths globally
in 2015.106 Accurate assessment of prognosis enables clinicians to focus their resources on their
most vulnerable patients, to decide on safety for interventional procedures and may also be
useful for stratification of entry into clinical trials. The best known prognostic index is the
BODE Index, which generates a composite score from the Body mass index, airflow Obstruction,
Dyspnoea, and Exercise capacity, with the latter measured by the six-minute walk (6MW) test
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(Table 4.1, page 100),40 which even on its own has predictive ability for mortality.248 However,
both BODE and the 6MW have received limited adoption in clinical practice, perhaps, in part,
because the 6MW requires a minimum thirty-metre corridor, and with the necessity for a training
walk with rest in between,127 which may in practice take over 30 minutes. It is unsurprising
therefore that NICE (National Institute for Health and Care Excellence) UK 2018 guidelines
for COPD included a recommendation not to use the BODE Index for prognosis in COPD,
as some components are time-consuming and not routinely available in primary care; of the
four components of BODE, the 6MW test is the one that is most unavailable in primary care
settings.200
Thus, a test that has sufficient predictive ability to replace the 6MW, and which is more
clinically practical might facilitate uptake of prognostic scoring. In the original BODE study the
authors considered individual measures which were known to have prognostic value and using the
same approach, having reviewed recent literature, we identified other tests reflective of physical
function. These were the short physical performance battery (SPPB), which is prognostic for
mortality in older individuals in the general population,157,274 and its components (i.e. four-metre
gait speed (4MGS), balance, and chair stand); quadriceps strength259 measured as maximum
voluntary contraction force (QMVC) and maximal sniff nasal inspiratory pressure (SNIP),188 as
potential alternative measures of musculoskeletal function.
The aim of our analysis was to first evaluate the association between the measures of skeletal
muscle function and all-cause mortality in stable COPD patients, and with the assumption that a
relationship would be found to investigate whether a BODE Index in which the 6MW component
(BODE6MW) was replaced by alternative musculoskeletal measures retained predictive ability.
Finally, we aimed to assess whether the prediction of all-cause mortality using BODE Index
can be improved by the addition (as opposed to substitution) of these measures to the standard
BODE.
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Table 4.1: Multidimensional risk factors, published prediction models for the prediction of mortality
in COPD. Placed in order of publication date.
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Age X X X
Sex X
BMI X X X X X X X X X
Questionnaires (MRC, ATS,
Fletcher, CRQ)
X X X X X X X X X X X
FEV1 % X X X X X X X X X X X X
6MW distance X X X X X X
Exacerbation X X X X
Exercise max. O2 consump-
tion
X
O2-use X
CVD X
Blood Oxygen (PaO2) X
Health status X
Activity X
QMVC X
Inflammatory markers (e.g.
IL-6 and fibrinogen)
X X X
Total sample size 625 611 444 8802 68 232 232 185 185 268 1843 549
Observed deaths (total No.) 162 94 206 166 22 79 79 71 71 83 168 26
Follow-up (months) 28 36 22 6-36 36 30 30 36 36 73 36 12
C-statistic 0.74 0.68 0.72 0.71 N/A 0.63 0.61 0.74 0.77 0.71 0.73 0.75
Abbreviations: BMI, body mass index. MRC, Medical Research Council. CRQ, Chronic Respiratory
Questionnaire. ATS, American Thoracic Society. FEV1, forced expiratory volume in one second. 6MW,
six-minute walk. SGRQ, St.George Respiratory Questionnaire. CVD, cardiovascular disease. PaO2,
partial pressure of oxygen. QMVC, quadriceps maximum voluntary contraction. IL-6, interleukin 6.
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4.2 Methods
4.2.1 Study design and participants
The ERICA study is a multi-centre observational, non-interventional, epidemiological cohort
study, with a sample size of 729 stable global initiative for chronic obstructive lung disease
(GOLD) stage II-IV107 COPD patients.184 A baseline assessment was undertaken between De-
cember 2011 and January 2014, with planned interval mortality obtained from the UK Office for
National Statistics (ONS) last updated for this study in November 2017. Analyses were limited
to three years of follow-up (August 2016).
4.2.2 Point assignment for components of BODE Index
Points for BODE Index were assigned and classified in quartiles as described by Celli et al., with
higher scores indicating a higher risk of mortality.40 The SPPB has a range of 0-12 points and
comprises three subtests scored 0-4. To preserve a four-category system, we combined 1 and 2
points. The SPPB itself was divided into 10-12, 7-9, 4-6 and <4 based on the cut-off score of
<10 to define functional limitation,20,216 and the distribution of the data. In the absence of a
generally accepted categorisation system, SNIP and QMVC were divided into quartiles (Table
4.2, page 102).
4.2.3 Statistical analysis
Hazard ratios (HR) were estimated using multivariable Cox regression, stratified by recruitment
centre, and adjusted for age and sex. Further analyses included body mass index (BMI), forced
expiratory volume in one second (FEV1), smoking status, and Medical Research Council (MRC)
dyspnoea. Multiple predictive models were developed according to the Transparent Reporting
of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) and guide-
lines for clinical prediction models.52,232,251 The pre-selected prediction models were: (i) BMI,
(ii) BMI + MRC dyspnoea, (iii) BMI + MRC dyspnoea + FEV1%, (iv) BMI + MRC dyspnoea
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Table 4.2: Assignment of points.
Variable 0 points 1 point 2 points 3 points
BODE
BMI (kg/m2) >21 ≤21
FEV1 (% predicted) ≥65 50-64 36-49 ≤35
Dyspnoea (MRC scale) 0-1 2 3 4
Six-minute walk distance (m) ≥350 250-349 150-249 ≤149
Alternative musculoskeletal
measures
SPPB (points) 10-12 7-9 4-6 <4
Four-metre gait speed (points) 4 3 1-2 0
Balance (points) 4 3 1-2 0
Chair stand (points) 4 3 1-2 0
SNIP (cm H2O) ≥71 54-70 39-53 ≤38
Abbreviations: BMI, body-mass index. FEV1, forced expiratory volume in one second. MRC, Medical
Research Council. SPPB, short physical performance battery. SNIP, sniff nasal inspiratory pressure.
+ FEV1% + 6MW, (v) BMI + MRC dyspnoea + FEV1% + SPPB, and (vi) BMI + MRC dys-
pnoea + FEV1% + SNIP. Linearity of continuous predictors was assessed visually. We tested
for violation of the proportional hazards assumption by including time interactions and visu-
ally examining Arjas plots. Discrimination (i.e. Harrell′s C-statistic10,202 and calibration (i.e.
Hosmer-Lemeshow test9 and calibration plots) were assessed using 10-fold cross validation with
200 replications.245 Effect of missing data was assessed in sensitivity analyses using multivariable
imputation by chained equations (MICE). Predictive mean matching was used for continuous
variables, ordered logistic regression (as continuous) for ordinal variables, multinomial logistic
regression for categorical variables, and logistic regression for binary variables. Derived vari-
ables such as SPPB (a composite score of 4MGS, balance, and chair stand) were estimated post
MICE using passive imputation. To minimise potential overfitting caused from using the same
imputed dataset for the training and test data for 10-fold cross-validation, we created 10 x 2
imputed datasets and used ten for model derivation and the other ten for model validation.
Thus, within each step of the cross-validation, the training and test datasets were from two
different imputations. We performed cross-validation separately for the ten pairs of imputed
datasets before combining estimates of interest using Rubin′s rules. Observational data is re-
ported according to the Strengthening The Reporting of OBservational Studies in Epidemiology
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(STROBE) statement.275
4.3 Findings
4.3.1 Descriptive statistics
In total, 714 individuals were followed by the ONS for survival status, of which 630 had complete
baseline data and were included in the primary analysis (Figure 3.4, page 64). Of the cohort,
386 (61%) were male, 192 (30%) were current smokers, 358 (57%) were identified as GOLD
stage II, and the median baseline age was 67 years (range 43-84 years; Tables 3.1 and 4.3,
pages 65 and 104). In total, 245 (39%) had defined functional limitation (SPPB score <10) with
a median (IQR) SPPB score of 10 (8-12), a median 6MW distance of 370 (268-440) metres, a
median QMVC of 30 (22-39) kg, and a median maximal SNIP of 53 (38-70) cm H2O.
4.3.2 Factors associated with all-cause mortality
The three years survival probability was 90% (88-93% CI) with an event rate of 3.3 (95% CI 2.6 to
4.3) per 100 person-years. Event rates differed by recruitment site: 2.4 (1.0 to 5.8) for Cambridge,
3.6 (1.9 to 7.0) for Edinburgh, 2.8 (1.9 to 4.1) for Cardiff, 3.3 (1.7 to 6.6) for Nottingham, and 7.1
(3.9 to 12.8) for London. In total 60 patients (10%) died after study enrolment, with a median
follow-up time of two years. Age-adjusted multivariable analysis identified multiple markers
associated with mortality including BMI (HR 0.91 per 1 point increase, 95% CI, 0.86 to 0.97,
p = 0.002), 6MW distance (HR 0.85 per 30-metre increase, 95% CI, 0.78 to 0.92, p <0.001),
SPPB (HR 0.81 per 1 point increase, 95% CI, 0.72 to 0.92, p = 0.002), 4MGS (HR 0.67 per 1
point increase, 95% CI, 0.49 to 0.93, p = 0.015), balance (HR 0.63 per 1 point increase, 95% CI,
0.48 to 0.82, p = 0.001), and SNIP (HR 0.81 per 10 cm H2O increase, 95% CI, 0.69 to 0.95, p
= 0.010; (Figures 4.1 4.2 and Table 4.4, pages 105-107). Chair stand and QMVC were not
associated with all-cause mortality, after further adjustment.
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Table 4.3: Baseline characteristics by functional limitation (n = 630).
Characteristic Total (%) N (%) SPPB, ≤9
points
SPPB ≥10
points
P
value
Description
Age (yrs.), median (IQR) 67 (62-73) 714 (100) 70 (63-75) 66 (62-71) <0.001
Male 386 (61) 714 (100) 129 (53) 257 (67) <0.001
Body mass index (kg/m2), median
(IQR)
27 (23-31) 707 (99) 28 (24-32) 26 (23-29) <0.001
Lung function
FEV1 %predicted, median (IQR) 53 (40-65) 712 (100) 52 (39-63) 54 (41-66) 0.265
Current smoker 192 (30) 709 (99) 73 (30) 119 (31) 0.767
MRC dyspnoea score 709 (99)
1 54 (9) - 7 (3) 47 (12) <0.001
≥2 576 (91) - 238 (97) 338 (88)
GOLD 713 (100)
Stage II 358 (57) - 131 (53) 227 (59) 0.357
Stage III 216 (34) - 89 (36) 127 (33)
Stage IV 56 (9) - 25 (10) 31 (8)
Musculoskeletal measures
6MW distance (metre), median
(IQR)
370 (268-440) 680 (95) 265 (174-344) 420 (360-470) <0.001
SPPB (0-12), median (IQR) 10 (8-12) 706 (99)
No functional limitation, ≥10 385 (61) -
Functional limitation <10 245 (39) -
4MGS score (0-4), median (IQR) 4 (3-4) 709 (99) 3 (3-4) 4 (4-4) <0.001
Balance points (0-4), median
(IQR)
4 (4-4) 711 (100) 4 (3-4) 4 (4-4) <0.001
Chair stand score (0-4), median
(IQR)
3 (1-4) 707 (99) 1 (1-1) 3 (3-4) <0.001
QMVC peak (kg), median (IQR) 30 (22-39) 687 (96) 25 (19-33) 32 (26-41) <0.001
SNIP (cm H2O), median (IQR) 53 (38-70) 688 (96) 44 (32-61) 59 (44-74) <0.001
Values are given as the median and interquartile range (IQR), or No. of cases (%). Baseline data of 630
individuals are included. P-values estimated using Wilcoxon-Mann-Whitney test for continuous data,
and Chi-square test for categorical data. Abbreviations: MRC, Medical Research Council. GOLD,
global initiative for obstructive lung disease. 6MW, six-minute walk. SPPB, short physical
performance battery. 4MGS, four-metre gait speed. QMVC, quadriceps maximum voluntary
contraction. SNIP, sniff nasal inspiratory pressure.
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4.3.3 Predictive models
Predictive modelling indicated slightly higher HR for SPPB and its components compared to
BODE6MW (Figure 4.3, page 109). The C-statistic was the highest for BODE6MW (C = 0.709,
95% CI, 0.680 to 0.737) but there was no significant difference in discriminative ability compared
to BODESPPB (C = 0.683, 95% CI, 0.647 to 0.712; Figure 4.3 and Table 4.5, pages 109 and
112). Neither was there a significant difference in risk discrimination when compared with the
BODE4MGS (C = 0.676, 95% CI, 0.643 to 0.700), BODEBALANCE (C = 0.686, 95% CI, 0.651 to
0.713), and the BODESNIP (C = 0.676, 95% CI, 0.637 to 0.703). When comparing BODESPPB
with its components, there were no significant differences in risk discrimination between indices.
Calibration tests and plots of the hazard models indicate good model fit and calibration for
3-year prediction of mortality (Figure 4.4, page 111).
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4.3.4 Practical example of using the BODE Index
Estimating an individuals′ BODE score with these indices is similar to the original BODE Index
(Table 4.2, page 102), with scores ranging between 0 and 10 points (Tables 4.6 4.7 and
Figure 4.5, pages 113 and 114). For example, when using the BODESNIP, an individual with a
BMI of ≤21 (1 point), FEV1 of 36-49% predicted (2 points), dyspnoea score of four (3 points),
and SNIP score of 54-70 cm H2O (2 points), has a total score of eight points out of ten. The
BODESNIP Index quartile 1 was defined by a score of 0-2, quartile 2 by a score of 3-4, quartile
3 by a score of 5-6, and quartile 4 by a score of 7-10. A BODESNIP Index score of eight would
then indicate a 23% predicted risk of early mortality over the next three years (Figure 4.4,
page 111). In other words, out of 100 individuals with the same BODESNIP score, 23 are likely
to die within the next three years.
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Table 4.6: Risk indices using point system, by survival status.
Risk indices Median (IQR) Survivors Non-survivors P value ¶
BODE6MW (0-10) 3 (1-5) 3 (1-5) 5 (2-7) <0.001
BODESPPB (0-10) 3 (1-4) 2 (1-4) 4 (2-6) <0.001
BODE4MGS (0-10) 3 (1-4) 2 (1-4) 4 (2-6) <0.001
BODEBALANCE (0-10) 2 (1-4) 2 (1-4) 4 (2-6) <0.001
BODESNIP (0-10) 4 (2-6) 4 (2-5) 5 (4-7) <0.001
¶Wilcoxon-Mann-Whitney test. Abbreviations: 6MW, six-minute walk. SPPB, short physical
performance battery. 4MGS, four-metre gait speed. SNIP, sniff nasal inspiratory pressure.
Table 4.7: Risk indices using point system, by cause of death.
Risk indices Pulmonary Cardiac Cancer Other P value ¶
BODE6MW (0-10) 6 (4-7) 2 (1-7) 2 (1-4) 3 (1-7) 0.004
BODESPPB (0-10) 5 (3-6) 2 (1-5) 2 (1-4) 4 (2-6) 0.004
BODE4MGS (0-10) 6 (3-6) 2 (1-5) 2 (2-3) 3 (2-6) <0.001
BODEBALANCE (0-10) 5 (3-6) 4 (1-6) 3 (1-3) 4 (2-5) 0.007
BODESNIP (0-10) 6 (4-8) 4 (2-6) 3 (3-4) 5 (3-7) 0.005
¶Kruskal-Wallis equality-of-populations rank test. Abbreviations: 6MW, six-minute walk. SPPB, short
physical performance battery. 4MGS, four-metre gait speed. SNIP, sniff nasal inspiratory pressure.
Compared to the composite scoring, use of continuous data did not improve discriminative
ability for any of the BODE indices significantly (Table 4.8, page 116). When assessing BODEs′
individual scoring components (i.e. BMI, FEV1%, dyspnoea, 6MW), most of BODEs′ predictive
ability was attributed to the 6MW component (C = 0.648, 95% CI, 0.609 to 0.673; Figure 4.6,
page 115). When replacing the 6MW component with the SPPB, or its components 4MGS or
balance, the C-index changed from 0.671 (95% CI 0.641 to 0.693) to 0.667 (95% CI 0.627 to
0.694), 0.670 (95% CI 0.634 to 0.694), and 0.682 (95% CI 0.646 to 0.702) respectively. When
replacing the 6MW component with SNIP, the C-index changed from 0.671 to 0.672 (95% CI
0.629 to 0.695).
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Figure 4.5: Survival risk indices, by quartiles with number at risk at different time points: (A)
BODE6MW, (B) BODESPPB, (C) BODE4MGS, (D) BODEBALANCE, and (E) BODESNIP. Mortality
data obtained from the UK Office of National Statistics. Abbreviations: 6MW, six-minute walk. SPPB,
short physical performance battery. 4MGS, four-metre gait speed. SNIP, sniff nasal inspiratory
pressure.
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Model
6MW
6MW + BMI
6MW + BMI + MRC
BODE6MW
C−statistic [95% CI]
0.648 [0.609 to 0.673]
0.695 [0.664 to 0.720]
0.689 [0.653 to 0.718]
0.671 [0.641 to 0.693]
Change C−stat [95% CI]
−0.022 [-0.049, 0.001]
 0.025 [ 0.003,  0.043]
 0.018 [-0.001, 0.039]
Reference
0.50 0.75 1.0
C−statistic
Figure 4.6: Change scores C-index. Individual components BODE. Abbreviations: CI, confidence
interval. 6MW, six-minute walk. BMI, body mass index. MCR, Medical Research Council.
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The BODE6MW had a significantly higher C-index (0.709, 95% CI 0.680 to 0.737) compared
to the ADO Index225 (age, dyspnoea and obstruction; FEV1; C = 0.649, 95% CI 0.604 to 0.678).
Adding age or any musculoskeletal measures to the BODE6MW did not significantly improve the
predictive ability of BODE (Figure 4.7, page 117). Measuring just SPPB resulted in a C-
statistic of 0.617, 95% CI 0.580 to 0.645).
Model
BODE6MW
BODE6MW+SPPB
BODE6MW+4MGS
BODE6MW+BALANCE
BODE6MW+SNIP
BODEALL
C−statistic [95% CI]
0.709 [0.680 to 0.737]
0.712 [0.682 to 0.741]
0.709 [0.676 to 0.739]
0.726 [0.696 to 0.755]
0.719 [0.689 to 0.748]
0.717 [0.680 to 0.752]
Change C−stat [95% CI]
0.50 0.75 1.0
C−statistic
Reference
0.003 [-0.016, 0.027]
0.000 [-0.015, 0.038]
0.017 [-0.006, 0.038]
0.010 [-0.013, 0.025]
0.008 [-0.023, 0.038]
Figure 4.7: C-indices with change scores, alternative BODE models. All models were stratified by
recruitment centre. BODEALL includes body mass index, MRC dyspnoea score, FEV1, 6MW, short
physical performance battery components four-metre gait speed and balance, and sniff nasal inspiratory
pressure.
4.3.5 Sensitivity analysis
All 714 individuals (n = 71 deaths after three years of follow-up) were included in sensitivity
analyses using multiple imputation of missing baseline values (Figures 4.8 4.9 4.10, pages
118-120). Hazard ratios decreased for all models except for the model based on SNIP, which
increased only slightly. Cross-validated C-indices decreased but were unchanged between the
different models (Table 4.9, page 121).
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Figure 4.8: Boxplots, after multiple imputation. (A) body mass index. (B) forced expiratory volume
in one second. (C) sniff nasal inspiratory pressure. (D) six-minute walk distance. Boxplots in the first
column presents data from the complete-case dataset. Boxplots in columns 1-20 present imputed data.
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Figure 4.9: Kernel density plots, after multiple imputation. (A) body mass index. (B) forced
expiratory volume in one second. (C) sniff nasal inspiratory pressure. (D) six-minute walk distance.
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4.4 Discussion
The main finding of the present study was that SPPB or its 4MGS and balance components, or
SNIP may substitute 6MW in BODE for the prediction of all-cause mortality in stable COPD
patients (GOLD stage II-IV). The study confirms prior observations that each test on its own
is associated with prognosis in simple age and gender adjusted analysis, but QMVC and chair
stand, however, performed less well.
4.4.1 Critique of the method
This study has limitations. Firstly, there is no independent validation cohort with a fully
comparable dataset. We addressed this issue using a cross-validation technique approach and
estimated C-indices through random partitioning of the dataset. Secondly, baseline data differed
amongst the recruitment centres but was addressed through stratification by centre. Thirdly,
there were missing data with evidence that some was not at random (Figure 3.3, page 63).
Analysing complete-case data may have introduced bias, and although HRs and C-statistics of
the models shifted following MICE, the main conclusions were unchanged. Subgroup analysis,
for example, assessing the predictive ability for different age groups was not possible due to
the limited number of events. Results should be interpreted with caution, however. Overall,
the study sample size was rather small limiting statistical power, making it difficult to provide
robust conclusions but instead our findings encourage further analysis in larger cohorts.
In many diseases and scoring systems, for example the ADO Index,225 age is a strong predic-
tor of death, and unsurprisingly we found the risk of death to rise with age. However, our data
showed that ADO compared to BODE6MW provides less discriminative ability, or even adding
age to the models did not provide any significant difference in discriminative ability.
The ERICA cohort consisted primarily of individuals GOLD staged II-III, making generali-
sations to those with very mild COPD, or those with very advanced disease difficult. Additional
deaths occurred beyond the three years of follow-up included in the primary analysis. However,
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three years of follow-up was chosen because insufficient deaths occur over a short time frame
while over a long time period, the predictive ability of BODE diminishes, both because ageing
is a strong predictive variable and because measured variables are so distant from the point of
death. Consistent with this, some very large COPD trials such as the TOwards a Revolution
in COPD Health (TORCH)174 and Study to Understand Mortality and Morbidity in COPD
(SUMMIT)256 have used 3-year follow-up.
The BODE Index is a point-based system using cut-off points, but Puhan et al. have already
pointed out the poor calibration of the original BODE Index resulting in an Updated BODE
Index.225 Such a score would have detracted from utility of the BODE at the time of its con-
ception but would be readily available as a phone or web based app now. However, our analysis
failed to demonstrate the superiority of continuous rather than categorical data. While this
may reflect lack of statistical power, or due to the fact that the SPPB and its components are
categorical, our data do not suggest any advantage for a model based on continuous variables.
On the other hand, even when outcomes lack statistical significance – a statement about the
likelihood of findings being due to chance – this differs from the clinical significance. Clinical
significance considers rather the practical value or relevance of a specific biomarker, or using
continuous variables for example, which does not necessarily consider statistical significance.
Some of our data did not have defined quartiles of normality and therefore these categories
were created from the dataset. This arbitrary point assignment may not be optimal and under-
mine validity. We do not know how well these quartiles would map to alternative or non-trial
populations and to what extent the categorisation we created or the matching to prognostic
impact would be maintained. Therefore, the validity of this scoring should be tested in an
alternative and independent cohort.
4.4.2 Significance of the findings
By 2030, chronic respiratory diseases, cardiovascular diseases and cancer are each predicted to
be responsible for a third of deaths globally.172 Existing COPD risk indices have so far failed
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to achieve widespread clinical adoption. In some cases this may be due to insufficient clinical
validation data, but in the case of BODE we speculate that impracticalities relating to the 6MW
component, especially such test duration, and the requirement of space and equipment, may play
a role.
The SPPB, however, is a simple test to measure lower limb function that requires only a
chair, clock and a four-metre flat surface taking less than five minutes. In early 2018, the
European Medicines Agency approved the SPPB as a measure of frailty for disease associated
with musculoskeletal decline.88 In fact, our data suggest that even substitution of a single test
that is quick (e.g. 4MGS or balance) does not result in any significant loss in predictive ability
compared with BODE6MW.
Another quick and simple measurement that may be performed at the bedside is the SNIP.
Measuring SNIP, however, requires a respiratory pressure metre costing approximate £1000,
which many primary care units do not have. Maximal SNIP reflects diaphragm function and is
therefore directly impacted by hyperinflation222,238 and also is susceptible to generalised cachec-
tic influences. In a separate cohort we found that SNIP was predictive of survival and indeed to
some extent slightly outperformed direct measurement of hyperinflation.188 Hyperinflation has
previously also been reported as predictor of poor prognosis.35
Several studies have tried to improve the BODE Index by adding additional markers (Table
4.1, page 100).267 Within the Evaluation of COPD Longitudinally to Identify Predictive Sur-
rogate End-points (ECLIPSE) study, for example, inflammatory markers such as fibrinogen
and C-reactive protein were added. However, only interleukin-6 improved the models′ predic-
tive performance,42 and other inflammatory markers did not improve performance significantly.
Moreover, adding exacerbation history does not show to substantially improve the prognostic
capacity of BODE for mortality.246
With regard to our final hypothesis, we were not able to demonstrate any significant improve-
ment in the predictive ability of the BODE6MW by adding alternative musculoskeletal measures,
specifically SPPB. We believe this is because they are likely to capture the same phenotypic
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information as 6MW. Strong correlations between 6MW and SPPB (and its components) have
been described previously149 and were to be expected as they both depend on lower limb func-
tion. The QMVC was moderately correlated with 6MW but performed less well. Relationships
between QMVC and SPPB were also expected since SPPB was designed as a test of lower limb
function. We suspect this explains why the SPPB can be easily substituted for 6MW but also
why it conferred no additional value when added to 6MW.
The superiority of the balance component is of interest and may reflect the impact of co-
morbidities in COPD beyond those traditionally captured by chest physicians, or indeed by
the current protocol. In particular impaired balance may reflect multiple pathologies beyond
musculoskeletal weakness. Sensory input is one such that would be impaired in patients with
poorly controlled diabetes or alcohol related neuropathy. Visual impairment might also impair
balance, as would cognitive issues. Although, only 128 individuals (20%) had a score below the
maximum four points. This may indicate that these individuals, especially those with 0-1 points
were extremely ill and possibly frail.
4.5 Conclusions
We conclude that the SPPB, and its 4MGS and balance components have potential to replace
the 6MW component in the BODE Index for our cohort without significant loss of predictive
ability in all-cause mortality, thus potentially enhancing the uptake of such risk measures in
clinical practice. Large prospective validation of such simpler measures to replace the 6MW
component for use in prognostic tools is warranted.
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Causes of death in COPD using the UK Biobank
Chapter summary
Background There is uncertainty about the incidence of fatal cardiovascular disease amongst
the chronic obstructive pulmonary disease (COPD) population. Early studies have suggested
that cardiovascular death occurs in one tenth of COPD patients, whilst more recent studies
suggest this is closer to one third. In the Evaluation of the Role of Inflammation in Chronic
Airways disease (ERICA) cohort there were only few cardiac deaths, much lower than expected.
Further investigations are required to confirm/ replicate these findings. The primary aim of this
study was to determine cause of death in the UK Biobank cohort by estimating age-standardised
all-cause and cause-specific mortality rates by sex in COPD, and compare these rates with those
found in the ERICA cohort. Secondly, we aimed to estimate the age-standardised non-fatal
cardiovascular disease incidence rates by sex in COPD, and compare these with those found in
the ERICA cohort.
Methods We analysed survival and causes of death of individuals with at least two spirom-
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etry measurements and complete information for sex, height and smoking status aged 40 years
and older identified in the UK Biobank data (n = 150,542) recruited between 2006 and 2018. We
compared outcomes between individuals with defined COPD and non-COPD. Chronic obstruc-
tive pulmonary disease was defined based on spirometry results and smoking history. Causes
of death and non-fatal cardiovascular related hospital admission were obtained from the UK
Office for National Statistics and the National Health Services respectively, and categorised us-
ing ICD-10 coding. Sex-specific mortality rates were age-standardised using the 2013 European
Standard Population. Hazard ratios were estimated using age- and sex-adjusted Cox regression.
Findings Cumulative survival was 98% (98-98% CI) at 5 years, 97% (97-97% CI) at 7 years,
and 96% (96-97% CI) at 9 years. The highest cause-specific mortality rates were cancer-related.
In both men and women, COPD had an associated threefold higher risk of early mortality.
In women, COPD had an associated fourfold higher risk of cardiac-related death and ninefold
higher risk of pulmonary death. In men, COPD was associated with a threefold higher risk of
cardiac-related death and sevenfold higher risk of pulmonary death.
Interpretation Findings in the UK Biobank indicate cancer to be the leading cause of death
in COPD with a lower cardiac-death rate than expected. Our findings may reflect the downward
trend in fatal cardiovascular disease incidence/ improved cardiovascular survival in COPD, and
an increased prevalence of death from other causes especially cancer and respiratory disease
(i.e. trumped by the speed of progression of these diseases). Chronic obstructive pulmonary
disease is, however, associated with higher all-cause mortality, including cardiac-specific death.
Differences in fatal and non-fatal cardiovascular disease event rates, and the associated risk by
sex suggests tailored COPD management and treatment to be important.
5.1 Background
There is controversy regarding the incidence of fatal and non-fatal cardiovascular (CV) disease
amongst the chronic obstructive pulmonary disease (COPD) population. Systematic analysis of
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CV comorbidity in patients with COPD reported individuals with COPD to have at least a twice
as high risk of non-fatal CV disease compared to those without.46 However, high levels of het-
erogeneity were found between studies. Cardiovascular co-morbidity is thought to significantly
contribute to both in-hospital and post-discharge mortality in COPD.8,53,98 Yet, a systematic
review on the risk of myocardial infarction (MI) and mortality in COPD suggests there is ev-
idence indicating COPD to be associated with a higher risk of MI and mortality after MI but
not in-hospital mortality.231 In addition, the recent Korean Health and Nutritional Examination
Survey (KNHANES, n = 24,429) found COPD to be associated with all-cause mortality but not
with increased CV mortality.247
Early studies have suggested that CV death occurs in only one tenth of COPD patients,32
whilst more recent studies suggest this closer to a third. A review on all-cause mortality in
COPD published in 2007 found that 35% of deaths have a respiratory cause, 27% CV, 21%
cancer, 10% other and 8% are unknown.174
The reliability of classifying causes of death from COPD, however, has been questioned with
potential under reporting of respiratory disease being the underlying cause of death.81,118,138
Competing risks of multiple diseases associated with mortality, especially for ageing populations
who are more likely to have multiple morbidities, may serve as an explanation. Likewise, minor
diseases such as pneumonia, which are common in COPD patients and particularly in the elderly,
have found to be often misclassified as an underlying cause of death.178
Furthermore, previous studies did not age-standardise death rates or separate by sex. For
most causes of death, rates differ by age and require death rates to be adjusted to a standard
age distribution. Failing to age-standardise mortality rates may result in variation of overall
death rates when comparing two or more populations. Mortality rates may also differ by sex.
For example, in the TOwards a Revolution in COPD Health (TORCH) study, causes of death
were similar between sexes but with higher mortality rates for men.39 In the Body mass index,
airflow Obstruction, Dyspnoea and Exercise (BODE) study, also higher all-cause mortality rates
and death related to pulmonary disease were found in men.71 In the Evaluation of the Role of
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Inflammation in Chronic Airways disease (ERICA) cohort about a third of individuals had non-
fatal CV disease with only very few CV related deaths. Out of 714 individuals with a total of
149 deaths during the study period, only eighteen (12%) of individuals died of cardiac causes,
much lower than expected. Further investigations, however, are required to confirm/replicate
these findings in both UK and non-UK populations.
One of the largest and most detailed UK-based population cohort studies with data made
available to any qualified health researcher is the UK Biobank. The UK Biobank contains a large
number of measurements, including lung performance measures obtained using spirometry. It
has followed-up individuals for survival status, including cause-specific death, and captured any
hospital admission including CV related ones since study enrolment.
The primary aim of this study was to determine cause of death within the UK Biobank,
estimate age-standardised all-cause mortality and cause-specific rates by sex and COPD status,
and compare these rates with those found in the ERICA cohort. Secondly, we aimed to estimate
the age-standardised non-fatal CV disease incidence rates by sex and COPD status, and compare
these with those found in the ERICA cohort study.
5.2 Methods
5.2.1 Study design and participants
Data from the UK Biobank (application P35826) were linked to mortality data obtained from
the UK Office for National Statistics, and electronic health record (EHR) data (i.e. hospital
admission data) obtained from the National Health Services. Data were collected between 2006
and 2010 with continuous follow-up of survival status. The UK Biobank is a large long-term
prospective national and international biobank study in the United Kingdom with approxi-
mately 500.000 individuals aged between 40-69 years. Individuals recruited in the UK Biobank
were expected to develop common diseases over time including lung and CV disease: 5000
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cases of COPD and 10.000 cases of myocardial infarction and coronary death eight years after
recruitment. Data were captured at 22 assessment sites across the UK and included demo-
graphics, medical history, measures of pulmonary function, and others. Full details are provided
elsewhere.255 Analysis were limited to those of white European ancestry, at least two forced ex-
piratory volume in one second (FEV1) and forced vital capacity (FVC) measures, and complete
information for spirometry method, sex, standing height, and smoking status, and aged above
forty years.
5.2.2 Definition of COPD
Individuals with COPD at baseline were identified using the following selection criteria: (i)
COPD defined as post-bronchodilator FEV1 of 80% or less of their predicted value, a baseline
FEV1/FVC ratio of <0.7 measured by spirometry, (ii) a smoking history of at least ten pack-
years, and (iii) Global initiative for Obstructive Lung Disease (GOLD) stage ≥II.107
5.2.3 Statistical analysis
Based on baseline disease, individuals were categorised according to defined COPD or non-
COPD (reference group). The primary outcome measure was cause-specific incidence of death
within the UK Biobank by COPD status. Causes of death were categorised according to the
international classification of diseases and related health problems 10th revision coding (ICD-10;
Table 5.1, page 133). The secondary outcome measure was hospitalised non-fatal CV disease
derived through EHR data. These data were first cleaned for episode status and events were
extracted from both primary and secondary positions of ICD-10 coding (Table 5.2, page 135).
Time to event (i.e. time to death or time to first hospitalised non-fatal CV disease) was defined
as time to death or admission from the baseline visit date to date of death or admission, or
censored at November 2018. Time to hospitalised non-fatal CV disease was defined as time
to first admission from the baseline visit to date of admission, or censored at November 2018.
Sex specific all-cause and cause-specific mortality rates were age-standardised using the 2013
131
European Standard Population.198 Hazard ratios (HRs) were estimated using Cox proportional
hazards regression, adjusted for age and sex. Demographics were described using number and
percentage for categorical variables, and the medians (inter-quartile ranges (IQR)) for continuous
variables.
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Table 5.2: Definitions of diagnoses for non-fatal cardiovascular disease – main ICD10
End point ICD-10 codes
Diseases of the arteries I70.2, I72, I73.9-I79, E10.5, E11-E14
Peripheral arterial disease I70.2, I73.9, E10.5, E11-E14
Diseases of arteries, arterioles and capillaries I72, I74-I79
Coronary heart disease I20.0-I20.1, I20.8-I21-I25
Angina I20.1, I20.8-I20.9
Unstable angina I20.0, I24
Coronary heart disease not otherwise specified I25
Acute MI, and certain current complications following
acute MI
I21, I23
Subsequent myocardial infarction I22
All stroke I60, I61, I.62, I63, I64, I65-I69, F01, G46.3-G46.7, G458,
G459
Subarachnoid haemorrhage I60
Intra-cerebral haemorrhage I61
Cerebral infarction I63
Stroke, not specified as haemorrhage or infarction I64
Stroke syndromes G46.3-G46.7
Transient ischaemic attack G458, G459
Other stroke I62, I65-I69, F01
Heart failure I11.0, I13.0, I13.2, I50
Heart failure I50
Hypertensive heart disease with (congestive) heart failure I11.0
Hypertensive heart and renal disease with (congestive)
heart failure
I13.0
Hypertensive heart and renal disease with both (conges-
tive) heart failure and renal disease
I13.2
Atrial fibrillation and flutter (I48) and hypertensive diseases (I10-I15) were considered risk factors and
therefore not included. Abbreviations: ICD-10, international classification of diseases 10th edition. MI,
myocardial infarction.
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5.3 Findings
5.3.1 Descriptive statistics
From a total of 502 595 individuals in the UK Biobank, 472 866 were of white European ancestry
but only 150 542 individuals had at least two FEV1 and FVC measures, complete phenotype
data (i.e. height and sex) and were aged >40 years and therefore included in the primary analysis
(Figure 5.1, page 137). Those without complete phenotype data (i.e. excluded from analysis)
were one year older (p <0.001) and more likely to be male (p <0.001) compared to those included.
Most missing data were present for FEV1 (68%) and FVC (25%) measures. Of those included,
9926 (7%) individuals were identified with COPD. The selected cohort in UK Biobank (n = 150
542) had slightly more women (58%) than men, the median age 57 years (range 41-72), 45%
were overweight, median FEV1 (IQR) was 2.7 (2.2-3.2) litre, and a third was an ever smoker at
baseline with 10% GOLD staged II or above (Table 5.3, page 136). Those with COPD were
older (p <0.001), had higher body mass index (BMI; p <0.001), had lower FEV1 (p <0.001)
and were more likely to be male (p <0.001) compared to those without COPD.
Table 5.3: Baseline characteristics (n = 150 542).
Characteristic Selected cohort Non-COPD COPD
No. (%) of participants 150 542 140 616 9926
Age at survey, median (IQR), years 57 (50-63) 57 (50-63) 61 (56-65)
Male sex, No. (%) 62 844 (42) 57 416 (41) 5428 (55)
BMI, median (IQR), kg/m2 27 (24-30) 27 (24-30) 28 (25-31)
FEV1, median (IQR), litre 2.7 (2.2-3.2) 2.7 (2.3-3.3) 1.9 (1.5-2.3)
Ever smoker, No. (%) 46 279 (31) 36 353 (26) 9926 (100)
GOLD stage, ≥II 23 118 (9) 13 192 (9) 9926 (100)
Values are given as the medians and interquartile ranges (IQR), or No. of cases (%). Baseline data of
150 542 patients included. Abbreviations: BMI, body mass index. FEV1, forced expiratory volume in
one second. GOLD, global initiative for obstructive lung disease.
5.3.2 Event and mortality rates
Cumulative survival was 98% (98-98% CI) at 5 years, 97% (97-97% CI) at 7 years, and 96%
(96-97% CI) at 9 years. Crude all-cause mortality and cause-specific mortality rates gradually
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Individuals in UK Biobank (n =
502 595)
Individuals not of white European
ancestry (n = 29 729)
Individuals of white European an-
cestry (n = 472 866)
Individuals with incomplete pheno-
type data (n = 320 869)
At least two FEV1 and FVC mea-
sures and complete information for
spirometry method, age, sex, stand-
ing height, and smoking status (n =
151 997)
>40 years of age (n = 150 542) Individuals ≤ 40 years of age (n =1455)
Included in analysis (n = 150 542)
COPD Subjects with spirometry
defined FEV1 of ≤ 80% predicted
value, and FEV1/FVC ratio <0.7,
smoking history of ≥10 pack years,
GOLD ≥2 (n = 9926)
Non-COPD Failed to meet COPD
selection criteria (n = 140 616)
Alive (n = 9056) | Dead (n = 870) Alive (n = 137 313) | Dead (n =3303)
Study entry
Ethnicity
Completeness
Age
Analysis
COPD criteria
FUP 9-yrs
Figure 5.1: Flow diagram of sample selection strategy, UK Biobank. Total number of deaths (n =
4173). Abbreviations: FUP, follow-up period. FEV1, forced expiratory volume one second. FVC, forced
vital capacity. GOLD, global initiative for obstructive lung disease.
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increased throughout the study period for both sexes (Figure 5.2, page 139). During 7-year
median follow-up a total of 4173 (3%) individuals died: 870 (9%) with COPD and 3303 (2%)
non-COPD. Age- and sex-adjusted survival rates indicated those with COPD to be at higher
risk of mortality (Figure 5.3, page 140). The leading primary (underlying) cause of death was
cancer followed by diseases of the circulatory system, respiratory system, and other (Figure
5.4, page 141). Individuals with defined COPD had a higher proportion of deaths related to
cardiac and respiratory diseases, and a lower proportion of deaths related to cancer compared
to those without COPD, regardless of sex.
Age- and sex-adjusted all-cause mortality rates after 9-year follow-up were higher in men
(0.53 per 100 person-years (95% CI 0.48 to 0.58)) than in women (0.28 (95% CI 0.25 to 0.31);
Figure 5.5, page 142). Death due to cancer had the highest rate followed by cardiac disease.
Chronic obstructive pulmonary disease was associated with higher all-cause and cause-specific
mortality, in particular men. All-cause mortality for individuals with COPD (1.23 [95% CI
0.97-1.50] per 100 person-years for men, and 0.77 [95% CI 0.53-1.01] for women) were higher
compared to those without COPD (0.45 [95% CI 0.40-0.50] for men, and 0.25 [95% CI 0.22-0.28]
for women). Cardiac death rates for COPD were 0.29 (95% CI 0.17-0.41) per 100 person-years
for men, and 0.11 (95% CI 0.04-0.18) for women compared to 0.10 (95% CI 0.08-0.12) and 0.03
(95% CI 0.02-0.04) for men and women without COPD, respectively.
Age- and sex-adjusted HRs for all-cause mortality were 2.70 (95% CI 2.43 to 2.93) and 3.06
(95% CI 2.69-3.47) for men and women with COPD, respectively (Figure 5.5, page 142). For
all-cause and cause-specific mortality, HRs were higher for women. Hazard ratios for cardiac
death for women with COPD were 3.55 (95% 2.57-4.89), and 2.81 (95% 2.32-3.41) for men with
COPD.
138
Non−COPD COPD
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
Years of follow−up
M
or
ta
lity
 ra
te
 (p
er
 1
00
 p
er
so
n−
ye
ar
s)
group
All-cause
Cancer
Cardiac
Other
Pulmonary
A Female
Non−COPD COPD
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
Years of follow−up
M
or
ta
lity
 ra
te
 (p
er
 1
00
 p
er
so
n−
ye
ar
s)
group
All-cause
Cancer
Cardiac
Other
Pulmonary
B Male
Figure 5.2: Crude annual all-cause and cause-specific mortality rates with 95% CI, by sex and COPD
status. Figure (A) indicates event rates by COPD status for women. Figure (B) indicates event rates
by COPD status for men.
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5.3.3 Non-fatal cardiovascular disease
During the study period there were in total 13 800 (9%) individuals admitted to hospital for non-
fatal CV disease. Age-adjusted overall non-fatal CV event rate was higher for men than women
(2.10 [95% CI 2.01-2.20] vs. 0.87 [95% CI 0.82-0.92] per 100 person-years; Figure 5.6, page
144). The group with defined COPD had a higher non-fatal CV event rate than the non-COPD
group, especially men (3.22 [95% CI 2.82-3.63] vs. 1.69 [95% CI 1.60-1.77] per 100 person-years).
Event rates for women with COPD compared to those without were 1.90 [95% CI 1.54-2.26] vs.
0.81 [95% CI 0.75-0.86] per 100 person-years, respectively.
Age- and sex-adjusted HRs for non-fatal CV disease rates were 2.28 (95% CI 2.10-2.46)
for women with COPD, and 1.88 (95% CI 1.78-1.99) for men with defined COPD at baseline
(Figure 5.6, page 144).
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5.3.4 Comparison with the ERICA cohort
In comparison with the ERICA cohort, UK Biobank participants were a median six years
younger, and had a median 0.6 litre (1.9 vs. 1.3 litre and 16% predicted (69% vs. 53%) higher
FEV1 (Table 5.4, page 146). In the UK Biobank there were fewer men (55% vs. 61%) and
more current smokers (43% vs. 31%). Body mass index, biochemical measures (i.e. white cell
count, neutrophils, and haemoglobin), resting heart rate and systolic blood pressure values were
similar between the two cohorts.
Age-standardised all-cause mortality rates were higher for both sexes in the ERICA cohort
(Figure 5.7, page 147). Cardiac death rates were higher for men, and slightly higher for both
sexes in the ERICA cohort. Namely, cardiac death rates in the UK Biobank cohort were 0.11
(95% CI 0.04-0.18) per 100 person-years compared to 0.17 (95% CI 0.00-0.41) in the ERICA
cohort, for women. Cardiac death rates in the UK Biobank cohort were 0.29 (95% CI 0.17-0.41)
per 100 person-years compared to 0.31 (95% CI 0.01-0.67) in the ERICA cohort, for men. In
the UK Biobank mortality rates were highest for cancer followed by cardiac and other causes of
death. The lowest rate of death was due to pulmonary disease, whereas the ERICA cohort had
the highest ratio of death due to pulmonary disease.
When comparing non-fatal CV disease event rates between the two cohorts, event rates for
men were rather similar between the two cohorts. Rates in the UK Biobank cohort were 3.22
(95% CI 2.82-3.63) per 100 person-years, compared to 3.21 (95% CI 2.17-4.32) in the ERICA
cohort (Figure 5.8, page 147). Event rates for women in the UK Biobank cohort were lower
than those for women in the ERICA cohort.
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Table 5.4: Comparison of baseline characteristics between the UK Biobank and ERICA cohorts.
Characteristic Total, UK
Biobank (COPD)
N (%) Total, ERICA
(COPD)
N (%)
Description
Age, median (IQR), years 61 (56-65) 9926 (100) 67 (62-73) 714 (100)
Male sex, No. (%) 5428 (55) 9926 (100) 434 (61) 714 (100)
BMI, median (IQR), kg/m2 28 (25-31) 9926 (100) 27 (23-31) 707 (99)
Lung function
FEV1, median (IQR), litre 1.9 (1.5-2.3) 9926 (100) 1.3 (0.9-1.7) 712 (100)
FEV1, median (IQR), % predicted 69 (60-75) 9926 (100) 53 (40-65) 712 (100)
Smoking status - current, n (%) 4287 (43) 9926 (100) 218 (31) 710 (99)
Ever smoker, n (%) 9926 (100) 9926 (100) 714 (100) 714 (100)
GOLD stage, ≥II 9926 (100) 9926 (100) 713 (100 713 (100)
Shortness of breath walking on
level ground (MRC IV)
1031 (10) 3321 (33) 146 (21) 709 (99)
Biochemical measures
WCC (mcL) 7.8 (6.6-9.2) 9502 (96) 7.1 (6.0-8.6) 704 (99)
Neutrophils (mm3) 4.8 (3.9-5.9) 9486 (96) 4.5 (3.6-5.6) 701 (98)
Haemoglobin (g/dL) 14.4 (13.6-15.3) 9502 (96) 14.3 (13.4-15.3) 703 (98)
Cardiovascular status
Heart rate (bpm) 72 (64-80) 9317 (100) 74 (66-82) 702 (98)
SBP (mmHg) 142 (129-156) 9302 (94) 142 (131-154) 706 (99)
PWV (m/sec) 10.2 (8.1-12.1) 3283 (33) 9.8 (8.4-11.8) 654 (92)
AIx (%) 22 (17-30) 172 (2) 28 (20-34) 699 (98)
Values are given as the medians and interquartile ranges (IQR), or No. of cases (%). Abbreviations:
BMI, body mass index. FEV1, forced expiratory volume in one second. GOLD, global initiative for
obstructive lung disease. MRC, Medical Research Council. WCC, white cell count. SBP, systolic blood
pressure. MAP, mean arterial pressure. CIMT, carotid intima-media thickness. PWV, pulse wave
velocity. AIx, augmentation index.
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Figure 5.7: Age-standardised mortality rates and hazard ratios with 95% CI after nine years of
follow-up, by sex and cohort study. Figures (A) presents all-cause and cause-specific mortality rates for
women, by cohort. Figure (B) presents all-cause and cause-specific mortality ratios, by sex and cohort.
Top rows indicate results from the selected UK Biobank cohort (U). Second rows indicate results from
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Figure 5.8: Age-standardised non-fatal cardiovascular event rates and hazard ratios with 95% CI
after nine years of follow-up, by sex. Top rows indicate results for women (F). Second rows indicate
results for men (M; coloured yellow).
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5.4 Discussion
This study evaluated age-standardised all-cause and cause-specific mortality, and non-fatal CV
disease rates by COPD status and sex, and the associated risk of COPD with these outcomes.
The main findings of this analysis were that despite the higher event rates for men, women
with COPD were at higher risk of both fatal- and non-fatal CV disease. In addition, COPD
in men was associated with a 2.7-fold higher risk of early mortality, including a 2.8-fold higher
risk of cardiac-related death and 7.4-fold higher risk of pulmonary death. Whereas in women,
COPD was associated with a threefold higher risk of early mortality including an 3.6-fold higher
associated risk of cardiac-related death and 9.4-fold higher risk of pulmonary death. In addition,
COPD in men was associated with a 1.9-fold higher risk of non-fatal CV disease, and 2.3-fold
higher risk in women.
Mortality rates were higher in ERICA than in the UK Biobank, although cardiac-related
death rates were similar. Non-fatal CV disease rates for women were higher in the ERICA co-
hort, yet for men these were similar. Pulmonary-related death was the primary cause of death
in ERICA, indicating a population with more severe pulmonary disease.
Differences between findings in the UK Biobank and the ERICA cohort may be explained
by the variation in populations, despite limiting analyses to individuals with COPD specific
spirometry results aged forty years of age and over. The population in ERICA was specifically
recruited because of their lung disease, and may have had more severe lung disease (i.e. worse
FEV1 and more shortness of breath) than individuals recruited in UK Biobank. Besides the
larger proportion of males (61%) recruited in ERICA, there may have been differences in geo-
graphical distribution between cohorts. Most participants in the ERICA study were recruited in
Cardiff followed by Nottingham, Edinburgh, Cambridge and London. Individuals from London
were slightly healthier compared to other sites and individuals from Cardiff (52%) had more
severe lung disease. Participants in the UK Biobank were primarily recruited in England/Wales
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with about 10% from Scotland. Overall, the UK Biobank cohort was younger, healthier and
included more women compared to ERICA, and therefore the two cohorts may not have been
that well comparable. Simultaneously in terms of the generalisability of the UK Biobank cohort,
compared to nationally representative data sources, individuals enrolled in the UK Biobank were
more likely to be female and older with higher socio-economic status than non-participants.97
Hence, in terms of generalisability, it may be difficult to generalise findings to other populations.
Findings need to be replicated in other and independent COPD cohorts to confirm findings.
For both cohorts, cause of death data were taken from death certificates provided by the
UK ONS. In addition to ONS, UK Biobank is also linked to the Cancer Registry, whereas
ERICA is not. However, this should have no impact on causes of death that were included in
these analyses as both cohorts use the same ICD-10 coding provided by ONS. However, the
reliability of classifying causes of death has been questioned and post-mortem analysis may
show different underlying causes of death. A systematic problem, beyond the control of those
analysing death data is that generally physicians completing death certificates usually know the
patient′s background, which may potentially lead to overestimation of individuals who died of
pulmonary disease and miss cardiac death. The appointment of a clinical endpoint committee,
similar to the TORCH study,174 as an alternative method could have been more reliable but
was not feasible.
In terms of comparing baseline CV status between the two cohorts, there were too few ob-
servations of objectives measures of arterial stiffness (i.e. augmentation index and pulse wave
velocity), and carotid intima-media thickness to compare these. There were also too few observa-
tions to make a comparison in the experienced shortness of breath, being a symptomatic marker
of disease impact. Considering other lung function measures were worse for ERICA participants,
it is likely that individuals in ERICA would have experienced higher levels of breathlessness than
those in UK Biobank.
This study has several potential limitations. Analyses were not adjusted for comorbidities,
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therefore not addressing any competing risks of other diseases associated with early mortality
than COPD. Apart from lung function measures and standard socio-demographics such as age
and sex, both cohorts captured different baseline measures making the inclusion of additional
covariates in the analyses difficult. In the UK Biobank, of the full white European ancestry
cohort (n = 472 866), about 1200 cases had a technical failure when completing spirometry,
another ∼1250 cases had unknown reasons for not completing this test, and almost another
1000 individuals could not have their lung function measured. These individuals may have
systematically differed from the population included in the analyses and may have had worse
lung function. Analyses were neither adjusted for drug treatment or smoking status at base-
line, potentially inducing bias. For example, the intake of drugs related to treating CV disease
may be associated with either increasing or decreasing the risk of CV disease.79,228,233,243,295 At
baseline 56% of individuals in the ERICA study were taking CV drugs indicating their CV risk
was already being addressed before study enrolment and may explain the lower incidence of CV
related disease. In addition, disease management such as maintenance medications has changed
over time,22 and there are treatment differences between those with and without COPD when
admitted to hospital for CV related events.249
Despite the literature indicating a third of deaths in COPD to be related to cardiac disease,
age-standardised mortality rates do not support the high incidence of cardiac-related death in
COPD. Leading causes of death in COPD were either cancer or pulmonary disease related, and
did not differ that much from the non-COPD population, which had also cancer as the leading
cause of death. Also, data from the UK Biobank evaluating cause-specific death in the general
population found 25% of men died of causes related to CV disease with 53% of cancer and 6% of
respiratory disease.103 In women only 12% died of CV disease with death attributed to cancer
(69%) as the main cause. About 4% died of respiratory disease. Besides reporting standardised
event rates by sex, which are more useful and reliable when analysing these outcomes instead of
proportions, and especially when comparing findings between studies, over the past few decades
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cardiac-related death in the UK general population has halved for both sexes.224 The reduction
in CV related death is primarily the result of prevention and improved heart disease treatment
and management.16,76 Also, where CV disease hospitalisation increased, the number of cardiac
deaths declined by nearly 70% between 1980-2013 with similar declines in coronary heart disease
and stroke.21 Our data may indicate a similar reduction in CV related death in COPD. Finally,
our results also add to the evidence of the importance of providing appropriate health care
interventions with consideration of sex differences, including increasing the awareness of COPD
in women and tailoring treatment strategies for prevention and treatment.136
5.5 Conclusions
Findings in the UK Biobank indicate cancer to be the leading cause of death in COPD with
a lower cardiac-death rate than expected. Our findings may reflect the downward trend in
fatal CV disease incidence/ improved CV survival in COPD, and an increased prevalence of
death from other causes especially cancer and respiratory disease (i.e. trumped by the speed of
progression of these diseases). Chronic obstructive pulmonary disease is, however, associated
with higher all-cause mortality, including cardiac-specific death. Differences in fatal and non-
fatal CV disease event rates, and the associated risk by sex emphasises the importance of tailored
COPD treatment and management.
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Exercise capacity traits and their association with
COPD exacerbations requiring hospital admission:
UK ERICA cohort linked with national hospital
statistics
Chapter summary
Background Acute exacerbations of chronic obstructive pulmonary disease (COPD) frequently
result in hospitalisation. Few reliable predictors exist, the strongest being exacerbation history.
Improving exercise capacity is known to reduce rate of hospitalisations. Our aim was to assess
the associations between musculoskeletal measures and risk and duration of acute exacerbation
of COPD requiring hospital admission.
Methods Clinical data from the Evaluation of the Role of Inflammation in Chronic Airways
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disease (ERICA) cohort were linked with hospital episode statistics capturing acute exacerbation
of COPD-related admissions. Negative binomial regression was used to evaluate associations of
musculoskeletal measures: six-minute walk distance, short physical performance battery and its
components, and quadriceps muscle strength with hospitalised acute exacerbation of COPD and
hospital length of stay for acute exacerbation of COPD.
Findings Of 714 individuals with COPD, 291 individuals experienced 762 hospitalised acute
exacerbation of COPD during five-year follow up. Poorer performance of musculoskeletal mea-
sures was associated with rate or longer duration of acute exacerbation of COPD. Six-minute
walk distance (incidence risk ratio (IRR) 1.67 per 30m decrements, 95% CI 1.42-1.97), lower
short physical performance battery score (IRR 1.08 per 1 point decrease, 95% CI 1.01-1.14) and
weaker quadriceps maximum voluntary contraction (IRR 1.02 per 1 kg decrease, 95% CI 1.00-
1.03) were associated with rates of hospitalised acute exacerbation of COPD. Similar associations
were observed for acute exacerbations of COPD-related hospital length of stay.
Interpretation Musculoskeletal measures were significantly associated with rate and du-
ration of hospitalised acute exacerbation of COPD. Physical capacity should be considered an
important treatable trait in reducing risk of hospitalised acute exacerbation of COPD, its as-
sessment incorporated in risk indices evaluating future exacerbation risk, and its improvement
should form a part of routine care for COPD.
6.1 Background
Acute exacerbations of COPD (AECOPD) are acute episodic flare-ups that often lead into
hospital admission and are associated with high mortality and morbidity. According to 2016-17
statistics of the National Health Services (NHS) Digital, more than 128,000 individuals with a
specific code for COPD exacerbation (ICD-10 J44.0, J44.1, J44.8, J44.9) in the United Kingdom
were admitted to hospital, of which 97% were emergency admissions with a median hospital
length of stay of three days.197
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Overall, there is a paucity of validated and reliable measures predicting risk of AECOPD.
Prior exacerbation history is currently the strongest factor reliably predicting future risk of
AECOPD including hospital admissions.131,234 Blood biomarkers such as fibrinogen179 and white
cell count,260 have been associated with a higher risk of AECOPD, but are not routinely used in
clinical practice. It has been proposed to use predictive models to improve discriminative ability
and identify high-risk individuals for AECOPD in an early stage. In 2017, a systematic review of
published prediction models for AECOPD concluded that out of thirty prediction models none
but two were validated; all but one failed to meet practical applicability.113
Exercise capacity is a promising marker of early deconditioning and is strongly associated
with a higher risk of mortality.104,281 There is a possibility that such exercise traits may help
identifying those people who have already started deconditioning at an early stage of disease
and may experience accelerated disease progression. In particular, AECOPD also contributes
to a decline in exercise capacity.125 The relationship of shorter 6MW distance with a higher
risk of mortality and exacerbation risk has been well-established.220,248 Further, there is a small
body of evidence indicating that other musculoskeletal measures used in assessment of exercise
capacity such as the short physical performance battery (SPPB) and the quadriceps maximum
voluntary contraction (QMVC) are also associated with a higher risk of mortality216,259 and
all-cause hospital readmission148 in COPD. In particular, the four-metre gait speed (4MGS)
test, a component of SPPB, was found to predict hospital readmission after AECOPD.148 With
the exception of the 6MW distance,248 to our knowledge, there is no evidence of studies that
have examined the association between exercise capacity measures such as SPPB, QMVC, and
AECOPD requiring hospital admission.
There are scientific and practical considerations for expanding our knowledge of musculoskele-
tal measures and their role in predicting COPD outcomes. Each of these measures tests different
properties of exercise, including cardiovascular capacity, lower limb function or musculoskeletal
weakness more specifically, coordination and balance. These different exercise capacity com-
ponents may reflect the impact of co-morbidity in COPD beyond those traditionally captured.
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Practical applicability in routine practice is another important consideration of expanding the
repository of exercise tests. Compared to the 6MW test, SPPB and its components are faster and
easier to complete in clinical practice, requiring a four-metre flat surface, chair and stopwatch
only. In addition, to facilitate generalisability of musculoskeletal measures in primary care, it is
important to evaluate their associations with COPD outcomes in different COPD populations.
Our primary aim was to evaluate the relationship between exercise capacity assessed with
musculoskeletal measures and risk of hospital admissions due to AECOPD. Further, we aimed
to determine a relationship between musculoskeletal measures and length of hospital stay for
initial AECOPD. To address these questions, we used a novel study design approach of combining
routinely collected hospital electronic health record data with a prospective COPD disease cohort
recruited in the Evaluation of the Role of Inflammation in Chronic Airways disease (ERICA)
cohort.
6.2 Methods
6.2.1 Study design and participants
Observational data is reported according to the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement.275 Data were used from the ERICA cohort,
a multi-centre observational, non-interventional, epidemiological study with a sample size of
729 stable COPD patients (Global Initiative for Chronic Obstructive Lung Disease (GOLD)
grade II-IV).107 Full study design and participant details are available in the published ERICA
cohort protocol.184 Patient level cohort data were linked to hospital admission data obtained
from the NHS admitted patient care dataset, Hospital Episodes Statistics (HES) in England,
Scotland and Wales, which captures all hospital admissions for AECOPD, since cohort baseline
visit until November 2017. Analyses were limited to five years of follow-up. Baseline data were
collected between December 2011 and January 2014. Demographic, clinical and patient reported
measures and biomarkers including musculoskeletal measures were collected at baseline. Prior
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exacerbation history was defined as self-reported antibiotics and/or steroids use in the previous
year (twelve months before baseline). Body mass index (BMI) was categorised according to
the World Health Organization.291 Disease severity was defined by GOLD stage and estimated
as described by the GOLD.107 Productive cough (i.e. phlegm) was defined using questionnaire
data and considered a surrogate marker of inflammation. Where there was missing data for
productive cough, data from the phlegm question of the St. George Respiratory Questionnaire
for COPD (SGRQ-C), and the COPD Assessment Test (CAT) were used. Productive cough was
dichotomised (never vs. other).
6.2.2 Study outcomes
The primary outcome measure was hospital admission for AECOPD. These data were first
cleaned for episode status and inpatient (i.e. hospitalised) AECOPD episodes were identified
using validated criteria (Table 6.1, page 158).230 Acute exacerbations of COPD were extracted
from both primary and secondary positions of international classification of diseases and related
health problems 10th revision coding (ICD-10). Only so-called definite and possible hospitalised
AECOPD were considered for this analysis (Figure 6.1, page 159). Priority was given to definite
AECOPD. Only episodes during the study follow-up were evaluated. Admission and discharge
dates were used to determine hospital length of stay (i.e. number of days) for initial AECOPD.
6.2.3 Potential predictor variables
All significant variables reported by Hurst et al.132 and musculoskeletal markers captured in
the ERICA cohort were considered. A full list of predictor variables is shown in Table 6.2,
page 159 including demographics, lung function measurements, blood markers, questionnaire
data, and exercise capacity traits. Measures of particular interest were SPPB and its compo-
nents (i.e. 4MGS, balance, chair stand), QMVC, and 6MW distance. Exacerbation history was
dichotomised (0 vs. ≥1).
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Table 6.1: ICD-10 codes to ascertain acute exacerbation in COPD in the hospital episode statistics.
End
point
ICD-10 codes Disease/
Category
Use to ascertain AECOPD usage
J22 Lower respiratory tract infection Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J41 Simple and mucopurulent chronic
bronchitis
Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J41.0 Simple chronic bronchitis Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J41.1 Mucopurulent chronic bronchitis Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J41.8 Mixed simple and mucopurulent
chronic bronchitis
Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J42 Unspecified chronic bronchitis Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J43 Emphysema Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J43.0 MacLeod’s syndrome Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J43.1 Panlobular emphysema Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J43.2 Centrilobular emphysema Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J43.8 Other emphysema Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J43.9 Emphysema, unspecified Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J44 Other chronic obstructive pul-
monary disease
Possible Use if COPD diagnosed in primary care data in First position of any finished
consultant episode
J44.0 Chronic obstructive pulmonary dis-
ease with acute lower respiratory in-
fection
Definite Any position of any finished consultant episode as per validation study
J44.1 Chronic obstructive pulmonary dis-
ease with acute exacerbation, un-
specified
Definite Any position of any finished consultant episode as per validation study
J44.8 Other specified chronic obstructive
pulmonary disease
Possible Ditto
J44.9 Chronic obstructive pulmonary dis-
ease, unspecified
Possible First position of any finished consultant episode as per validation study
J45 Asthma Potential If increased sensitivity required, use if COPD diagnosed in primary care
data in First position of any finished consultant episode
J45.0 Predominantly allergic asthma Potential If increased sensitivity required, use if COPD diagnosed in primary care
data in First position of any finished consultant episode
J45.1 Nonallergic asthma Potential If increased sensitivity required, use if COPD diagnosed in primary care
data in First position of any finished consultant episode
J45.8 Mixed asthma Potential If increased sensitivity required, use if COPD diagnosed in primary care
data in First position of any finished consultant episode
J45.9 Asthma, unspecified Potential If increased sensitivity required, use if COPD diagnosed in primary care
data in First position of any finished consultant episode
J45 Asthma Potential If increased sensitivity required, use if COPD diagnosed in primary care
data in First position of any finished consultant episode
J46 Status asthmaticus Potential If increased sensitivity required, use if COPD diagnosed in primary care
data in First position of any finished consultant episode
J47.0 Bronchiectasis with acute lower res-
piratory infection
Potential If increased sensitivity required, use if COPD diagnosed in primary care
data in First position of any finished consultant episode
J47.1 Bronchiectasis with (acute) exacer-
bation
Potential If increased sensitivity required, use if COPD diagnosed in primary care
data in First position of any finished consultant episode
J47.9 Bronchiectasis, uncomplicated Potential If increased sensitivity required, use if COPD diagnosed in primary care
data in First position of any finished consultant episode
J96.0 Acute respiratory failure Potential If increased sensitivity required, use if COPD diagnosed in primary care
data in First position of any finished consultant episode
J96.2 Acute and chronic respiratory fail-
ure
Potential Use to ascertain AECOPD usage
Abbreviations: ICD-10, international disease classification tenth edition. AECOPD, acute exacerbation
of chronic obstructive pulmonary disease.
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Figure 6.1: Type of acute exacerbation of COPD, by recruitment centre. Hospital admission data
obtained from the National Health Service (NHS) Digital, NHS Wales, and NHS Scotland.
Table 6.2: Covariates considered
Description Lung func-
tion
Biochemical
measures
Cardiovascular
status
Questionnaires Musculoskeletal
measures
Age FEV1 Glucose Resting heart
rate
SGRQ-C 6MW distance
Sex Smoking status Fibrinogen CAT SPPB
BMI Exacerbation
history
CRP 4MGS
Phlegm GFR Balance
Neutrophils Chair stand
Haemoglobin QMVC
Total choles-
terol
White cell count and Medical Research Council dyspnoea score were omitted due to collinearity with
musculoskeletal measures. Abbreviations: BMI, body mass index. FEV1, forced expiratory volume in
one second. CRP, C-reactive protein. GFR, glomerular filtration rate. SGRQ-C, St. George respiratory
questionnaire for COPD. CAT, COPD assessment test. 6MW, six-minute walk. SPPB, short physical
performance battery. 4MGS, four-metre gait speed. QMVC, quadriceps maximum voluntary
contraction.
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6.2.4 Statistical analysis
Missing values were present. Only complete cases were considered. Negative binomial regres-
sion was used to examine the association between musculoskeletal measures and (i) the rate of
AECOPD within the study period, and (ii) length of hospital stay (per day). Analyses were ad-
justed for exposure times (time between baseline visit date and earliest of death, or end of study
period). Regression estimates are presented as incidence-rate ratios (IRR). Markers transformed
on the natural log scale were exponentiated by a factor of 0.736 to represent a two-fold increase
in risk.
Relationships between baseline variables were quantified using Spearman′s pair-wise correla-
tions; values <0.30 were considered weak, 0.30-0.50 as moderate, and >0.50 as strong (Figure
3.30, page 83).51 All analyses were stratified by recruitment site, and adjusted for age and
sex. Further analyses were adjusted for BMI, smoking status, and covariates found to be of
significance in the main multivariate model by Hurst et al.,132 namely exacerbation history
(previous year), forced expiratory volume in one second (FEV1) measured in litres, and produc-
tive cough. Covariates were tested for collinearity resulting in the omission of Medical Research
Council (MRC) dyspnoea score and white cell count (WCC). Predictors for the final analyses
were derived sequentially, firstly estimating the association of each individual variable fully ad-
justed, following stepwise regression including the significant variables only, whilst considering
collinearity and clinical utility. Only predictors with a significance level above α 0.1 for backward
selection and α 0.05 for forward stepwise selection were considered. For each stepwise regression
model, likelihood ratio tests were conducted to determine if independent variables should remain
in the model or not, and the maximum number of variables considered in each model were based
on the least number of events.266
As sex and exacerbation history can act as effect modifiers, in sensitivity analyses, we ex-
plored analysis stratified by these factors and tested for interactions.
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6.3 Findings
6.3.1 Missing data
Missing values were present and described in Figures 6.2 6.3, pages 161-162. Those with
missing values for 6MW distance (n = 31) had a higher rate of AECOPD-related hospital
admission (p = 0.047).
Age
Sex
GOLD
FEV1
Smoking
Exacerbation
Phlegm
BMI
SPPB
Cholesterol
Haemoglobin
CAT
HR
Neutrophils
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CRP
SGRQ
Glucose
QMVC
6MW
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Figure 6.2: Percentage of missing values. Abbreviations: GFR, glomerular filtration rate. 6MW,
six-minute walk. QMVC, quadriceps maximum voluntary contraction. CRP, C-reactive protein. HR,
heart rate. CAT, COPD assessment test. SPPB, short physical performance battery. BMI, body mass
index. FEV1, forced expiratory volume in one second. GOLD, global initiative for obstructive lung
disease.
6.3.2 Descriptive statistics
The mean number of acute exacerbations for COPD were 1.3 vs. 0.6 with a variance of 6.2 vs.
2.6 for those with an exacerbation history compared to those without, indicating over-dispersed
count data. In total, 714 individuals with stable COPD were included in the analysis, of whom
291 (41%) experienced at least one hospital admission for AECOPD during the study follow-up;
159 (22%) had multiple events (Figure 3.4, page 64). The resulting event rate for hospitalised
AECOPD was 11 events (95% CI 10-13) per 100 person-years (Figure 6.4, page 163). Overall,
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Figure 6.3: Missing data patterns. Abbreviations: SGRQ, St. George respiratory questionnaire for
COPD. QMVC, quadriceps maximum voluntary contraction. 6MW, six-minute walk. GFR, glomerular
filtration rate.
127 (18%) individuals died and, of these, the majority 103 (81%) had died following hospitalised
AECOPD. At baseline, the mean age of the cohort was 67 ± 8 years with 61% males. A third of
the cohort was overweight, another third obese. Exacerbations during the year prior to baseline
were reported by 67% individuals with a corresponding mean of 2 (interquartile range (IQR;
1-4) events per person-year. Mean FEV1 was 1.3 ± 0.5 litre with third current smokers. About
half of the cohort (51%) experienced breathlessness on exercise (MRC grade ≥3) and 46% had
productive cough on most mornings (Table 6.3, page 165). Median length of hospital stay for
initial AECOPD-related admission was 3 (IQR 1-7) days.
For those readmitted, the median time to hospital readmission was 179 (54-421) days, of
whom 65 individuals (41%) were readmitted to hospital within 90 days after initial admission
and had a median length of stay of 3 (2-7) days. Those with an exacerbation history at baseline
were younger (p = 0.027), male (p <0.001), had lower forced expiratory volume in one second
(p <0.001), worse dyspnoea scores (p = 0.002), and higher inflammatory levels of fibrinogen
(p = 0.001) and C-reactive protein (p = 0.019) compared to those without. Shorter walking
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Figure 6.4: Yearly event rates, frequency and duration of AECOPD-related hospital admission.
Figures display (A) mean event rates with 95% confidence intervals per 100 person-years during study
period, (B) AECOPD frequency, and (C) AECOPD duration. Depth of blue indicates the cumulative
number of individuals with first AECOPD during the study period: 1 year (n = 86), 2 years (n = 160),
3 years (n = 213), 4 years (n = 266) and 5 years of follow-up (n = 291). Red dashed line indicates the
median number of hospital admissions for AECOPD amongst those experienced an AECOPD.
Abbreviations: N, indicates the number of participants. AECOPD, acute exacerbation of chronic
obstructive pulmonary disease.
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distance (p <0.001), lower SPPB scores (p = 0.003), or the components 4MGS (p <0.001) and
chair stand (p = 0.003) but not balance (p = 0.630), and QMVC (p <0.001) were also reported
for those with an exacerbation history at baseline.
6.3.3 Factors associated with rate of AECOPD-related hospital admission
Musculoskeletal measures of 6MW distance, SPPB and its 4MGS, and chair stand components,
and QMVC were associated with the risk of AECOPD-related hospital admission (Figure 6.5
and Table 6.4, pages 167-166). Balance was not associated with the outcome. Six-minute walk
distance (IRR 1.13 per 30 metre decrease, 95% CI 1.08 to 1.17, p <0.001), FEV1 (IRR 0.84 per
100 ml increase, 95% CI 0.81 to 0.86, p <0.001) or disease severity measured by GOLD (IRR
2.51 per increase to next stage, 95% CI 2.04 to 3.10, p <0.001), and males (IRR 2.41, 95% CI
1.77 to 3.29, p <0.001) had the highest associated IRRs. Stepwise regression, including variables
fully adjusted and significantly associated with AECOPD-related hospital admission rate only,
retained the following predictors: males (IRR 2.14, 95% CI 1.55 to 2.96, p <0.001), FEV1, (IRR
0.88 per 100 ml increase, 95% CI 0.85 to 0.91, p <0.001), exacerbation history ≥1 (IRR 1.96,
95% CI 1.39 to 2.76, p <0.001), CAT (IRR 1.03 per 1 point increase, 95% CI 1.01 to 1.05, p =
0.010), resting heart rate (IRR 1.01 per 1 bpm increase, 95% CI 1.00 to 1.03, p = 0.025), and
6MW distance (IRR 1.08 per 30 metre decrease, 95% CI 1.04 to 1.12, p <0.001; Table 6.5,
page 167).
6.3.4 Factors associated with AECOPD-related hospital stay
Including data from individuals admitted to hospital only (n = 291), multivariable analysis iden-
tified multiple markers to be associated with AECOPD-related hospital stay (Figure 6.6 and
Table 6.8, pages 169-170). All musculoskeletal measures, except for QMVC were associated
with longer AECOPD-related hospital stay (Table 6.4 and Figure 6.5, pages 166-167). Age
(IRR 1.83 per 10 year increase, 95% CI 1.48 to 2.26, p <0.001), 6MW (IRR 1.14 per 30 metre
decrease, 95% CI 1.08 to 1.20, p <0.001), and SPPB (IRR 1.18 per 1 point decrease, 95% 1.10
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Table 6.3: Baseline characteristics.
Characteristic Total Without AECOPD With AECOPD
Description Median (IQR) or n (%)
Age (years) 67 (62-73) 68 (62-74) 67 (63-72)
Sex, n (%)
Male 434 (61) 262 (62) 172 (59)
Female 280 (39) 160 (38) 120 (41)
Body mass index (kg/m2) 27 (23-31) 27 (24-31) 26 (23-31)
Musculoskeletal measures
6MW distance (metre) 366 (255-440) 398 (298-462) 326 (210-404)
SPPB (0-12) 10 (8-11) 10 (8-12) 10 (8-11)
No functional limitation, ≥10, n (%) 414 (58) 254 (61) 160 (55)
Functional limitation <10, n (%) 292 (41) 163 (39) 129 (45)
- 4MGS score (0-4) 4 (3-4) 4 (3-4) 4 (3-4)
- Balance points (0-4) 4 (4-4) 4 (4-4) 4 (4-4)
- Chair stand score (0-4) 3 (1-4) 3 (1-4) 2 (1-3)
QMVC peak (kg), median (IQR) 30 (22-39) 31 (23-40) 28 (20-35)
Lung function
FEV1 1.3 (0.9-1.7) 1.5 (1.1-1.9) 1.1 (0.8-1.4)
Smoking status, n (%)
Current 218 (31) 131 (31) 87 (30)
Former 492 (69) 291 (69) 201 (70)
GOLD, n (%)
Grade II 406 (57) 291 (69) 115 (40)
Grade III 240 (34) 112 (27) 128 (44)
Grade IV 68 (10) 19 (5) 48 (16)
Exacerbation history, 1 year (≥1) 473 (66) 247 (59) 226 (79)
Phlegm, n (%)
Never 46 (7) 237 (57) 144 (50)
Other 662 (94) 181 (43) 146 (50)
Biochemical measures
log Glucose (mmol/L) 1.59 (1.50-1.69) 4.9 (4.5-5.3) 4.9 (4.5-5.4)
log Fibrinogen (g/dL) 1.22 (1.06-1.36) 1.19 (1.03-1.36) 1.25 (1.10-1.39)
log C-reactive protein (mg/L) 1.21 (0.47-2.00) 1.10 (0.48-1.85) 1.39 (0.43-2.19)
GFR (mL/min/1.73 m2) 87 (76-101) 87 (77-100) 88 (76-102)
Neutrophils (mm3) 4.5 (3.6-5.6) 4.3 (3.5-5.5) 4.8 (3.7-5.7)
Haemoglobin (g/dL) 14.3 (13.4-15.3) 14.3 (13.4-15.2) 14.4 (13.4-15.4)
Total cholesterol (mmol/L) 5.0 (4.3-5.8) 5.0 (4.2-5.7) 5.0 (4.3-5.9)
Cardiovascular status
Heart rate (bpm) 74 (66-82) 72 (65-81) 77 (67-84)
Questionnaires
SGRQ-C (0-100) 51 (34-66) 43 (29-61) 57 (45-71)
CAT (0-40) 20 (13-26) 18 (12-24) 22 (17-28)
Values are given as the median and interquartile range (IQR), or No. of cases (%). Baseline data of
study participants are included. Abbreviations: MRC, Medical Research Council. GOLD, global
initiative for obstructive lung disease. WCC, white cell count. SGRQ-C, St George’s respiratory
questionnaire for COPD. CAT, COPD assessment test. 6MW, six-minute walk. SPPB, short physical
performance battery. 4MGS, four-metre gait speed. QMVC, quadriceps maximum voluntary
contraction.
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Table 6.4: Adjusted multivariable associations with frequency of AECOPD-related hospital admission.
5 year (n = 714, of whom 291 had AECOPD)
Baseline Characteristics Incidence risk ratio
(95% CI). Adjusted
for age and sex a
P
value c
Incidence risk ratio
(95% CI). Multivari-
able adjusted b
P
value c
Description
Age - per 10 year increase 0.97 (0.81 to 1.17) 0.773 0.88 (0.74 to 1.04) 0.126
Sex - male 1.01 (0.74 to 1.39) 0.932 2.41 (1.77 to 3.29) <0.001
Body mass index - per 1 point increase 0.96 (0.94 to 0.98) 0.002 1.00 (0.98 to 1.02) 0.947
Lung function
FEV1 - per 100 ml increase 0.83 (0.80 to 0.85) <0.001 0.84 (0.81 to 0.86) <0.001
Smoking status - current 1.25 (0.89 to 1.76) 0.192 1.15 (0.84 to 1.57) 0.382
GOLD stage - per increase to next stage 2.71 (2.21 to 3.33) <0.001 2.51 (2.04 to 3.10) <0.001
Exacerbation history (1 year), ≥1 2.52 (1.79 to 3.53) <0.001 1.94 (1.40 to 2.67) <0.001
Productive cough - yes 1.90 (1.00 to 3.61) 0.049 1.04 (0.79 to 1.38) 0.768
Biochemical measures
Glucose - per 1 log unit increase 1.43 (0.53 to 3.87) 0.477 1.77 (0.69 to 4.53) 0.231
Fibrinogen - per 1 log unit increase 3.43 (1.71 to 6.88) 0.001 1.95 (1.03 to 3.68) 0.04
CRP - per 1 log unit increase 1.18 (1.03 to 1.35) 0.018 1.10 (0.98 to 1.25) 0.116
GFR - per 1 unit increase 1.01 (1.00 to 1.02) 0.093 1.00 (0.99 to 1.01) 0.621
Neutrophils - per 1 unit increase 1.22 (1.12 to 1.33) <0.001 1.14 (1.05 to 1.24) 0.001
Haemoglobin - per 1 unit increase 0.98 (0.89 to 1.09) 0.722 0.96 (0.88 to 1.06) 0.429
Total cholesterol - per 1 unit increase 1.00 (0.87 to 1.15) 0.955 0.93 (0.82 to 1.06) 0.269
Cardiovascular status
Heart rate - per 1 bpm increase 1.04 (1.02 to 1.05) <0.001 1.02 (1.01 to 1.03) <0.001
Questionnaire data
SGRQ-C - per 4 point increase 1.13 (1.10 to 1.17) <0.001 1.07 (1.03 to 1.10) <0.001
CAT - per 1 point increase 1.09 (1.07 to 1.11) <0.001 1.05 (1.03 to 1.07) <0.001
Musculoskeletal measures
Six-minute walk distance - per 30 metre
decrease
1.19 (1.15 to 1.24) <0.001 1.13 (1.08 to 1.17) <0.001
SPPB score (0-12) - per 1 point decrease 1.14 (1.07 to 1.22) <0.001 1.08 (1.01 to 1.14) 0.019
Functional limitation (SPPB) - yes 1.68 (1.21 to 2.33) 0.002 1.22 (0.91 to 1.64) 0.179
4MGS score (0-4) - per 1 point decrease 1.46 (1.20 to 1.76) <0.001 1.19 (1.00 to 1.41) 0.048
Balance score (0-4) - per 1 point decrease 1.11 (0.93 to 1.33) 0.246 1.07 (0.91 to 1.25) 0.434
Chair stand score (0-4) - per 1 point de-
crease
1.25 (1.11 to 1.40) <0.001 1.14 (1.02 to 1.26) 0.016
QMVC peak - per 1 kg decrease 1.05 (1.03 to 1.07) <0.001 1.02 (1.00 to 1.03) 0.039
Incidence rate ratios were estimated based on negative binomial regression. All analyses were adjusted
for recruitment site. a Adjusted for age and sex b Further adjusted for body mass index, smoking
status, forced expiratory volume in one second, productive cough, and exacerbation history. c P values
based on negative binomial regression.
Variables MRC dyspnoea score and white cell count were omitted due to collinearity. Abbreviations:
CI, confidence intervals. FEV1, forced expiratory volume in one second. GOLD, global initiative for
obstructive lung disease. GFR, glomerular filtration rate. SGRQ-C, St. George respiratory
questionnaire for COPD. CAT, COPD assessment test. 6MW, six-minute walk. SPPB, short physical
performance battery. 4MGS, four-metre gait speed. QMVC, quadriceps maximum voluntary
contraction.
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Model
6MWD − per 30 meter decrease
SPPB − per 1 point decrease
4MGS − per 1 point decrease
Balance − per 1 point decrease
Chair stand − per 1 point decrease
QMVC − per 1 kg decrease
Obs.
669
693
696
698
694
676
IRR [95% CI]
per unit
1.13 [1.08 to 1.17]
1.08 [1.01 to 1.14]
1.19 [1.00 to 1.41]
1.07 [0.91 to 1.25]
1.14 [1.02 to 1.26]
1.02 [1.00 to 1.03]
IRR [95% CI]
per 1SD
1.67 [1.42 to 1.97]
1.19 [1.03 to 1.38]
1.15 [1.00 to 1.33]
1.06 [0.92 to 1.22]
1.19 [1.03 to 1.37]
1.22 [1.01 to 1.47]
0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4
Incidence risk ratio (standardised)
Figure 6.5: Associations of baseline musculoskeletal measures and rate of hospitalised acute
exacerbation of chronic obstructive pulmonary disease in the ERICA cohort. Risk indicated as
incidence risk ratios (IRR). Estimates derived using negative binomial regression. Analyses adjusted for
recruitment site. Age, sex, body mass index, smoking status, forces expiratory volume in one second,
productive cough, and exacerbation history were included as covariates. Abbreviations: Obs, number of
observations included in analysis. IRR, incidence risk ratios. CI, confidence intervals. SD, standard
deviation. 6MWD, six-minute walk distance. SPPB, short physical performance battery. 4MGS,
four-metre gait speed. QMVC, quadriceps maximum voluntary contraction.
Table 6.5: Factors associated with rate of AECOPD-related hospital admission in the stepwise
multivariable model.
Stepwise selection (n = 610)
Factor IRR (95% CI) P value
Sex - male 2.14 (1.55 to 2.96)) <0.001
FEV1 - per 100 ml increase 0.88 (0.85 to 0.91) <0.001
Exacerbation history, ≥1 1.96 (1.39 to 2.76) <0.001
CAT - per 1 point increase 1.03 (1.01 to 1.05) 0.010
Resting heart rate – per 1 bpm increase 1.01 (1.00 to 1.03) 0.025
6MW distance – per 30 metre decrease 1.08 (1.04 to 1.12) <0.001
Adjusted for recruitment site. Abbreviations: IRR, incidence risk ratios. CI, confidence intervals.
FEV1, forced expiratory volume in one second. CAT, COPD assessment test. 6MW, six-minute walk.
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Table 6.6: Factors associated with rate of AECOPD-related hospital admission, by exacerbation
history.
Exacerbation history (n = 439) No exacerbation history (n = 222)
Factor IRR (95% CI) P
value
IRR (95% CI) P
value
P-
value
¶
Sex – male 2.03 (1.43 to 2.87) <0.001 3.80 (1.75 to 8.26) 0.001 0.029
FEV1, – per 100 ml increase 0.87 (0.83 to 0.90) <0.001 0.89 (0.83 to 0.95) 0.001 0.896
Exacerbation history, ≥1 N/A N/A N/A N/A N/A
CAT – per 1 point increase 1.02 (1.00 to 1.05) 0.029 1.04 (1.00 to 1.09) 0.051 0.865
Resting heart rate – per 1
bpm increase
1.01 (1.00 to 1.03) 0.07 1.01 (0.99 to 1.04) 0.363 0.760
6MW distance – per 30 me-
tre decrease
1.06 (1.02 to1.11) 0.005 1.14 (1.05 to 1.23) 0.002 0.174
¶P values of interaction with exacerbation history. Adjusted for recruitment site. Abbreviations: IRR,
incidence risk ratios. CI, confidence intervals. FEV1, forced expiratory volume in one second. CAT,
COPD assessment test. 6MW, six-minute walk.
Table 6.7: Factors associated with rate of AECOPD-related hospital admission, by sex.
Female (n = 257) Male (n = 404)
Factor IRR (95% CI) P
value
IRR (95% CI) P
value
P-
value
¶
Sex – male N/A N/A N/A N/A N/A
FEV1, – per 100 ml increase 0.86 (0.80 to 0.92) <0.001 0.88 (0.84 to 0.91) <0.001 0.607
Exacerbation history, ≥1 3.48 (1.70 to 7.13) 0.001 1.38 (0.95 to 1.99) 0.087 0.030
CAT – per 1 point increase 1.02 (0.99 to 1.06) 0.125 1.03 (1.00 to 1.05) 0.034 0.905
Resting heart rate – per 1
bpm increase
1.03 (1.01 to 1.05) 0.014 1.00 (0.99 to 1.02) 0.567 0.193
6MW distance – per 30 me-
tre decrease
1.06 (1.00 to 1.13) 0.057 1.09 (1.04 to 1.14) <0.001 0.6743
¶P values of interaction with sex. Adjusted for recruitment site. Abbreviations: IRR, incidence risk
ratios. CI, confidence intervals. FEV1, forced expiratory volume in one second. CAT, COPD
assessment test. 6MW, six-minute walk.
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to 1.27, p <0.001) were the strongest associated variables. Stepwise regression, including vari-
ables fully adjusted and significantly associated with hospital length of stay only, retained the
following predictors: age (IRR 1.53 per 10 year increase, 95% CI 1.18 to 1.98, p = 0.001), BMI
(IRR 0.93 per 1 point increase, 95% CI 0.90 to 0.96, p <0.001), glucose (IRR 2.89 per twofold
increase, 95% CI 1.18 to 7.05, p = 0.020), and SPPB (IRR 1.19 per 1 point decrease, 95% CI
1.10 to 1.30, p <0.001; Table 6.9, page 171).
Model
6MWD − per 30 meter decrease
SPPB − per 1 point decrease
4MGS − per 1 point decrease
Balance − per 1 point decrease
Chair stand − per 1 point decrease
QMVC − per 1 kg decrease
Obs.
268
283
284
285
284
276
IRR [95% CI]
per unit
1.14 [1.08 to 1.20]
1.18 [1.10 to 1.27]
1.31 [1.03 to 1.67]
1.45 [1.13 to 1.86]
1.32 [1.16 to 1.49]
1.02 [1.00 to 1.04]
IRR [95% CI]
per 1 SD
1.75 [1.39 to 2.2]
1.49 [1.24 to 1.79]
1.25 [1.02 to 1.53]
1.39 [1.12 to 1.72]
1.46 [1.23 to 1.72]
1.28 [0.99 to 1.65]
0.8 1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4
Incidence risk ratio (standardised)
Figure 6.6: Associations of baseline musculoskeletal measures and hospital length of stay after
admission for acute exacerbation of chronic obstructive pulmonary disease in the ERICA cohort. Risk
indicated as incidence risk ratios (IRR). Estimates derived using negative binomial regression. Analyses
adjusted for recruitment site. Age, sex, body mass index, smoking status, forces expiratory volume in
one second, productive cough, and exacerbation history were included as covariates. Abbreviations:
Obs, number of observations included in analysis. IRR, incidence risk ratios. CI, confidence intervals.
SD, standard deviation. 6MWD, six-minute walk distance. SPPB, short physical performance battery.
4MGS, four-metre gait speed. QMVC, quadriceps maximum voluntary contraction.
6.3.5 Sensitivity analysis for rate of AECOPD-related hospital admission
Overall, IRRs were higher for men and 6MW distance for those with no exacerbation history
(Tables 6.6 6.10, pages 168 and 172). Incidence risk ratios of exacerbation history were higher
for women when stratifying by sex (Tables 6.7 6.11, pages 168 and 173). When testing for
interactions, both exacerbation history and sex were significant.
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Table 6.8: Adjusted multivariable associations with AECOPD length of stay.
5 year (n = 291 individuals with AECOPD)
Baseline characteristics Incidence risk ratio
(95% CI). Adjusted
for age and sex a
P
value c
Incidence risk ratio
(95% CI). Multivari-
able adjusted b
P
value c
Description
Age - per 10 year increase 1.78 (1.45 to 2.20) <0.001 1.83 (1.48 to 2.26) <0.001
Sex - male 0.84 (0.58 to 1.21) 0.354 0.84 (0.56 to 1.26) 0.399
Body mass index - per 1 point increase 0.96 (0.94 to 0.99) 0.011 0.96 (0.93 to 0.99) 0.009
Lung function
FEV1 - per 100 ml increase 0.96 (0.91 to 1.00) 0.063 0.97 (0.93 to 1.02) 0.269
Smoking status - current 1.39 (0.93 to 2.09) 0.11 1.2 (0.78 to 1.87) 0.409
GOLD stage - per increase to next stage 1.14 (0.86 to 1.50) 0.374 1.15 (0.87 to 1.53) 0.335
Exacerbation history (1 year), ≥1 0.63 (0.41 to 0.97) 0.035 0.62 (0.39 to 0.97) 0.037
Productive cough - yes 0.75 (0.34 to 1.66) 0.483 1.12 (0.77 to 1.62) 0.559
Biochemical measures
Glucose - per 1 log unit increase 7.89 (2.67 to 23.33) <0.001 8.78 (2.81 to 27.49) <0.001
Fibrinogen - per 1 log unit increase 2.50 (1.11 to 5.61) 0.027 3.14 (1.37 to 7.18) 0.007
CRP - per 1 log unit increase 1.07 (0.92 to 1.24) 0.407 1.14 (0.97 to 1.35) 0.107
GFR - per 1 unit increase 0.99 (0.98 to 1.00) 0.05 0.98 (0.97 to 1.00) 0.014
Neutrophils - per 1 unit increase 1.07 (0.97 to 1.18) 0.164 1.04 (0.93 to 1.16) 0.525
Haemoglobin - per 1 unit increase 0.94 (0.83 to 1.05) 0.273 0.91 (0.80 to 1.03) 0.134
Total cholesterol - per 1 unit increase 0.93 (0.81 to 1.08) 0.358 0.93 (0.79 to 1.09) 0.349
Cardiovascular status
Heart rate - per 1 bpm increase 1.00 (0.99 to 1.02) 0.478 1.00 (0.98 to 1.01) 0.665
Questionnaire data
SGRQ-C - per 4 point increase 1.00 (0.96 to 1.03) 0.857 1.02 (0.97 to 1.06) 0.449
CAT - per 1 point increase 0.99 (0.97 to 1.01) 0.504 1.00 (0.98 to 1.03) 0.892
Musculoskeletal measures
Six-minute walk distance - per 30 metre
decrease
1.11 (1.05 to 1.16) <0.001 1.14 (1.08 to 1.20) <0.001
SPPB score (0-12) - per 1 point decrease 1.15 (1.06 to 1.24) <0.001 1.18 (1.10 to 1.27) <0.001
Functional limitation (SPPB) - yes 1.84 (1.27 to 2.68) 0.001 2.01 (1.37 to 2.94) <0.001
4MGS score (0-4) - per 1 point decrease 1.29 (1.01 to 1.65) 0.045 1.31 (1.03 to 1.67) 0.029
Balance score (0-4) - per 1 point decrease 1.44 (1.12 to 1.84) 0.004 1.45 (1.13 to 1.86) 0.003
Chair stand score (0-4) - per 1 point de-
crease
1.24 (1.09 to 1.40) 0.001 1.32 (1.16 to 1.49) <0.001
QMVC peak - per 1 kg decrease 1.03 (1.01 to 1.05) 0.002 1.02 (1.00 to 1.04) 0.056
Incidence rate ratios were estimated based on negative binomial regression. All analyses were adjusted
for recruitment site. a Adjusted for age and sex b Further adjusted for body mass index, smoking
status, forced expiratory volume in one second, productive cough, and exacerbation history. c P values
based on negative binomial regression.
Variables MRC dyspnoea score and white cell count were omitted due to collinearity. Abbreviations:
CI, confidence intervals. FEV1, forced expiratory volume in one second. GOLD, global initiative for
obstructive lung disease. GFR, glomerular filtration rate. SGRQ-C, St. George respiratory
questionnaire for COPD. CAT, COPD assessment test. 6MW, six-minute walk. SPPB, short physical
performance battery. 4MGS, four-metre gait speed. QMVC, quadriceps maximum voluntary
contraction.
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Table 6.9: Factors associated with AECOPD-related hospital admission length of stay in the stepwise
multivariable model.
Stepwise selection (n = 233)
Factor IRR (95% CI) P value
Age - per 10 year increase 1.53 (1.18 to 1.98) 0.001
BMI - per 1 point increase 0.93 (0.90 to 0.96) <0.001
Glucose - per twofold increase 2.89 (1.18 to 7.05) 0.020
SPPB - per 1 point decrease 1.19 (1.10 to 1.30) <0.001
Adjusted for recruitment site. Abbreviations: BMI, body mass index. SPPB, short physical
performance battery. IRR, incidence risk ratio. CI, confidence interval.
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Table 6.10: Adjusted multivariate associations with AECOPD frequency, by exacerbation history.
5 year (n = 714, of whom 291 had AECOPD)
Exacerbation history (n = 473) No exacerbation history (n = 236)
Baseline characteristics Incidence risk ratio
(95% CI). Multivari-
able adjusted a
P
value b
Incidence risk ratio
(95% CI). Multivari-
able adjusted a
P
value b
Description
Age - per 10 year increase 0.90 (0.74 to 1.09) 0.283 0.69 (0.47 to 1.02) 0.063
Sex - male 2.05 (1.46 to 2.89) <0.001 5.39 (2.55 to 11.41) <0.001
Body mass index - per 1 point increase 0.98 (0.96 to 1.01) 0.128 1.08 (1.02 to 1.15) 0.01
Lung function
FEV1 - per 100 ml increase 0.85 (0.82 to 0.88) <0.001 0.80 (0.75 to 0.86) <0.001
Smoking status - current 1.07 (0.75 to 1.52) 0.723 1.10 (0.58 to 2.11) 0.762
GOLD stage - per increase to next stage 2.17 (1.73 to 2.74) <0.001 3.74 (2.36 to 5.93) <0.001
Exacerbation history (1 year), ≥1
Productive cough - yes 1.14 (0.84 to 1.56) 0.408 1.23 (0.63 to 2.42) 0.539
Biochemical measures
Glucose - per 1 log unit increase 1.71 (0.57 to 5.10) 0.337 2.50 (0.36 to 17.33) 0.353
Fibrinogen - per 1 log unit increase 1.98 (0.99 to 3.97) 0.055 1.96 (0.44 to 8.60) 0.375
CRP - per 1 log unit increase 1.18 (1.03 to 1.35) 0.018 0.90 (0.66 to 1.22) 0.5
GFR - per 1 unit increase 1.00 (0.99 to 1.01) 0.458 0.99 (0.97 to 1.01) 0.264
Neutrophils - per 1 unit increase 1.15 (1.06 to 1.26) 0.002 1.07 (0.88 to 1.30) 0.518
Haemoglobin - per 1 unit increase 0.95 (0.86 to 1.05) 0.302 1.12 (0.88 to 1.41) 0.358
Total cholesterol - per 1 unit increase 0.95 (0.83 to 1.10) 0.497 1.01 (0.72 to 1.40) 0.969
Cardiovascular status
Heart rate - per 1 bpm increase 1.02 (1.01 to 1.03) 0.003 1.02 (0.99 to 1.05) 0.122
Questionnaire data
SGRQ-C - per 4 point increase 1.07 (1.03 to 1.11) 0.001 1.07 (1.00 to 1.15) 0.037
CAT - per 1 point increase 1.04 (1.02 to 1.06) <0.001 1.07 (1.02 to 1.11) 0.004
Musculoskeletal measures
Six-minute walk distance - per 30 metre
decrease
1.11 (1.06 to 1.16) <0.001 1.16 (1.06 to 1.26) 0.001
SPPB score (0-12) - per 1 point decrease 1.11 (1.04 to 1.19) 0.003 0.94 (0.80 to 1.10) 0.435
Functional limitation (SPPB) - yes 1.40 (1.01 to 1.95) 0.046 0.81 (0.43 to 1.54) 0.524
4MGS score (0-4) - per 1 point decrease 1.28 (1.07 to 1.54) 0.008 0.82 (0.48 to 1.42) 0.476
Balance score (0-4) - per 1 point decrease 1.13 (0.95 to 1.35) 0.175 0.71 (0.45 to 1.12) 0.14
Chair stand score (0-4) - per 1 point de-
crease
1.18 (1.05 to 1.33) 0.006 1.02 (0.82 to 1.28) 0.827
Incidence rate ratios were estimated based on negative binomial regression. All analyses were stratified
by recruitment centre and exacerbation history. a Adjusted for age, sex, body mass index, smoking
status, forced expiratory volume in one second, and productive cough. b P values based on negative
binomial regression.
Variables MRC dyspnoea score and white cell count were omitted due to collinearity. Abbreviations:
CI, confidence intervals. FEV1, forced expiratory volume in one second. GOLD, global initiative for
obstructive lung disease. GFR, glomerular filtration rate. SGRQ-C, St. George respiratory
questionnaire for COPD. CAT, COPD assessment test. 6MW, six-minute walk. SPPB, short physical
performance battery. 4MGS, four-metre gait speed. QMVC, quadriceps maximum voluntary
contraction.
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Table 6.11: Adjusted multivariate associations with AECOPD frequency, by sex.
5 year (n = 714, of whom 291 had AECOPD)
Male (n = 434) Female (n = 280)
Baseline characteristics Incidence risk ratio
(95% CI) a
P
value b
Incidence risk ratio
(95% CI) a
P
value b
Description
Age - per 10 year increase 0.89 (0.72 to 1.11) 0.313 0.77 (0.58 to 1.02) 0.073
Sex - male
Body mass index - per 1 point increase 1.02 (0.99 to 1.06) 0.237 0.98 (0.95 to 1.01) 0.242
Lung function
FEV1 - per 100 ml increase 0.84 (0.81 to 0.87) <0.001 0.81 (0.76 to 0.87) <0.001
Smoking status - current 0.87 (0.57 to 1.32) 0.502 1.51 (0.96 to 2.36) 0.073
GOLD stage - per increase to next stage 2.87 (2.21 to 3.73) <0.001 2.01 (1.41 to 2.87) <0.001
Exacerbation history (1 year), ≥1 1.50 (1.03 to 2.18) 0.033 3.45 (1.78 to 6.67) <0.001
Productive cough - yes 1.05 (0.72 to 1.51) 0.81 1.19 (0.78 to 1.82) 0.409
Biochemical measures
Glucose - per 1 log unit increase 0.66 (0.19 to 2.31) 0.516 6.67 (1.68 to 26.56) 0.007
Fibrinogen - per 1 log unit increase 1.42 (0.61 to 3.3) 0.412 2.96 (1.08 to 8.14) 0.035
CRP - per 1 log unit increase 1.08 (0.92 to 1.26) 0.373 1.18 (0.97 to 1.45) 0.104
GFR - per 1 unit increase 1.00 (0.99 to 1.01) 0.69 1.00 (0.99 to 1.02) 0.947
Neutrophils - per 1 unit increase 1.01 (0.90 to 1.13) 0.899 1.30 (1.16 to 1.46) <0.001
Haemoglobin - per 1 unit increase 0.96 (0.86 to 1.08) 0.525 0.93 (0.78 to 1.10) 0.383
Total cholesterol - per 1 unit increase 0.93 (0.79 to 1.10) 0.403 0.93 (0.76 to 1.13) 0.469
Cardiovascular status
Heart rate - per 1 bpm increase 1.01 (1.00 to 1.03) 0.082 1.03 (1.01 to 1.05) 0.001
Questionnaire data
SGRQ-C - per 4 point increase 1.06 (1.02 to 1.11) 0.004 2.40 (1.54 to 3.74) <0.001
CAT - per 1 point increase 1.05 (1.02 to 1.08) <0.001 1.06 (1.01 to 1.11) 0.023
Musculoskeletal measures
Six-minute walk distance - per 30 metre
decrease
1.12 (1.07 to 1.18) <0.001 1.04 (1.01 to 1.08) 0.005
SPPB score (0-12) - per 1 point decrease 1.03 (0.94 to 1.12) 0.546 1.15 (1.05 to1.26) 0.002
Functional limitation (SPPB) - yes 1.03 (0.71 to 1.50) 0.876 1.70 (1.05 to 2.73) 0.029
4MGS score (0-4) - per 1 point decrease 1.09 (0.84 to 1.40) 0.527 1.40 (1.10 to 1.78) 0.007
Balance score (0-4) - per 1 point decrease 0.95 (0.71 to 1.27) 0.732 1.11 (0.91 to 1.35) 0.303
Chair stand score (0-4) - per 1 point de-
crease
1.06 (0.93 to 1.21) 0.378 1.35 (1.13 to 1.61) 0.001
Incidence rate ratios were estimated based on negative binomial regression. Analyses were stratified by
recruitment centre and sex. a Adjusted for age, body mass index, smoking status, forced expiratory
volume in one second, productive cough, and exacerbation history. b P values based on negative
binomial regression.
¶Variables MRC dyspnoea score and white cell count were omitted due to colinearity. Abbreviations:
CI, confidence intervals. FEV1, forced expiratory volume in one second. GOLD, global initiative for
obstructive lung disease. GFR, glomerular filtration rate. SGRQ-C, St. George respiratory
questionnaire for COPD. CAT, COPD assessment test. 6MW, six-minute walk. SPPB, short physical
performance battery. 4MGS, four-metre gait speed. QMVC, quadriceps maximum voluntary
contraction.
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6.4 Discussion
This is the first study demonstrating the potential use of SPPB in predicting AECOPD-related
hospital admission. In addition, 6MW distance, known to predict mortality in individuals with
COPD, was found to be associated with AECOPD-related hospital admission, after adjusting for
common and known predictive covariates. Our findings show that multiple measures including
multiple exercise capacity traits were associated with both AECOPD-related hospital admission
rate and duration. The strongest associated measure for admission, however, was lung function
measured as FEV1, or GOLD stage as defined by FEV1% predicted. For AECOPD-related
hospital duration, both SPPB and 6MW distance, following age, were the strongest associated
measures. Sensitivity analysis indicated that 6MW distance might potentially be more useful
in predicting admission rate in males and those with no history of exacerbation. Exacerbation
history is known to reliably predict future risk of AECOPD including hospital admissions. In
our cohort, women had a significantly higher number of previous exacerbations at baseline
compared to men. In addition, exacerbation history was stronger associated with AECOPD-
related admission for women than men and therefore may be more useful for future prediction
of AECOPD-related hospital admission in women.
Over a study period of five years, over 40% had at least one admission with nearly one fifth of
the cohort experiencing multiple visits. In addition, many individuals had readmissions within
six months after initial admission, with an equal amount of time spent in hospital as the initial
admission. Of those readmitted, about 20% died within the first year after initial admission.
Unfortunately, the study was not designed to evaluate the associations between baseline variables
and hospital readmission but considering the high number of readmissions and deaths following
AECOPD-related admission, monitoring individuals at set intervals to identify those at high-
risk could prove useful allowing timely intervention and preventing or minimising the number
of readmission and premature mortality. Recently EDGE, for example, a mobile self-managing
COPD platform has been introduced to monitor symptoms including heart rate to recognise and
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start treatment of exacerbations early.90
The 6MW test is a reflection of cardiovascular status, in addition to lower limb function
(i.e. musculoskeletal function), but perhaps also a good proxy measure of overall health. The
6MW test, however, has received limited adoption in clinical practice. The 4MGS – a test of
lower limb function – being faster and more practical than the 6MW performed slightly less well
than the 6MW, but might have more potential in clinical practice when considering the clinical
practicalities.
This study has several limitations. Hospital episode statistics were obtained from the NHS
Digital (England), NHS Scotland and NHS Wales. Apart from admission and discharge dates,
we did not have spell data (i.e. total continuous stay and use of a hospital bed) available for
individuals registered with the NHS Scotland and NHS Wales. The study period covered the
time from study enrolment until the end of study, or death. Some individuals, however, may
have been admitted to hospital for AECOPD shortly before study enrolment and these events
will have not been electronically captured but potentially through self-reported exacerbation
history. Although, self-reported data is known to suffer from recall bias.96 Due to the limited
number of events we were unable to stratify by GOLD stage (i.e. indicator of disease severity),
exacerbation history, and sex to assess the association between baseline measures and AECOPD-
related hospital stay (i.e. duration) for those admitted to hospital. Also, we explored for non-
linearity of variables considered but had not enough power to identify any difference. For SPPB
scores, a majority of individuals scored towards the highest possible score. Despite this, a high
proportion of individuals with COPD had physical limitations but it may indicate that SPPB is
not sensitive enough to discriminate sufficiently between those with and without the event. There
were differences for most measures between recruitment sites. For example, individuals from
London were slightly healthier compared to other sites, and individuals from Cardiff had more
severe lung disease; however we caution that the departments at each of the five participating
hospitals had variations in practice making analysis in difference in prognosis between sites of
doubtful value. We addressed this by adjusting for recruitment site in our analyses. Even
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though the ERICA study included participants from centres throughout the UK, the cohort
consisted primarily of individuals GOLD staged II-III. This limits generalising results to those
with mild or advanced COPD. Future studies, using larger cohorts and/or different geographical
populations, should replicate our findings. Missing data was present, reducing the overall sample
size and statistical power limiting to make robust conclusions. In order to optimise the analysis,
we included as many observations as possible and reported the number of observations included
in each analysis. Analyses were adjusted for productive cough, believed to be an indicator of
inflammation. A large proportion had productive cough on most mornings but there was no
significant association with the outcomes in our cohort. According to Hurst and colleagues,
WCC and MRC dyspnoea score were found to be significantly associated with AECOPD.132
We excluded these variables from the analysis due to collinearity, allowing us to evaluate the
association of novel exercise capacity traits with the outcomes of interest.
This study has several strengths. Firstly, individuals were clinically stable upon recruitment.
Secondly, event rates were stable throughout the study period, which is not only encouraging
but also rates were comparable to those in large cohort studies including Evaluation of COPD
Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE).270 Hospital admissions
were identified using validated criteria, and only definite and possible episodes were included
in the analysis. In contrast to self-reported hospital admission, which may suffer from under-
reporting,203,236 AECOPD episodes were captured using electronic health record data. Individu-
als had different observation periods. The use of study inclusion and admission (i.e. event) dates
allowed to adjust for exposure time and therefore used the correct probability distributions.
Considering that both the SPPB and 6MW distance were associated with admission rate
and duration, one potential scenario would include to use both tests to determine the physical
capacity of an individual whilst assessing their risk of hospital admission rate within five years,
and their hospital length of stay for initial AECOPD-related admission. It has been shown that
exercise capacity can be improved through pulmonary rehabilitation, and is known to positively
impact hospital utilisation. Exercise capacity traits such as the SPPB and 6MW may be good
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candidates for training purposes, in addition to assessing an individual′s exercise capacity. Of
these two, the SPPB is clinically more practical than 6MW, as there is often too little time
available in clinic to perform a 6MW test and often patients are in need of additional oxygen.
In addition, those who are very ill might have difficulty completing the 6MW test due to the
intensity and physical impact. Our results show, however, no causality but merely an association
between musculoskeletal strength and AECOPD admission and length of stay.
Future studies, using larger cohorts, should assess the predictive value of exercise capacity
traits including SPPB and its component 4MGS, and the 6MW test, and demonstrate if physical
training such as strengthening of the quadriceps improves pulmonary outcomes. In addition,
evaluating these measures repeatedly at different time intervals would allow estimation of the
association between AECOPD-related hospital admission rate, duration, and readmission at
different time points.
6.5 Conclusions
There is potential for the use of SPPB in predicting AECOPD-related hospital admission and
length of hospital stay within a COPD population with moderate to severe disease. The SPPB
is a measure requiring low commitment that could be measured routinely.
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Do arterial stiffness or carotid intima-media thickness
improve on a Framingham approach when predicting
cardiovascular disease in COPD?
Chapter summary
Background Individuals with chronic obstructive pulmonary disease (COPD) have increased
risk of fatal and non-fatal cardiovascular disease. Cardiovascular risk is traditionally predicted
using ′Framingham′ risk factors (age, sex, smoking, high-density lipoprotein, total cholesterol,
systolic blood pressure, diabetes, and the prescription of drugs to treat cardiovascular disease).
However, newer measures, specifically arterial stiffness and carotid intimal thickness are thought
to better capture systemic disease, and therefore may better identify high-risk individuals. Here
we aimed to evaluate these measures against Framingham′ risk factors for the prediction of
cardiovascular events in a UK COPD population.
179
Methods Clinical data from the Evaluation of the Role of Inflammation in Chronic Airways
disease (ERICA) cohort were linked with UK National Health Services electronic health record
data, with cardiovascular events identified using ICD-10 coding. Non-fatal cardiovascular events
were obtained from the UK Office for National Statistics, and adjudicated by cardiovascular and
respiratory physicians. Associations were estimated using stratified multivariable Cox regression,
and assessed by C-indices with 10-fold cross-validation and replication.
Findings Out of 714 individuals, 237 (33%) had at least one cardiovascular event during
median follow-up of 4.5 years. Of the Framingham risk factors, age (hazard ratio (HR) 1.40 per
10-year increase, 95% CI 1.16 to 1.70), systolic blood pressure (HR 0.92 per 10 mmHg increase,
95% CI 0.84 to 0.99), self-reported diabetes (HR 3.07, 95% CI 2.21 to 4.27), and self-report
use of drugs to treat cardiovascular disease (HR 2.10, 95% CI 1.52 to 2.90) were significantly
associated with mortality. Measures of arterial stiffness and carotid intima-media thickness were
not associated with cardiovascular events. Measures of exercise capacity four-metre gait speed
(HR 1.07 per one sec. increase; C = 0.717) and six-minute walk distance (HR 0.91 per 30 metre
increase; C = 0.728) were significantly associated with cardiovascular disease and improved the
discriminative ability when added to Framingham risk factors.
Interpretation Our data does not support the use of objective measures of arterial stiff-
ness and carotid intima-media thickness in addition to Framingham risk factors for predicting
cardiovascular events within COPD. Similarly, blood pressure measurement and smoking status
do neither add to the predictive ability of Framingham within the ERICA cohort. Age, systolic
blood pressure, diabetes and cardiovascular drugs, and exercise capacity measures four-metre
gait speed and six-minute walk distance are predictive. Moreover, despite the presence of car-
diovascular disease, cardiac death is not common in patients with COPD. This may reflect a
downward trend in fatal cardiovascular disease incidence/ improved cardiovascular survival, or
an increased prevalence of death from respiratory causes.
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7.1 Background
Chronic obstructive pulmonary disease (COPD) leads to a higher risk of cardiovascular (CV)
disease, increasing the risk of non-fatal CV disease 2.5 times and a third dying of cardiac
causes.46,174 Reduced lung function is associated with systemic inflammation.276 The elevated
CV risk in COPD may be explained by the increased inflammatory burden and consequential
effects leading to aortic stiffness and increased arteriosclerosis load. Current CV disease risk
prediction algorithms focus mostly on the classical Framingham risk factors: age, sex, smoking,
high-density lipoprotein (HDL), total cholesterol, systolic blood pressure (SBP, diabetes, and
the use of drugs to treat CV disease.62 The Framingham risk score predicts an individual′s 10-
year risk of coronary heart disease, peripheral artery disease, and heart failure and improves the
prediction of CV events and premature death.156
The predictive ability of the Framingham risk factors, the inclusion of alternative markers,
and the comparison of the discriminative ability of Framingham with alternative measures has
been evaluated in various population groups including elderly70 and a multitude of comorbidities
including diabetes,143 metabolic syndrome,279 and chronic kidney disease.283 How Framingham
risk factors and several other biomarkers for CV disease perform in a COPD population, however,
is unclear.
Elevated pulse wave velocity (PWV), a measure of aortic stiffness, has been reported in
patients with COPD,94 but its predictive value is not known. Likewise, other proxy measures of
arterial stiffness augmentation index (AIx) and carotid intima-media thickness (CIMT) are also
predictors in some populations and have the potential of clinically predicting CV disease. Both
arterial stiffness and CIMT are predictors of CV disease in the general population.119,162,258
Adding these to the Framingham Risk Score was found to provide, albeit minor, improvement
in the predictive ability.73 Using these alternative measures, in particular measures of arterial
stiffness, is thought to identify high-risk patients in an early stage of disease, which in turn
could lead to opportunities to slow disease progression and to support decision makers in their
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judgements regarding treatment planning and resource allocation. Evidence across several small
studies, taken together, suggests that measures of arterial stiffness are worth further investigation
but conclusive evidence is lacking.91
Thus, the aims of our study were firstly to determine incidence of fatal- and non-fatal CV
disease, and evaluate the association of classical Framingham risk factors and with subsequent
fatal and non-fatal CV events in stable Global initiative for chronic Obstructive Lung Disease
(GOLD) stage II-IV107 COPD patients using clinical data from the Evaluation of the Role of
Inflammation in Chronic Airways disease (ERICA) cohort and UK electronic health record data.
Secondly, we aimed to determine the association of measures of arterial stiffness and CIMT, and
incident CV disease, and assess their added value above and beyond Framingham risk factors.
Lastly, we used the opportunity to determine the association of alternative measures including
musculoskeletal function, thought to better capture systemic problems, and CV disease, and
their added value above and beyond Framingham risk factors.
7.2 Methods
7.2.1 Study design and participants
The ERICA study is a multi-centre observational, non-interventional, epidemiological cohort
study, with 729 stable GOLD stage II-IV107 COPD patients, established to identify important
CV and musculoskeletal biomarkers that could be targeted to improve the outcomes of COPD
patients. Full details of the protocol have been provided elsewhere.184 Data captured included
demographics, pulmonary function measures, biochemical markers, measures of arterial stiffness
(i.e. PWV, AIx, and CIMT), and measures of musculoskeletal function (i.e. four-metre gait speed
(4MGS) and six-minute walk (6MW) test).
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7.2.2 Clinical measures
After four hours of fasting, with no bronchodilators for six hours, and ten minutes of supine
rest CV measures were taken using an SphygmoCor system. Pulse wave velocity (i.e. velocity of
blood pressure pulse) was measured between the femoral and carotid arteries, and the average
of two measurements was taken, as described by Wilkinson et al.,286 Carotid intima-media
thickness (i.e. extend of arteriosclerotic process) of the common carotid arteries was measured
using B-mode ultrasound at a distance of 1 cm from the carotid bulb with a 7–12 MHz linear
probe to estimate the extent of atherosclerosis for each individual.61 For each artery 3 x 10 sec.
loops were recorded. The thickest artery of the two was included in the analysis. Augmentation
index was derived from the ascending aortic pressure waveform.
Diabetes status and use of drugs for CV disease treatment were self-reported and captured at
baseline. Cardiovascular disease-related treatment included drugs such as simvastatin, warfarin,
eplerenone, bendroflumethiazide, digoxin, and ramipril. Disease severity was defined according
to GOLD classification.107 Points for the BODE Index, which generates a composite score from
the Body mass index (BMI), airflow Obstruction, Dyspnoea, and Exercise capacity, with the
latter measured by the 6MW test, were assigned as described by Celli et al.40
7.2.3 Cardiovascular events
Clinical data were linked to electronic healthcare records (i.e. admitted patient care data) ob-
tained from the UK National Health Service (NHS) Digital, NHS Scotland, and NHS Wales.
Non-fatal CV events were extracted from both primary and secondary international statistical
classification of diseases and related health problems 10th revision coding (ICD-10) positions,
and included diseases of the arteries, all stroke, and heart failure (Table 7.1, page 184). Atrial
fibrillation and flutter, and hypertensive diseases were excluded. Fatal events were obtained
from the UK Office for National Statistics (ONS) and cardiac deaths were adjudicated by CV
and respiratory physicians.
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Table 7.1: Definitions of diagnoses by ICD-10 coding.
End point ICD-10 codes
All cardiovascular disease E10.5, E11-E14, F01, G46.3-G46.7, G458, G459
I11.0, I13.0, I13.2, I20.0-I20.1, I20.8-I21-I25, I50, I60, I61, I.62,
I63, I64, I65-I69, I70.2, I71.3-I71.9, I72, I73.9-I79, R96 + cardiac
death
Diseases of the arteries I70.2, I72, I73.9-I79, E10.5, E11-E14
Peripheral arterial disease I70.2, I73.9, E10.5, E11-E14
Diseases of arteries, arterioles and capillaries I72, I74-I79
Coronary heart disease I20.0-I20.1, I20.8-I21-I25
Angina I20.1, I20.8-I20.9
Unstable angina I20.0, I24
Coronary heart disease not otherwise specified I25
Acute myocardial infarction (MI), and certain cur-
rent complications following acute MI
I21, I23
Subsequent myocardial infarction I22
All stroke I60, I61, I.62, I63, I64, I65-I69, F01, G46.3-G46.7, G458, G459
Subarachnoid haemorrhage I60
Intra-cerebral haemorrhage I61
Cerebral infarction I63
Stroke, not specified as haemorrhage or infarction I64
Stroke syndromes G46.3-G46.7
Transient ischaemic attack G458, G459
Other stroke I62, I65-I69, F01
Heart failure I11.0, I13.0, I13.2, I50
Heart failure I50
Hypertensive heart disease with (congestive)
heart failure
I11.0
Hypertensive heart and renal disease with (con-
gestive) heart failure
I13.0
Hypertensive heart and renal disease with both
(congestive) heart failure and renal disease
I13.2
Cardiac death Adjudicated
Other vascular deaths R96, I71.3-I71.9
Sudden death, cause unknown R96
Abdominal aortic aneurysm I71.3-I71.9
Atrial fibrillation and flutter (I48) and hypertensive diseases (I10-I15) were considered risk factors and
therefore not included.
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7.2.4 Outcomes and predictors of interest
The primary outcome measure was defined as the new occurrence (first event) of fatal or non-fatal
CV disease. Time to event was calculated from the difference between the baseline visit date and
either the date of death or first CV event up to November 2017, when follow-up discontinued.
The association between Framingham risk factors (i.e. age, sex, smoking, HDL, total cholesterol,
systolic blood pressure, diabetes, and the use of drugs to treat CV disease) and CV disease were
evaluated. In addition, measures of arterial stiffness, CIMT and alternative measures thought
to better capture systemic disease, and CV disease and their added value above and beyond
Framingham risk factors were evaluated.
7.2.5 Statistical analysis
Hazard ratios (HRs) were estimated using Cox regression, stratified by recruitment centre, and
adjusted for age and sex. In addition, PWV was adjusted for mean arterial pressure (MAP) and
heart rate, and AIx was adjusted for heart rate and height. Further analyses included Framing-
ham risk factors as covariates. Discrimination (i.e. Harrell′s C-statistic)10,202 was assessed using
10-fold cross validation with 200 replications.245 Hazard ratios for log-transformed biomarkers
represent a twofold increase in the biomarker. Associations between the clinical measures were
quantified using Spearman’s rank correlations, with values <0.30 considered as weak, 0.30-0.50
as moderate, and >0.50 as strong.51
There were missing values. Data were assessed for the level and type of missing data, and
completion patterns (Figures 3.1 3.2, pages 61 and 62). There were about 10% missing values
for variables CIMT (n = 66) and PWV (n = 60), with <5% missing values for other variables.
Missing values were addressed using multiple imputations using chained equations (MICE). The
time-to-event outcome was included using the non-parametric Nelson-Aalen estimator. Predic-
tive mean matching was used for continuous variables, ordered logistic regression (as continuous)
for ordinal variables, multinomial logistic regression for categorical variables, and logistic regres-
sion for binary variables. Derived variables such as the BODE Index (a composite score of BMI,
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forced expiratory volume in one second (FEV1), Medical Research Council dyspnoea score, and
6MW distance) and GOLD stage were estimated post MICE using passive imputation. Observa-
tional data is reported according to the Strengthening The Reporting of OBservational Studies
in Epidemiology (STROBE) statement.275
7.3 Findings
7.3.1 Descriptive statistics
Of the 729 individuals included in the study, 714 were linkable with hospital admission and sur-
vival records, and included in the analysis (Figure 3.4, page 64). The mean age was 67 years
old (range 43-89 years) and 434 (61%) individuals were male. A third of the cohort smoked, and
402 individuals (56%) were taking CV drugs at baseline. Median (interquartile range (IQR))
SBP was 142 mmHg (131-154), PWV 9.8 m/sec (8.4-11.8), CIMT 0.81 (0.71-0.96), and AIx
28% (20-34; Tables 7.1 7.2 7.3, pages 184-187). Baseline characteristics have been reported
in Figures 3.25 3.26 3.27, pages 79-80.
7.3.2 Association of Framingham risk factors with CV events, and their predictive
value
In total, six individuals had a fatal CV event and 231 individuals (33%) experienced a non-
fatal CV event during median follow up for 4.5 years. The CV incidence rate was 8.8 (95% CI
7.7 to 10.0) per 100 person-years. Of the Framingham risk factors, only age, SBP, and self-
reported diabetes and use of drugs to treat CV disease were significantly associated with CV
events (Figure 7.1 and Table 7.2, pages 189 and 187). Systolic blood pressure was negatively
associated with CV disease; primarily for those with mild COPD (HR 0.88, 95% CI 0.78 to 0.99,
p = 0.030; aged 70 years and above (HR 0.87, 95% CI 0.78 to 0.97, p = 0.012; taking CV drugs
(HR 0.86, 95% CI 0.78 to 0.95, p = 0.003), and males (HR 0.87, 95% CI 0.79 to 0.96, p = 0.007).
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Table 7.2: Hazard ratios for cardiovascular disease with measured baseline levels of risk factors.
Median (IQR) or
n (%)
HR (95% CI) a P value HR (95% CI) b P value
Framingham risk factors
Age - per 10 year increase 67 (62-73) 1.50 (1.26 to 1.78) <0.001 1.40 (1.16 to 1.70) <0.001
Sex - males 434 (61) 1.16 (1.02 to 1.06) 0.282 1.17 (0.88 to 1.56) 0.283
Smoking - current 218 (31) 0.93 (0.69 to 1.25) 0.641 0.93 (0.69 to 1.26) 0.654
HDL - per 1 mmol/L in-
crease
1.4 (1.2-1.7) 0.61 (0.44 to 0.85) 0.003 0.94 (0.67 to 1.31) 0.721
Total cholesterol - per 1
mmol/L increase
5.0 (4.3-5.8) 0.71 (0.63 to 0.81) <0.001 0.94 (0.82 to 1.08) 0.392
SBP - per 10 mmHg increase 142 (131-154) 0.92 (0.85 to 0.99) 0.023 0.92 (0.84 to 0.99) 0.031
Diabetes - yes 82 (12) 4.18 (3.11 to 5.63) <0.001 3.07 (2.21 to 4.27) <0.001
CV drug treatment - yes 402 (56) 2.61 (1.94 to 3.52) <0.001 2.10 (1.52 to 2.90) <0.001
Values are given as the median and interquartile range (IQR), or No. of cases (%). Baseline data of 714
patients are included. All models are stratified by recruitment site.
a Adjusted for age and sex
b Adjusted for Framingham risk factors: age, sex, smoking, high-density lipoprotein, total cholesterol,
systolic blood pressure, diabetes, cardiovascular drug treatment. Abbreviations: CI, confidence interval.
HDL, high-density lipoprotein. SBP, systolic blood pressure. CV, cardiovascular.
Table 7.3: Hazard ratios for cardiovascular disease with measured baseline levels of risk factors.
Median (IQR) or
n (%)
HR (95% CI) a P value HR (95% CI) b P value
Measures of arterial
stiffness
PWV - per 1 m/sec increase 9.8 (8.4-11.8) 1.04 (0.98 to 1.10) 0.171 0.99 (0.93 to 1.06) 0.843
CIMT - per 1 mm increase 0.81 (0.71-0.96) 1.27 (0.62 to 2.60) 0.512 1.22 (0.58 to 2.54) 0.602
AIx - per 5% increase 28 (20-34) 0.85 (0.78 to 0.92) <0.001 0.93 (0.85 to 1.02) 0.129
Values are given as the median and interquartile range (IQR), or No. of cases (%). Baseline data of 714
patients are included. All models are stratified by recruitment site.
a Adjusted for age and sex
b Adjusted for Framingham risk factors: age, sex, smoking, high-density lipoprotein, total cholesterol,
systolic blood pressure, diabetes, cardiovascular drug treatment.
PWV further adjusted for mean arterial pressure and resting heart rate. AIx further adjusted for
resting heart rate and height. Abbreviations: CI, confidence interval. PWV, pulse wave velocity.
CIMT, carotid intima-media thickness. AIx, augmentation index.
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The discriminative ability of all Framingham risk factors combined had a C-statistic of 0.701,
95% CI 0.695 to 0.706). Self-reported use of CV drugs (C = 0.638, 95% CI 0.630 to 0.647) and
diabetes (C = 0.616, 95% CI 0.607 to 0.622) followed by age (C = 0.594, 95% CI 0.588 to 0.602)
contributed most to the discriminative ability.
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7.3.3 Association of arterial stiffness measures with CV events, and their predictive
value
Except for the AIx (HR 0.85 per 5% increase, 95% CI 0.78 to 0.92, p <0.001), none of the arterial
stiffness measures were significantly associated with CV disease, after adjustment for age and sex
(Figure 7.2 and Table 7.3, pages 191 and 187). After further adjustment for Framingham risk
factors neither was AIx. Arterial stiffness did not statistical significantly change discriminative
ability of Framingham.
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7.3.4 Association of alternative measures with CV events, and their predictive value
Multivariable analysis identified several alternative measures that were associated with CV
events (Figure 7.3 and Table 7.4, pages 193 and 194). Inflammatory markers C-reactive
protein (CRP; HR 1.11 per twofold increase, 95% CI 1.02 to 1.21, p = 0.013) and fibrinogen
(HR 1.59 per twofold increase, 95% CI 1.07 to 2.39, p = 0.023), blood glucose (HR 1.94 per
twofold increase, 95% CI 1.07 to 3.52, p = 0.030), BMI (HR 1.04 per 1 kg/m2 increase, 95%
CI 1.01 to 1.06, p = 0.002), and FEV1 as GOLD stage (HR 1.27 per 1 stage increase, 95%
CI 1.04 to 1.56, p = 0.021) were associated with a higher risk of CV events. Musculoskeletal
measures 4MGS (HR 0.72 per 1 second increase, 95% CI 0.71 to 0.72, p = 0.009) and 6MW
distance (HR 0.73 per 30 metre increase, 95% CI 0.72 to 0.73, p <0.001) were associated with
a lower risk of CV events. Predictive modelling indicated statistical significant improvement in
risk discrimination when adding 4MGS (C = 0.717, 95% CI 0.712 to 0.722) or 6MW distance (C
= 0.728, 95% CI 0.723 to 0.733) to the Framingham risk factors. Adding BMI, 4MGS, 6MW,
and BODE all together to the Framingham risk factors resulted in a C-index of 0.731 (95% CI
0.727 to 0.737).
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Table 7.4: Hazard ratios for cardiovascular disease with measured baseline levels of risk factors.
Median (IQR) or
n (%)
HR (95% CI) a P value HR (95% CI) b P value
Other risk factors
CRP - per twofold increase 1.21 (0.47 to 2.01) 1.13 (1.05 to 1.23) 0.002 1.11 (1.02 to 1.21) 0.013
Fibrinogen - per twofold in-
crease
1.22 (1.06 to 1.36) 1.71 (1.15 to 2.56) 0.009 1.59 (1.07 to 2.39) 0.023
Glucose - per twofold in-
crease
1.59 (1.50 to 1.69) 2.40 (1.33 to 4.33) 0.004 1.94 (1.07 to 3.52) 0.03
BMI - per 1 kg/m2 increase 27 (23-31) 1.07 (1.04 to 1.09) <0.001 1.04 (1.01 to 1.06) 0.002
GOLD - per 1 stage increase 1 (1-2) 1.19 (0.98 to 1.45) 0.083 1.27 (1.04 to 1.56) 0.021
4MGS - per 1 second in-
crease
4.2 (3.5-5.2) 1.10 (1.05 to 1.16) <0.001 1.07 (1.02 to 1.13) 0.009
6MW distance - per 30 me-
tre increase
366 (255 to 440) 0.91 (0.88 to 0.94) <0.001 0.91 (0.89 to 0.95) <0.001
BODE - per 1 point increase 3 (1-5) 1.12 (1.07 to 1.18) <0.001 1.13 (1.07 to 1.19) <0.001
Values are given as the median and interquartile range (IQR), or No. of cases (%). Baseline data of 714
patients are included. All models are stratified by recruitment site.
a Adjusted for age and sex
b Adjusted for Framingham risk factors: age, sex, smoking, high-density lipoprotein, total cholesterol,
systolic blood pressure, diabetes, cardiovascular drug treatment. Abbreviations: CI, confidence interval.
CRP, C-reactive protein. BMI, body mass index. GOLD, global initiative for chronic obstructive lung
disease. 4MGS, four-metre gait speed. 6MW, six-minute walk. BODE, body mass index, obstruction,
dyspnoea, exercise.
7.4 Discussion
Four of the classical Framingham risk factors were shown to have prognostic power for the
prediction of CV events, but contrary to our hypothesis predictive power was not improved by
any of the measured biomarkers of CV function. The inverse relationship with SBP may be
due to confounding and can possibly be explained by advancing age related to frailty.204 By
examining other data from the ERICA dataset we show that several other measures, specifically
CRP, fibrinogen, BMI, GOLD stage, 4MGS, and 6MW, were significantly associated with CV
events above and beyond Framingham risk factors. The C-statistic of Framingham risk factors
with BMI, 4MGS, 6MW and BODE Index combined, is similar to adding the 6MW only. This
indicates 6MW is the main component driving the improvement of discriminative ability.
Tests such as the 4MGS and 6MW distance are proxy measures of overall mobility and
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physical functioning including CV fitness.161 Exercise capacity and CV fitness are known to
be associated with fatal and non-fatal CV disease.201 Simultaneously, exercise-based cardiac
rehabilitation reduces risk of heart disease.12 GOLD stage (i.e. FEV1) is a reflection of airflow
limitation and also known to be associated with CV disease.191 For every 10% reduction in
lung performance, fatal- and non-fatal CV disease were reported to increase by 28% and 20%,
respectively.240 Fibrinogen is useful in identifying high risk individuals for COPD exacerbation
and early mortality.83 And although analysis of cross-sectional data from the ERICA study
indicated no relationship between fibrinogen and CV manifestations in COPD,183 analysis of
the prospective data suggests fibrinogen to be associated with fatal- and non-fatal CV disease
in COPD. That the associations between previously mentioned biomarkers and CV events re-
main significance after adjustment for Framingham risk factors indicate their potential value for
identifying high risk individuals within a COPD population.
Age- and sex-adjusted Cox regression indicated a negative association between AIx and CV
events. This association disappeared, however, after including other Framingham risk factors.
There was also a negative association with smoking but this was not significant. About a third
of the ERICA population were current smokers, yet all individuals had at least ten pack-years
of smoking. Individuals with COPD and such a smoking history might already be at a higher
risk for most diseases including CV disease, regardless of their smoking status, and therefore
may explain why smoking status did not add any value in predicting CV events.
7.4.1 Strength and limitations
It could be argued that we did not have enough patients to detect any difference in arterial
stiffness and CIMT measurements between high- and low-risk individuals. It should also be
noted that while a systematic review including seventeen studies concluded that arterial stiffness
was a strong predictor of CV disease,273 this was primarily the case for individuals at higher risk
and more severe disease including renal failure, whom were not included in the ERICA study.
Definitions of CV disease and arterial stiffness measurement differed amongst included studies
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and most failed to adjust for height and MAP. Also, we excluded hypertension, atrial fibrillation
and flutter as outcomes, since these are rather risk factors and not necessarily a CV event, and
may therefore limit comparability with the studies included in the systemic review. Differences
in baseline CV risk may also explain the absence of association between arterial stiffness and
CV events.273 With the few number of events we were unable to examine this. The Framingham
Risk Score has not yet been calibrated for the COPD population. The recalibration, an index
of accuracy, allows to adapt the risk score to the COPD population, addressing potential over-
or underestimation, and therefore may return different risk estimates.
This study has potential limitations. There was no validated algorithm available to identify
CV events in electronic health record data. Previously CV disease endpoints have been validated
using the Clinical Practice Research Datalink (CPRD) classification algorithm121 combined with
extensive clinical input.18 We did, however, not have access to CPRD data and defined CV
disease based on classifications used by the Emerging Risk Factors Collaboration.86 Efforts are
being made to reach a consensus in the use of clinical CV endpoints.123 We extracted CV
events from both primary and secondary ICD-10 positions. Selecting the primary position only
would indicate the underlying cause of diagnosis specifically but most CV events were recorded in
secondary positions, indicating the primary admission might be related to something else than for
cardiac reasons with CV disease seen as comorbidity. We did not have an independent validation
cohort, which is commonly required when assessing the predictive ability of biomarkers. To
address this, we used cross validation techniques (i.e. random partitioning of the dataset). In
addition, we used replication in the cross validation to account for the relatively small number
of observations aiming to prevent potential overfitting of the models.245 Baseline data varied
amongst recruitment centres for most variables. We addressed this by stratifying by recruitment
centre. Generalisability is limited to those with mild to moderate disease, as the majority of
the cohort was GOLD staged II-III. Overall, the study had a relatively small sample size, which
might have contributed to several Framingham risk factors not to be associated with CV events
in COPD. We used multiple imputation techniques nonetheless to improve the statistical power
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and precision. Missing data is common in clinical studies and epidemiological research. Ignoring
missing data and analysing complete data only may introduce bias and provide misleading
results.250 Multiple imputation replaces missing values with estimates based on the observed
data. The correct and appropriate use of multiple imputation techniques is expected to improve
the validity of clinical findings.
7.4.2 Significance of the findings
Cardiovascular disease is predicted to be accountable for a third of deaths globally.172 However,
in the ERICA cohort only very few cardiac deaths were reported with most deaths related to
pulmonary disease. This might be the result of biased death certificates, potentially leading
to misclassification and underreporting of cardiac death.138 Since the nineties, death rates for
circulatory disease, primarily due to ischaemic heart disease, and cancer have both declined
largely.209 Regardless, despite the recommendations of measuring arterial stiffness in clinical
practice164 we found no evidence in the ERICA cohort that would support screening for arterial
stiffness in COPD. In addition, most missing values were present for measures of arterial stiffness,
likely because producing high quality data is difficult and time consuming. Instead, our data
supports the inclusion of musculoskeletal measures in predicting CV events in COPD. Both the
6MW test and 4MGS statistically improved the discriminative ability, with the 4MGS having
more potential when considering clinical practicalities. It is faster and easier to complete than
the 6MW test and requires only a stopwatch and a short flat walking surface. Moreover, despite
the presence of CV disease, cardiac death is not common in patients with COPD. This may
reflect a downward trend in fatal CV disease incidence/ improved CV survival, or an increased
prevalence of death from respiratory causes.
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7.5 Conclusions
We show that age, diabetes and taking drugs to treat CV disease are predictors of CV disease in
a COPD population but measures of arterial stiffness and CIMT do not provide any additional
value to predicting CV disease. In addition, alternative measures thought to better capture
systemic problems, in particular the 6MW distance and the 4MGS test were significantly asso-
ciated with CV events, and may improve the predictive ability above and beyond Framingham
risk factors.
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8
General Discussion
Summary of the key findings
The overall aim of this doctoral research was to identify and evaluate the relationships between
existing and novel biomarkers, and questionnaire data and electronic health record data, and
determine if and how these biomarkers can predict common clinical outcomes (i.e. acute exacer-
bation of chronic obstructive pulmonary disease (COPD), hospitalisation, and mortality) within
a COPD population.
Some of the key scientific questions in COPD at present relate to the evaluation of the useful-
ness of novel biomarkers such as cardiovascular (CV) and musculoskeletal measures in predicting
common clinical outcomes. The six-minute walk (6MW) distance is by far the most studied
biomarker in COPD. Before this research, evidence about the usefulness of alternative measures
four-metre gait speed (4MGS), short physical performance battery (SPPB), quadriceps maxi-
mum voluntary contraction (QMVC), and sniff nasal inspiratory pressure (SNIP) in predicting
clinical outcomes in COPD was limited. Similarly, there was little known about the associations
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of objective CV measures augmentation index (AIx), pulse wave velocity (PWV) and carotid
intima-media thickness (CIMT), and clinical outcomes in COPD. This research aimed to fill this
gap and contribute to the unmet need of evaluating extra-pulmonary manifestations in COPD.
Findings of this research indicate that regardless of the clinical outcome, the 6MW test is
the superior test compared to any of the alternative measures in terms of discriminative ability.
In the systematic review and meta-analysis (Chapter 2), alongside inflammatory marker C-
reactive protein, 6MW distance was also the only marker associated with mortality, exacerbation
and hospitalisation. Nevertheless, analysis in Chapter 3 indicated that most of the missing
data following CV measures were related to the 6MW test. Though, there are alternative mea-
sures that could potentially replace the 6MW test in predicting clinical outcomes in COPD.
Analysis in Chapter 4 showed that the SPPB and its 4MGS and balance components, and the
SNIP have potential to replace the 6MW component in the BODE (Body mass index, airflow
Obstruction, Dyspnoea and Exercise) Index when predicting mortality without significant loss
in discriminative ability. In addition to predicting mortality, analysis in Chapter 6 showed
the SPPB to also have potential in predicting acute exacerbations of COPD-related hospital
admission and length of stay. The QMVC, however, the exception of musculoskeletal measures,
was found not to perform that well in predicting clinical outcomes in COPD. Despite the su-
perior performance of the 6MW in predicting outcomes in COPD, it is encouraging that these
alternative measures have the potential of replacing the 6MW in predicting clinical outcomes in
COPD.
Moreover, analysis of the Evaluating the Role of Inflammation in Chronic Airways disease
(ERICA) and UK Biobank cohorts inChapter 5 showed that despite the believe cardiac death is
common in COPD, the primary cause of death is related to cancer and pulmonary disease. This
may also explain findings in Chapter 7, where CV measures of interest were not predictive
for clinical outcomes. Then again, alternative measures 4MGS and especially the 6MW test
improved the predictive ability of a Framingham approach when predicting CV disease in COPD.
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8.1 Strengths and limitations
The ERICA cohort is a well-phenotyped cohort. Despite ERICA being an observational cohort
study, making it difficult to prove causality, the study was prospective by design which in turn
reduces the likelihood of reversed causality and allowed to calculate risk estimates. Missing data
is common in clinical observational studies as a result of e.g. failed recordings or measurement
errors, study participants skipping visits, or individuals being lost to follow-up. Despite clear
study protocols, there were missing data, in particular for CV measures and 6MW with evidence
that some data were not missing at random. With sensitivity analysis we aimed to address this,
comparing complete-case with imputed data but the presence of missing data was likely related
to the difficulty of generating high quality data of these measures, and the physical intensity
required to perform the 6MW test. Although there were missing data for baseline variables and
follow-up questionnaire data, the greatest strength of this research is the linkage with electronic
health record (EHR) data that indicate any hospital admission or death report for each study
participant for the full study duration. Only fifteen individuals (2%) of all those recruited could
not be included in the analysis because they were not followed-up. A comparison of self-reported
CV events with EHR data showed almost perfect agreement (>80%) after the first year of follow-
up. In addition, the use of EHR data allowed evaluation of the association between multiple
biomarkers with multiple outcomes. Electronic health record data are better in capturing the
heterogeneity of COPD than cohort studies relying on questionnaire data only. On the other
hand, a large retrospective observational study evaluating the use of EHR data in predicting
outcomes emphasised potential biases in using EHR data affecting the ability of predicting
clinical outcomes.2
The ERICA study was conducted in multiple centres throughout the UK, increasing the
diversity of study participants and facilitating the generalisation of findings. Baseline data
differed though amongst the recruitment centres. The centre in London, for example, had
slightly healthier individuals, whereas individuals from Cardiff had more severe disease. This
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was addressed by stratification of recruitment centre. Also, most individuals in the ERICA
cohort were diagnosed with mild to moderate disease, making it difficult to generalise findings
to those in early stage or the very advanced disease. There were no socio-economic details
captured in the ERICA cohort, therefore analyses were not adjusted for this. Socio-economic
status may affect the incidence rates of AECOPD and mortality.
The overall sample size of the ERICA study was relatively small, reducing statistical power
and limiting the making of robust conclusions. The ERICA study was originally designed and
powered on the basis of a tertile analysis of variables PWV and QMVC, based on an estimated
sample size of 800 individuals with COPD.184 However, this sample size is not sufficient when
developing or evaluating multivariable prognostic models and may have resulted in failing to
capture the significance of associations of specific biomarkers. In order to produce robust find-
ings that are measurable and comparable, the sample size should preferably have been estimated
based on the D or C -statistic.140 In developing the modified BODE Indices based on alternative
musculoskeletal measures we used multiple imputation to maximise the sample size, and used
cross validation with replication to prevent model overfitting and to avoid relying on the avail-
ability of another independent dataset, but in essence findings rather generate new hypothesis
and do require replication in larger and non-UK cohorts.
I have attempted to obtain access to alternative datasets including the UB Biobank, CPRD
and US-based Million Veterans Program (MVP). Financial and time restrictions prevented ob-
taining access to at least CPRD and MVP data. To some extent we have been able to validate
some of the findings in the UK Biobank. Using data from the UK Biobank we have tried to
replicate findings related to CV disease incidence in COPD, in particular cardiac death. Both
the ERICA and UK Biobank cohorts are likely a better representation on the UK than the
TORCH trial, which was a highly selective population. We could not validate findings related
to musculoskeletal weakness, since these biomarkers were not captured by the UK Biobank. For
only a limited number of individuals CIMT and PWV were recorded. To identify CV disease,
events were captured using ICD-10 coding based on the Emerging Risk Factors Collaboration.
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However, there was absence of a validated algorithm. Using a different set of codes would likely
have resulted in a different number of individuals with defined CV disease. Despite these weak-
nesses, this research has many strengths in addition to having unique features, and serves as a
great foundation for further analysis.
8.2 Public health implications
The hypothesis was that several new predictors would be useful in predicting clinical outcomes
in COPD. Of all measures evaluated, age and the 6MW test were most predictive of the out-
comes but findings in the ERICA cohort indicate several significant associations between mus-
culoskeletal measures and common clinical outcomes in COPD. These novel biomarkers may
have potential for inclusion in risk prediction in primary care settings, such as the BODE Index,
aimed at identifying high-risk individuals in an earlier stage of disease when timely intervention
is still possible. The BODE Index was introduced in 2004 but it has failed to be widely adopted
clinically, likely due to space and time constraints relating to the 6MW. These alternative mus-
culoskeletal measures require only low commitment allowing for routine measurement and thus
may improve the uptake of risk prediction indices in clinical practice. For example, the chair
stand component of the SPPB in particular could be useful as a standalone test in time-limited
settings such as primary care. More importantly, no other study provides data suggesting that in
patients with stable COPD, SPPB or the chair stand are associated with hospitalised AECOPD
incidence as well as related length of stay, and this information further adds support for SPPB
being used as a drug development tool and endpoint for clinical trials addressing AECOPD,
especially since the European Medicines Agency (EMA) favours the SPPB as the measure of
choice in the assessment of frailty.
Findings also indicate that the assessment of physical capacity and its improvement should
form a part of routine care for COPD in order to, for example, reduce acute exacerbation of
COPD (AECOPD) risk. We demonstrated that simple and amenable to routine care exercise
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capacity test, SPPB or its components like chair stand have similar associations with a higher
risk of AECOPD requiring hospital admission as the 6MW test. These specific musculoskeletal
markers are modifiable traits, in particular chair stand and balance are modifiable measures,
making them ideal for training and testing purposes, and could be incorporated in physical re-
habilitation programs, in addition for usage in predicting clinical outcomes. Not only is effective
treatment lacking, prevention of these clinical outcomes is much more efficient and has a lower
cost associated for healthcare systems. The SPPB, and in particular its chair stand component,
are usable in both primary and secondary care, for evaluating risk of mortality, and hospital
admission and stay in COPD. The SPPB can aid in decision making and prioritising healthcare
resources. In addition, most notably pulmonary rehabilitation can increase physical capacity.263
Although the available data are mixed, some reports suggest that novel strategies can reduce
hospital admission rates by early application of telemedicine techniques. However, these inter-
ventions have costs and thus in terms of prioritising patients who will derive most benefit it is
suggested that SPPB is a useful too.
These exercise capacity traits can also easily be combined with wearables and other elec-
tronic devices. Technological advancement has allowed for capturing a wealth of information at
increased accuracy through, for example, monitoring physical activity. Evidence shows that even
simple pedometers can improve physical activity,176 and smartphone-based physical activity is
well received by both patients and providers.160. In 2013, EDGE a mobile self-managing COPD
platform was introduced aimed at monitoring symptoms including oxygen levels and heart rate
to recognise and start treatment of exacerbations early.90 Medopad, another recent development,
allows in addition to recording symptoms and disease related questions, individuals to perform
a standardised 6MW test. These and other wearables and devices could in turn be linked to
EHR data and primary care data to feed data allowing to monitor disease progression, and warn
patients and health care providers timely when intervention is needed.84
To facilitate the adoption of newly developed risk models, including the BODE Index based
on the SPPB, interactive platforms such as Shiny – an R package for building interactive web
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applications – could prove useful to clinicians and promote uptake of the Index. When commu-
nicating the clinical utility of risk models, decision curve analysis would an appropriate method,
which would in turn also facilitate the adoption of risk prediction models in clinical practice.271
If fatal- and non-fatal major CV events in COPD are less common, reflected through a
downward trend in CV disease incidence/ improved CV survival and an increased prevalence
of death from other causes especially respiratory and cancer, it is important to update clinical
guidelines. Considering the limited resources available and increasing healthcare expenditure it
is important to avoid unnecessary diagnostic testing, for example, measuring arterial stiffness in
COPD when they are not predictive of clinical outcomes.
8.3 Future research
Future investigations could focus on evaluating and validating the predictive ability of biomarkers
in larger studies with longer follow-up times. Emphasis should be placed on ensuring biomarkers
are generalisable (i.e. more diversity in ethnicity and comorbidities) and practical for clinical
use. Most studies on COPD are conducted in the developed world, particularly in Europe where
clinical guidelines are already in place with good diagnostic facilities. Many studies have too
small sample sizes and/or too short follow-up periods, are cross-sectional in design resulting
in over-estimation of effect sizes, or lack generalisability to a ’real world population’ limiting
generalisability or even preventing the estimation of the predictive value of a risk factor.47,102
Especially with the increasing interest of including genetic data in risk prediction models, large
sample sizes are required. Future investigations could focus on the external validation of existing
risk models or perhaps combined models, ideally tailored to the individual with potentially
adding novel predictors such as genetic variants aimed at maximising patient benefit. The use
of genetic data may improve prediction accuracy, and potentially identify novel genetic causes
that e.g. play a role in the development of lung disease and lifestyle behaviour.1 Recommended
techniques include Mendelian randomisation (MR) analysis – a method using genetic variants
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to confirm causality between risk factor and outcome. Alternative techniques that may further
improve prediction accuracy, and are particularly well suited for genetic data, include machine
learning (ML) techniques such as random forest and neural networks.284 The basic principle
of ML relates to data inference; using estimates from past samples to predict new data using
statistical, probabilistic and optimisation tools.182 Moreover, ML allows predicting risks and
outcomes for alternative populations based on minimal datasets requiring population socio-
demographic characteristics only.163 For example, these models can potentially be applied to
understudied populations where the number of deaths due to COPD is the highest such as
in India and Bangladesh. Studies like the Bangladesh Risk of Acute Vascular Events study
(BRAVE) – a 16,000-person case-control study of CV disease – and BangladEsh Longitudinal
Investigation of Emerging Vascular Events (BELIEVE) – a 100,000-person prospective cohort
study in Bangladesh – could provide opportunities to study this and capture lung function
measurements in addition to CV related ones. These datasets contain phenotypic and genotypic
data including lung function test results and clinical outcomes.
More specifically, I propose future research directions related to assessing frailty and multi-
organ tissue loss in COPD, assessing the clinical impact of risk prediction, estimating years
of life lost (YLL) due to COPD, including genetic data in risk prediction, and I highlight the
importance of considering the cost implications of risk prediction for the healthcare system.
8.3.0.1 Frailty and multi-organ tissue loss
Other areas of particular importance in COPD relate to frailty and predicting related events
such falls and fractures using hospital admission data. In 2012, Gale et al. linked increased
physical impairment and frailty in COPD patients.100 Maddocks et al. assessed the prevalence
of frailty in COPD and its effect on pulmonary rehabilitation completion.166 Frailty was found
in 25% of patients and resulted in non-completion of the program. Frailty is common in COPD,
and there is increasing interest in assessing this within the COPD population.24 Moreover,
Lahouse and colleagues assessed frailty in COPD and the risk of mortality, and found increased
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frailty with severe airflow limitation, shortness of breath, and frequent exacerbations.153 As a
result of osteoporosis – one of the clinical features of frailty – fractures are common in COPD
patients and is characterised by decreased skeletal resistance.37,110 The use of steroids in COPD
is thought to contribute to these fractures but this has not been studied well. In addition,
systemic inflammation is believed to prolong fracture healing time and increase complication
rates.50
Frailty, also known as age-related physical disability (ICD-10 R54), can be defined using
modified Fried criteria.145 Although there is overlap, the difference between sarcopenia and
frailty is that sarcopenia refers to muscle mass atrophy related to ageing, and frailty relates to a
geriatric syndrome linked with a higher risk of falls, fractures and hospitalisation.44 According
to the European working group on sarcopenia in older people, sarcopenia (i.e. ICD-10 M62.84)
is defined as low muscle mass and weakness measured by the fat free mass index (FFMI) and
4MGS with cut-off points of FFMI <8.5 kg/m2 for men and <5.75 kg/m2 for woman, and <0.8
m/s respectively.60 Modified Fried criteria include (i) self-reported unintentional weight loss,
(ii) muscle weakness derived through predicted quadriceps strength estimated using Seymour′s
equation,237 (iii) exhaustion measured by the COPD assessment test (CAT) [item 8 ≥3] or St.
George′s respiratory questionnaire for COPD (SGRQ-C) [Q10.f], (iv) self-reported slowness of
walking (<3 mph), slowness while walking measured by the SGRQ-C [Q12.c] or a score of <4
in 4MGS, and (v) low levels of activity measured by CAT [Q5] or SGRQ-C [Q13 or Q14]. A
frailty score of 0 would be considered not frail, 1-2 pre-frail, and >2 as being frail. Preliminary
findings in the ERICA and evaluation of COPD longitudinally to identify predictive surrogate
end-points (ECLIPSE) cohorts show disease progression to be associated with increasing tissue
loss, both pulmonary and extra-pulmonary.41 Future research could examine the association of
musculoskeletal markers and clinical outcomes in those with a so-called multi-organ loss of tissue
COPD phenotype.
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8.3.0.2 Net reclassification index
No significant loss in discriminative ability does not necessarily mean there is no meaningful
difference. The C-index is a well-known model performance measure but merely an indicator of
discriminative ability. Despite its popularity it has been argued that this metric has limitations
such as limited clinical relevance, and when changes are marginal its interpretation becomes
difficult. This was indeed the case when comparing the C-indices of the different models, based on
the 6MW, SPPB or other measures. The net reclassification improvement (NRI) is a quantitative
method – focussing on clinical outcomes rather than model performance – to estimate the number
of individuals that are correctly or incorrectly reclassified. For example, when comparing the
BODE based on 6MWwith BODE based on SPPB the C-index may have no significant difference
but the NRI may actually indicate the number of individuals that are being reclassified into a
lower or higher BODE Index quartile. Despite NRI is popular and may indicate the potential
public health implications, simultaneously it has been suggested to provide misleading results
with high NRI statistics actually being a result of poorly fitted models.217 In addition, clear
risk thresholds are required that do currently not exist for the BODE Index, and with >3
risk categories, which is the case with the BODE Index, NRI may therefore potentially not be
suitable.146
Alternatively, having a risk index with good discriminative ability and/or high NRI that is
unlikely to be widely adopted in clinical practice, it might be worthwhile to make a trade-off
between model performance and clinical practicality. Using indirect methods such as discrete
choice experiments to elicit preferences of various stakeholders (e.g. clinicians and statisticians)
may provide useful insights in how much discriminative ability stakeholders are willing to trade
for improved clinical uptake (i.e. benefit-risk assessment).269
8.3.0.3 Years of life lost
Beyond standardised mortality rates, estimating YLL quantifies reduced life expectancy due to
disease. It is a measure of premature mortality and considers the number of years an individual
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would have lived without the disease. Years of life lost takes the age of death into account,
providing bigger weights at younger age. Years of life lost can be estimated by sex and based
on the number of deaths at different age categories and multiplied by the remaining years of
life expected. It enables healthcare planners to set priorities in addressing disease interventions
at a population level. Proposed analysis includes estimating sex-specific potential YLL due to
premature all-cause and cause-specific mortality caused by COPD in both the ERICA and UK
Biobank cohorts.
8.3.0.4 Genetic risk prediction
Conventional diagnostics rely primarily on spirometry. However, more recently there is increas-
ing interest in stratifying individuals based on their genetic make-up and determine their risk
for future events. Single gene testing provides information of a single gene function, whereas
whole-genome sequencing (WGS) provides information about the full genetic makeup of the in-
dividual organism at a single point in time. It is believed that WGS will benefit patients through
identifying individuals at high risk for common clinical outcomes such as early mortality and
CV events including heart attacks and stroke. Genetic risk scores, where genomic data is inte-
grated with conventional risk factors are increasingly being developed, as evidence indicates the
inclusion of genetic data in risk prediction to outperform models based on traditional predictors
only.147
Findings in the ERICA cohort indicated only very few cardiac deaths. Evidence indicates the
possible involvement of a genetic component in COPD. Those affected could potentially benefit
from individual risk profiling based on genetic or genomic sequencing – collectively referred to as
next generation sequencing (NGS).194 A possible causal factor could be a genetic determinant
such as MMP-12 – a gene known to play a role in lung damage and associated with COPD
onset.130 Mendelian randomisation analysis suggest that increased levels of MMP-12 may protect
patients from coronary heart disease but increases COPD susceptibility.257 MMP-12 and other
genetic activity can be measured using the appropriate gene arrays. Future research could include
209
to develop and validate a prediction model using, for example, ML techniques including genetic
and other risk factors identified through MR analysis, in order to stratify COPD patients and
identify those who are at high risk for clinical outcomes in an early stage of disease. Proposed
analysis include to determine which stratifiers could identify those who are likely to have clinical
outcomes, determine the association between selected biomarkers and their relationship with
clinical outcomes, and if genetic markers such as MMP-12 protects patients from coronary heart
disease but increase COPD susceptibility. Other analysis could include developing, validating
and comparing the predictive ability of genetic and non-genetic risk models, assess the predictive
ability of these models comparing population data of different cohorts, ideally from different
countries, assess the feasibility of applying the risk models to understudied populations using
ML techniques, and estimate the effectiveness of the different models.
8.3.0.5 Healthcare system
The number of people who could be saved, for example, if AECOPD could be diagnosed ear-
lier depends highly on the ability of a healthcare system to identify high-risk individuals in an
early stage of disease. Population-based screening programs allow screening at a single point
in time or sequentially – depending on set risk thresholds an individual might require addi-
tional testing (e.g. genetic sequencing following spirometry) or may support improving lifestyle
behaviour.287 The impact of risk prediction, however, is often limited. Risk models frequently
fail widespread clinical adoption due to their impracticalities, methodological shortcomings or
associated costs.67,113,267 In addition, providing individuals with personalised risk information
has so far not shown to improve lifestyle or screening adherence.264 With healthcare becoming
increasingly complex and challenging, there is a need for a multidisciplinary approach. Epi-
demiology and health economics each consider different areas of evidence and can enhance the
analysis, providing healthcare policy makers with more robust and comprehensive data. Whilst
healthcare expenditure continues to rise, high emphasis is placed on the economic evaluation
of healthcare innovation. Despite clear guidelines on evaluating clinical and cost effectiveness
210
exist,199 a majority of published studies lack any health economic assessment.268 For NGS this
is partly attributed to the lack of clinical trials.288 There is no current evidence on the additional
health benefits produced by the extra information from NGS, or whether the analysis plus clini-
cal action based on additional findings provides value for money to the healthcare system. Policy
makers are unclear about the clinical utility of NGS and are concerned it could be an expensive
addition to existing diagnostics.117 In order to estimate the full impact of risk prediction, the
clinical applicability and cost implications of genomic risk prediction needs to be evaluated.
Future research could assess the impact of genetic and genomic data, and the use of EHR data
in predicting clinical outcomes whilst considering the clinical practicalities and cost implications.
The objectives could be to develop a decision analytical framework for the economic evaluation
(i.e. cost-effectiveness and budget impact analysis), calculate the costs of using conventional and
genetic-based risk prediction, and estimate the incremental cost and effects of a genetic-based
model to determine the clinical utility and health economic impact of risk prediction in COPD,
and provide health policy recommendations for healthcare improvement.
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Abstract
Extrapulmonary manifestations are recognized to be of increasing clinical 
importance in Chronic Obstructive Pulmonary disease. To investigate cardiovascular 
and skeletal muscle manifestations of COPD, we developed a unique UK consortium 
funded by the Technology Strategy Board and Medical Research Council 
comprising industry in partnership with 5 academic centres. ERICA (Evaluating the 
Role of Infl ammation in Chronic Airways disease) is a prospective, longitudinal, 
observational study investigating the prevalence and signifi cance of cardiovascular 
and skeletal muscle manifestations of COPD in 800 subjects. Six monthly follow up 
will assess the predictive value of plasma fi brinogen, cardiovascular abnormalities 
and skeletal muscle weakness for death or hospitalization. 
As ERICA is a multicentre study, to ensure data quality we sought to minimise 
systematic observer error due to variations in investigator skill, or adherence 
to operating procedures, by staff training followed by assessment of inter- and 
intra-observer reliability of the four key measurements used in the study: pulse 
wave velocity (PWV), carotid intima media thickness (CIMT), quadriceps maximal 
voluntary contraction force (QMVC) and 6-minute walk distance (6MWT). This 
report describes the objectives and methods of the ERICA trial, as well as the inter- 
and intra-observer reliability of these measurements.
COPD, 11:552–559, 2014
ISSN: 1541-2555 print / 1541-2563 online
Copyright © Informa Healthcare USA, Inc.
DOI: 10.3109/15412555.2014.898031
Introduction
Although COPD is primarily a lung disease, it is now widely recognised 
that COPD is a heterogeneous condition with a range of extra-pulmonary 
manifestations including cachexia (1), peripheral muscle dysfunction (2, 3), 
cardiovascular disease (4, 5) and osteoporosis (5, 6) that have an eff ect on the 
severity of the condition. 
Two of these extrapulmonary manifestations, namely cardiovascular and 
skeletal muscle dysfunction, represent a key unmet need in patients with 
COPD that require the development of new therapies. Cardiovascular dis-
ease is the second-leading cause of death in patients with COPD (7), and 
even subjects with mild spirometric abnormalities have an increased risk of 
admission or death from cardiovascular causes (8). Similarly skeletal muscle 
weakness (2, 3) and biopsy abnormalities (9) exist even in patients with mild 
airfl ow obstruction and are associated with an increased risk of death (10). 
A combination of systemic and local factors such as physical inactivity, oxida-
tive stress, cachexia, exposure to cigarette smoke and infl ammation are thought 
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to contribute towards the skeletal muscle dysfunction seen 
in COPD (11). Since pulmonary rehabilitation is a highly 
eff ective therapy in COPD that increases quadriceps 
strength (12), targeting this abnormality is likely to trans-
late into patient benefi t. Objectively measured physical 
activity relates to muscle mass (3), especially in mild dis-
ease, and in a survival analysis by Waschki and co-workers 
(13), the combination of physical activity measurement 
and assessment of vascular status predicted mortality bet-
ter than either alone, suggesting that the cardiovascular 
and skeletal muscle phenotypes are not identical.
Persistent systemic infl ammation has been linked 
with poorer outcomes in COPD and has been identifi ed 
as a novel COPD phenotype (14). Recent data suggest 
that fi brinogen is a promising, stable biomarker of sys-
temic infl ammation, and that elevated fi brinogen levels 
relate to frequent exacerbations and mortality in COPD 
(15–17). Previous studies have suggested that almost a 
third of COPD patients suff er from 2 or more exacerba-
tions per year, with a fi fth of COPD patients requiring 
hospitalizations over the course of 1 year (18). For these 
reasons, the COPD Biomarkers Qualifi cation Con-
sortium (CBQC) has submitted fi brinogen for consid-
eration for qualifi cation as a drug development tool by 
the Food and Drug Administration (FDA). CBQC was 
established in 2010 with the aim of collating anonymised 
data from clinical and observational trials (Figure 1).
Trials such as ECLIPSE (19), GSK-supported inves-
tigator-sponsored eclipse extension study NTR3221, 
ARCADE (20), PROactive (Clinicaltrials.gov number 
NCT01388218) and MRC/ABPI WP4 (Clinicaltrials.gov 
number NCT01620645) will contribute data towards 
ERICA, thus allowing a suffi  ciently large dataset to 
conclusively establish the value of biomarkers or drug 
development tools (DDTs) as stratifi cation tools (21). 
Nevertheless there remains a paucity of data to assess 
whether fi brinogen will also be a satisfactory biomarker 
for extrapulmonary manifestations of COPD.
Plasma fi brinogen independently predicts cardio-
vascular risk in the general, healthy population (22), 
however, the value of fi brinogen in the prediction of 
the cardiovascular and skeletal muscle manifestations 
of COPD, and in the interplay between these pheno-
types, requires further evaluation. For this reason we 
conceived the ERICA (Evaluating the Role of Infl amma-
tion in Chronic Airways disease) study. Th e study has 
three specifi c aims. First, to determine how eff ectively 
plasma fi brinogen predicts the cardiovascular and/or 
skeletal muscle manifestations of COPD. Second, to 
determine how fi brinogen and other specifi c measures 
of cardiovascular and muscle function predict longer-
term outcomes including death, disability and hospital 
admission, and third, to determine the extent to which 
subsets of COPD patients with cardiovascular or muscle 
manifestations overlap. For this purpose, a cardiovas-
cular manifestation is defi ned as an abnormally raised 
aortic pulse wave velocity and a skeletal muscle manifes-
tation is defi ned as quadriceps muscle weakness.
Th e current report describes the objectives and 
methods of the ERICA trial, and the standardisation 
procedures undertaken with the objective to improve 
inter- and intra-observer reliability of measurements 
used in the study.
Methods
Subjects
A maximum of 800 COPD patients are to be recruited 
over a period of 2 years. Th e study is powered on the basis 
of a tertile analysis of the two key cardiovascular and mus-
cular biomarkers, systemic  arterial stiff ness as measured 
by aortic pulse wave velocity (PWV) and skeletal muscle 
function, measured as quadriceps maximal voluntary 
contraction (QMVC). Assuming an average PWV of 
10 (SD 1.0) m/s and a minimal clinically relevant diff er-
ence of 0.4 m/s, 230 patients per tertile will provide 90% 
Figure 1. Clinical and Observational studies contributing data towards the COPD Biomarker Qualifi cation Consortium (CBQC) and their sources of funding.
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power at p < 0.01 to detect this diff erence between the top 
and bottom quartiles. For QMVC, assuming an average 
QMVC of 32 (SD 8) kg, 220 patients per tertile will pro-
vide 90% power at a signifi cance of p < 0.01 in order to 
detect the minimum clinical diff erence of 3 kg between 
the top and bottom tertiles. Allowing for a 10% dropout 
rate and incomplete datasets, approximately 800 patients 
were calculated to be required. Recruitment is on target to 
fi nish in autumn 2013. Table 1 describes the inclusion and 
exclusion criteria for subject participation in the study. All 
participants provided written, informed consent.
Study design
ERICA is an on-going longitudinal, observational, 
prospective study being conducted at 5 centres in the 
UK, which is presently funded for 2 years by the UK 
Technology Strategy Board/MRC. As the study was 
not a trial, the study is registered with the UK Clini-
cal Research Network Study Portfolio with UKCRN ID 
11101 (http://public.ukcrn.org.uk/Search/StudyDetail.
aspx?StudyID=11101); the UKCRN is a publically 
searchable database. 
Following baseline visits to perform study measure-
ments, participants are followed up at 6 monthly inter-
vals for 2 years with telephone or postal questionnaires 
to assess the frequency of COPD exacerbations. For this 
study, we have defi ned exacerbations as self-reported 
increase in COPD symptoms that required treatment 
with antibiotics and/or steroids and severe exacerbations 
as those that require hospital admission. Th e develop-
ment of cardiac co-morbidity is assessed through new 
self-reported cardiac symptoms such as exertional chest 
pain or ankle swelling, physician diagnoses of angina, 
myocardial infarction, stroke or hypertension and the 
introduction of new concomitant cardiac medication 
since the last patient visit or questionnaire. 
To assess the impact of COPD on the patient, we used 
Medical Research Council (MRC) dyspnoea scores, 
COPD Assessment Tool and the St George’s Respiratory 
COPD Questionnaire, whilst physical activity is self-
reported. Th ere are no prohibited medications in the 
study. All subjects continued their routine prescribed 
medications throughout the study and the patient’s 
physician may off er treatments (e.g. medication change, 
rehabilitation) in line with the patients’ needs. Th ese 
treatment changes are captured at the 6 monthly calls/
questionnaires. Th e study is being conducted in accor-
dance with the Declaration of Helsinki and good clinical 
practice guidelines.
Th e research was given a favourable opinion by the 
Cambridge South East Research Ethics Committee and 
the local research and development departments at each 
participating site. Th e trial steering committee comprises 
physicians and scientists from fi ve UK academic centres, 
two academic physicians independent of the recruiting 
centres and representatives from GlaxoSmithKline.
Outcome measurements
Study assessments are performed at baseline over two 
visits. Standardised procedures are used in all centres as 
defi ned in the study procedure manual. Measurements 
that are of primary interest are plasma fi brinogen, aortic 
PWV, carotid intima media thickness (CIMT), 6-minute 
walk distance (6MWT) and QMVC. Methods for these 
5 procedures are described here, but all study param-
eters are listed in Table 2. For all study procedures a 
Standard Operating Procedure (an SOP) was generated 
to which all partners adhered. Patients will be registered 
for long-term health outcomes through Hospital Epi-
sode Statistics (HES), a central UK database recording 
all admissions to National Health Service (NHS) hospi-
tals, and the NHS Information Centre from the Offi  ce 
for National Statistics (previously the Medical Research 
Information Service), which can report on the status of 
study participants and provide follow up data for longi-
tudinal studies within the UK.
Fibrinogen
For determination of plasma fi brinogen, whole blood is 
collected into a vacutainer tube (sodium citrate as the 
anticoagulant) by venepuncture from a peripheral vein 
after a 4-hour fast. Plasma is prepared by centrifugation 
at 2000 × g for 10 min. Plasma fi brinogen is measured 
in fresh plasma samples using an automated, modifi ed 
Clauss method [HemosIL Fibrinogen-C XL, Instru-
mentation Laboratories(23)]. Th e assay method is a 
direct measurement of functional fi brinogen and is the 
method most commonly used in clinical laboratories. 
Daily testing on a fi brinogen calibrator was carried out 
at the Royal Brompton and Harefi eld NHS hospital lab-
oratory and Addenbrookes hospital laboratory to assess 
inter-assay variability.
Table 1. Inclusion and exclusion criteria for study participants
Inclusion Exclusion
Clinical diagnosis of COPD Inability to provide written, informed consent
Baseline post-bronchodilator Forced expiratory volume in the fi rst second (FEV1) of 80% or 
less of their predicted value, a baseline FEV1/forced vital capacity (FVC) ratio of < 0.7
A known diagnosis of α1-antitrypsin defi ciency, known 
neurological or skeletal muscle disease 
Age > 40 years Pregnancy
A smoking history of at least 10 pack years Ongoing participation in a trial of an experimental drug
Clinical stability for at least 4 weeks, without any hospitalisations or exacerbations 
requiring treatment at the time of study measurements
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Table 2. Description of standardized assessments carried out on all study subjects as described in the study manual and existing studies that are carrying out these 
assessments for the COPD Biomarker Qualifi cation Consortium
Assessment Description
Existing studies contributing data from assessments 
towards ERICA
Post bronchodilator Spirometry: 
FEV1 and FVC
Performed within one hour of administration of patient’s own 
bronchodilators
ARCADE, ECLIPSE extension, PROactive, Longitudinal 
determination of skeletal muscle dysfunction in COPD, MRC 
WP4 consortium
Cardiovascular Assessments
Blood Pressure Average of fi nal 2 out of 3 measurements, taken after 
10 minutes of rest 
ARCADE, ECLIPSE extension, Longitudinal determination of 
skeletal muscle dysfunction in COPD, MRC WP4 consortium
12-lead Electrocardiogram (ECG) A standard 12 lead (10 electrode) ECG recorded with the patient 
in a supine position and at a recording speed of 25 mm/sec
ARCADE, PROactive, MRC WP4 consortium
Arterial Stiffness Assessments of carotid-femoral pulse wave velocity (PWV) and 
aortic augmentation index (AIx) via Sphygmocor device after 
4 hours of fasting and 6 hours without bronchodilators. 
ARCADE, Longitudinal determination of skeletal muscle 
dysfunction in COPD
Carotid Intima Media Thickness 
(CIMT)
B-mode ultrasound measurement of bilateral common carotid 
intima media thickness to assess subclinical atherogenesis (25)
ARCADE
Skeletal muscle assessments
Quadriceps Maximal Volitional 
Contraction (QMVC)
Best effort from 6 volitional, isometric quadriceps contractions 
of the right leg as described by Edwards et al. (27). Predicted 
QMVC was calculated according to Seymour et al. (2)
PROactive, Longitudinal determination of skeletal muscle 
dysfunction in COPD, MRC WP4 consortium
Sniff Nasal Inspiratory Pressure 
(SNIP)
A non-invasive measure of inspiratory muscle strength using 
a hand-held MicroRPM (respiratory pressure meter). The most 
negative of a minimum 3 efforts will be used for data analysis
PROactive
Exercise/ Physical performance 
assessments
6-minute walk test (6MWT) Supervised walking test as per American Thoracic Society 
guidelines (26), but without a practice test
ARCADE, ECLIPSE extension, PROactive, MRC WP4 
consortium
Short Physical Performance 
Battery
A composite assessment of lower extremity function comprising 
standing balance, 4 meter gait speed and sitting-to-standing 
speed (35)
MRC WP4 consortium
Anthropometrics Height, weight, body mass index (BMI). ARCADE, ECLIPSE extension, PROactive, Longitudinal 
determination of skeletal muscle dysfunction in COPD, MRC 
WP4 consortium
Bioimpedance and Fat-free mass Estimated using single-frequency (50 kHz) bioelectrical 
impedance analysis via TANITA BC 418 MA (Tanita Corporation, 
Tokyo, Japan).
ARCADE, ECLIPSE extension, PROactive, Longitudinal 
determination of skeletal muscle dysfunction in COPD, MRC 
WP4 consortium
Health Outcomes
Health status and symptom 
assessment
COPD specifi c St George’s COPD respiratory questionnaire 
(SGRQ-C) and COPD assessment tool (CAT)
ARCADE, ECLIPSE extension, PROactive, Longitudinal 
determination of skeletal muscle dysfunction in COPD, MRC 
WP4 consortium
Breathlessness, exacerbation 
frequency and treatment, physical 
activity and smoking habit
Medical Research Council (MRC) dyspnoea score and postal 
questionnaire at baseline and repeated at 6 monthly intervals 
for 2 years
Biomarkers
Blood samples Taken after 4 hours of fasting. Samples stored for plasma, 
serum and DNA and analysed for plasma fi brinogen, urea and 
electrolytes, full blood count, high sensitivity C-reactive protein, 
glucose, Hba1c and lipid profi le. 
Urine Spot urine sample; taken after 4 hours of fasting
Pulse wave velocity
Following 10 minutes of supine rest, brachial blood 
pressure was measured three times, and an average 
of the fi nal two readings was used for analysis. Aortic 
PWV is measured via the SphygmoCor device (AtCor, 
West Ryde, Australia), between the carotid and femoral 
arteries, using a piezoelectric tonometer placed over the 
artery and ECG gating, as previously described in detail 
(24). Th e path length is calculated by subtracting the 
distance between the carotid pulse and supra-sternal 
notch, from the femoral artery supra-sternal notch 
distance. Measurements are made following 4 hours of 
fasting, and 6 hours without bronchodilator use.
Carotid intima media thickness
Carotid intima media thickness (25) was measured via 
B-mode ultrasound, using a 7–12 MHz linear probe. Meas-
urements were taken after 10 minutes of supine rest. Both 
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the right and left common carotid arteries are scanned at 
a distance of 1 cm from the carotid bulb. Images are not 
ECG gated, and three 10 second loops are recorded for 
each carotid artery. Images are then transferred in DICOM 
format to be analysed via Vascular Tools 5 software (Medi-
cal Imaging Application LLC, Coralville, USA).
Six-minute walk test
Six-minute walk distance is measured in accordance 
with the guidelines of the American Th oracic Society 
(26) except that a practice walk was not performed due to 
time constraints. Although subjects could set their own 
walking pace, it was emphasized that they cover as many 
laps as possible over a standard 30 m, level track during 
the 6 minutes. Subjects were permitted to use their usual 
medications prior to the test, and were given standard-
ised encouragement only at the end of each minute dur-
ing the walking test. Where oxygen was required during 
the walking test, an additional researcher carried the 
oxygen cylinder for the patient, but behind the patient in 
order not to infl uence the patient’s pace. 
Quadriceps maximal volitional contraction
QMVC force was measured using the technique of 
Edwards et al. (27) and expressed as a percentage of pre-
dicted values using the equations developed by Seymour 
and co-workers (2). Patients were verbally encouraged 
to make a maximal contraction by pushing out (i.e. 
extension) against an inextensible strap placed above 
the ankle. Th e manoeuvre is repeated six times with a 
minimum 20-second interval between eff orts. We used 
the highest value of contraction which could be sus-
tained for 1 second for analysis.
Harmonising inter-site data collection
Prior to study recruitment, all centres participated in cen-
tralised training, individual site training and standardi-
sation visits. Amongst study measurements, QMVC, 
6MWT, PWV and CIMT were identifi ed as most prone 
to systematic error due to variability in equipment and 
expertise across sites. Intra- observer reliability measure-
ments were therefore carried out using 10 volunteer sub-
jects at each site. Additionally, unlike the 6MWT, QMVC 
measurement was novel to most sites, and requires the 
observer to verbally encourage as well as correct patient 
technique, therefore inter-observer reliability measure-
ments were carried out on 10 volunteers at each site. 
Intra-class correlation coeffi  cients were used to measure 
inter- and intra-user reliability. Statistical analysis was 
carried out using IPB SPSS v 19.
Results
Inter-assay %CV values based on a fi brinogen calibrator 
tested daily are 6.7% for Royal Brompton Hospital and 
9.4% for Cambridge University Hospital.
Intra- and inter-observer variability are shown in 
Table 3. Th e initial intra-class correlation coeffi  cient 
(ICC) at one centre for QMVC was entered erroneously; 
a repeat set revealed an ICC of 0.60. As this was less 
than the agreed target of 0.85, recommendations were 
implemented and a fi nal intra-observer repeatability 
ICC of 0.96 was observed. 
Once a site demonstrated competency in all relevant 
research techniques, they were allowed to recruit study 
participants. Table 4 reports the baseline characteristics 
of the fi rst 10 subjects recruited at each site, in order to 
provide an example of the likely eventual type of patients 
who will be recruited to the cohort.
Discussion
Th e main conclusions drawn from setting up ERICA 
are fi rst that technically demanding measurements, like 
PWV, carotid media thickness and maximal voluntary 
contraction force can be made in patients with COPD. 
Secondly, with relatively little training measurements 
can be made with good repeatability and low inter-
observer variability. Finally, participants recruited to the 
trial so far appear representative of a typical convenience 
cohort for COPD trials and there does not appear to be a 
great deal of variance between individual sites. 
Harmonising inter-site data collection is essential in 
multi-centre studies for the production of valid, reliable 
results. Centralised training followed by individual site 
visits has enabled standardisation of techniques, and col-
lection of inter- and intra-observer reliability allowed iden-
tifi cation of problems prior to the commencement of study 
recruitment. We would therefore endorse the current 
practice that researcher competency in performing novel 
techniques should be formally evaluated in multi-site trials 
prior to subject recruitment to ensure good quality data.  
Currently if planning a large trial of either an ana-
bolic or cardiovascular therapeutic that addresses 
 extrapulmonary disease manifestations in COPD, an 
investigator would be hampered by insuffi  cient detail 
regarding subsets of patients who are most likely to 
Table 3. Intra-observer reliability for Pulse Wave Velocity (PWV), 6-minute walk 
test (6MWT) and quadriceps maximal volitional contraction (QMVC) and inter-
observer reliability measurements for QMVC in 10 volunteers as measured by 
fi nal intra-class correlation coeffi cients
Intra-observer reliability
(n = 10)
Inter-observer 
reliability
(n = 10)
Site PWV (m/s) 6MWT (m) QMVC (kg) CIMT (mm) QMVC (kg)
1 0.99 0.98 0.97 0.98 0.99
2 1.00 0.92 0.90 0.99 0.88
3 1.00 0.98 0.98 0.97 0.98
4 0.99 0.99 0.96 0.89 0.92
5 0.96 0.99 0.96 0.94 0.98
Overall 1.00 0.99 0.95 0.98 0.98
Intra-class correlation coeffi cients for intra-observer reliability of Pulse Wave Velocity 
(PWV), 6 minute walk test (6MWT), Quadriceps Maximal Volitional Contraction (QMVC) 
and Carotid intima media thickness (CIMT), and inter-observer reliability for QMVC mea-
surements, measured on 10 volunteers at each of the 5 participating sites.
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benefi t. Although cardiovascular and skeletal muscle 
dysfunction are serious and common co-morbidities in 
COPD, they are not observed in all patients diagnosed 
with the disease. At this time it is also unclear whether 
there is an association between manifestations of skel-
etal muscle or cardiovascular dysfunction in COPD and 
the knowledge of their functional consequences is lim-
ited. It would be particularly attractive to have a blood 
biomarker which permitted selection of patients with 
these disease manifestations for clinical trials assessing 
effi  cacy as large all comer trials are likely to fail (28). 
More data are available for cardiovascular disease 
than skeletal muscle weakness, but in both cases the 
evidence is that these extra-pulmonary manifestations 
of COPD are present only in a minority of patients. In a 
review of approximately 46,000 case records of patients 
managed in a Kaiser Permanante program several car-
diovascular co-morbidities were identifi ed in a minority 
of patients (at most 25%) though the group as a whole 
had a 2–3-fold increased risk of subsequent cardiovas-
cular-related admission (8). In relation to the measures 
used in this study only very small data sets exist; in the 
study of Maclay et al. (29) roughly half the participants 
were above the threshold of 10 m/s considered to rep-
resent increased future cardiovascular risk. Skeletal 
muscle dysfunction, while common, is present in only 
a minority of patients with COPD whether judged by 
weakness (2) or muscle size (3).  Interestingly the preva-
lence of skeletal muscle weakness, probably around 30% 
of patients, is not greatly infl uenced by disease severity 
judged by FEV1 (3). We have previously discussed the 
diffi  culties of developing an anabolic agent for patients 
with COPD elsewhere (28).
Fibrinogen is attractive as a biomarker, as it is a com-
monly available test, acceptable, relatively inexpensive 
and easy measure in clinical practice. Infl ammatory 
markers such as TNF-alpha, IL-6, CRP and p-selectin 
have been shown to relate to disease severity in some 
studies, however individual variability for these markers 
is high (30). A panel of 34 infl ammatory markers was 
recently assessed in the ECLIPSE study, with plasma 
fi brinogen emerging as the most repeatable biomarker 
in stable patients with COPD. Although other infl am-
matory markers such as C-reactive protein and interleu-
kin-6 were also raised in COPD patients as compared 
to healthy controls, these biomarkers displayed wide 
variability in stable subjects with COPD over 3 months. 
Fibrinogen has additionally been shown to relate to 
Table 4. Baseline characteristics of the fi rst 50 study recruits at participating sites
Centre 1
n = 10
Centre 2
n = 10
Centre 3
n = 10
Centre 4
n = 10
Centre 5
n = 10
Overall
n = 50
Age (years) 68.6 (12.2) 65.9 (7.2) 68.1 (9.0) 67.1 (6.3) 71.8 (5.9) 68.3 (8.3)
Male: Female 10:0 4:6 5:5 6:4 9:1 34:16
Height (m) 173.3 (10.2) 165.8 (10.8) 165.5 (7.6) 170.8 (9.7) 172.2 (5.4) 169.5 (9.2)
Weight (kg) 85.2 (22.4) 72.8 (16.9) 66.4 (15.1) 80.0 (19.6) 78.1 (16.2) 76.5 (18.7)
Fat-free Mass (kg) 59.2 (11.9) 48.9 (12.2) 45.4 (9.8) 53.9 (14.1) 55.8 (6.9) 52.6 (11.9)
BMI (kg/m2) 27.9 (5.4) 26.3 (4.8) 24.2 (5.3) 27.2 (5.5) 26.3 (5.1) 26.4 (5.1)
Smoking (pack-years) 52 (29) 32 (14) 39 (23) 66 (31) 53 (31) 48 (28)
Current smokers (%) 10 10 60 10 10 20
FEV1 (% predicted) 47.4 (18.5) 57.8 (10.5) 59.7 (18.3) 60.1 (15.5) 44.3 (17.2) 53.9 (17.0)
FEV1 (L) 1.34 (0.53) 1.43 (0.39) 1.43 (0.51) 1.61 (0.43) 1.26 (0.54) 1.41 (0.48)
FVC (L) 3.29  (1.09) 2.50 (0.58) 3.02 (0.80) 3.10 (0.87) 3.50 (0.63) 3.08 (0.85)
FEV1/ FVC 0.42 (0.13) 0.57 (0.08) 0.47 (0.10) 0.53 (0.13) 0.34 (0.12) 0.47 (0.14)
6MW distance (m) 354 (113) 324 (100) 425 (112) 352 (97) 384 (118) 368 (109)
Fibrinogen (g/L) 3.5 (0.72) 3.89 (0.95) 3.44 (0.44) 3.24 (0.59) 3.5 (0.42) 3.51 (0.66)
Seated Systolic BP (mm Hg) 140 (15) 140 (18) 142 (21) 133 (14) 147 (18) 140 (17)
Seated Diastolic BP (mm Hg) 77 (6) 77 (13) 80 (12) 79 (5) 83 (10) 79 (12)
PWV (m/s) 10.5 (1.8) 9.3 (3.9) 11.7 (3.9) 7.5 (2.8) 11.8 (3.1) 10.2 (3.5)
QMVC (kg) 35.4 (12.6) 31.7 (15.0) 29.1 (7.7) 34.5 (8.6) 36.0 (9.4) 33.4 (10.8)
QMVC (% predicted) 71.5 (16.5) 73.9 (26.6) 74.8 (16.3) 77.5 (15.3) 79.3 (18.6) 75.4 (18.5)
SNIP (cm H2O) 70.9 (12.1) 59.1 (22.6) 72.7 (18.7) 72.4 (16.6) 55.4 (19.7) 66.1 (19.0)
SPPB score (of 12) 9.8 (1.87) 9.9 (2.33) 10.4 (1.78) 10.7 (1.25) 10.6 (1.71) 10.3 (1.78)
MRC score (of 5) 2.8 (0.92) 2.8 (1.03) 2.1 (0.74) 2.1 (0.74) 2.9 (1.29) 2.54 (0.99)
SGRQ-C score 48.8 (16.4) 59.3 (20.2) 39.4 (13.6) 47.5 (20.8) 45.7 (21.7) 48.1 (19.1)
CAT score 17.8 (6.9) 19.5 (9.0) 17.7 (6.7) 17.5 (9.5) 16.5 (7.7) 17.8 (7.8)
Values expressed as mean, with standard deviation in brackets.
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 disease severity and is predictive of death both in COPD 
and other conditions (15,31). 
However it is largely unknown to what extent fi brino-
gen has a predictive value to diagnose cardiovascular 
dysfunction and especially skeletal muscle dysfunction in 
COPD. Data from very large studies have demonstrated 
that COPD patients with a self-reported history of cardio-
vascular disease have higher fi brinogen levels (16), but the 
relationship between fi brinogen and other measures with 
predictive value for future cardiovascular disease, such as 
pulse wave velocity and carotid intima media thickness 
used in ERICA, is unknown. Eickhoff  and colleague used 
a third detailed and predictive measure, fl ow mediated 
dilatation, and found no relationship with fi brinogen, but 
their cohort was limited to 60 patients (32). Several stud-
ies that have investigated fi brinogen and cardiovascular 
disease in COPD have often excluded those with severe 
cardiovascular disease (15), which runs the risk of bias-
ing results, and also leaves a data gap for patients most 
at risk from cardiovascular death. Importantly therefore 
pre-existing cardiovascular disease is not an exclusion 
criterion for our study. 
Although both quadriceps strength, measured as 
QMVC and fi brinogen were related to lower physical 
activity in COPD patients measured by accelerometry 
in a prior smaller report (33), its relationship to skeletal 
muscle strength has not been examined before in a large 
cohort of patients. Our study additionally measures several 
aspects of muscle function, specifi cally QMVC, Sniff  Nasal 
Inspiratory Pressure (SNIP) (34), Short Physical Perfor-
mance Battery (SPPB) (35) and 6-minute walk distance. 
Th e short physical performance battery may prove to be 
of particular interest from a regulatory perspective since it 
is widely used in academic gerontology. Th e 4-metre gait 
speed, which is a component of the SPPB predicts death in 
elderly people and is reproducible in COPD (36).
Conclusions
In conclusion, ERICA is the fi rst large prospective study 
to examine the interplay between fi brinogen, skeletal 
muscle and cardiovascular manifestations of COPD, as 
well as their relation to exacerbations and mortality. At 
the conclusion of the study we will be able to determine 
whether cardiovascular and muscle dysfunction pheno-
typic “sets” commonly overlap and to what extent fi brino-
gen is a useful marker of these sets. Identifi cation of the 
relationship between co-morbidities and potential pre-
dictive biomarkers of COPD will help the development of 
future therapies, and may be useful diagnostically.
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TABLE: Baseline data
GENERIC Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
Trial trial Pre-filled by 
application
Site site Text: n01=Cambridge, 
n02=Edinburg, 
n03=Cardiff, 
n04=Nottingham, 
n05=London
Drop down: 
Cambridge, 
Edinburgh, Cardiff, 
Nottingham, London
n01=Cambridge, 
n02=Edinburg, 
n03=Cardiff, 
n04=Nottingham, 
n05=London
Only one option 
possible
Label label Pre-filled by 
application
Person ID, date of 
birth, status
Subject ID personid Assigned by database
Visit cycle visitcycle Assigned by database
Form cycle formcycle Assigned by database
Repeat number repeatnumber Assigned by database
Site ID siteid Text: 1=N01, 2=N02, 
3=N03, 4=N04, 5=N05
Drop down: 
Cambridge, 
Edinburgh, Cardiff, 
Nottingham, London
1=N01, 2=N02, 
3=N03, 4=N04, 5=N05
Only one option 
possible
Visit date visitdate Date dd/mm/yyyy
Date of birth edob Date dd/mm/yyyy
Sub ID subid Assigned by database
Macro ID macroid Assigned by database
Gender eligsex Number: 1=Female, 
2=Male
Drop down: Female, 
Male
1=Female, 2=Male Only one option 
possible
Informed consent consent1 Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Informed consent consall Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Date of informed 
consent
consentdate Date dd/mm/yyyy Should be ≤ visitdate
Age ageeligibility Number nn yrs Must be ≥40
Ethnicity ethinicity Number: 1=Black/ 
African-Caribbean/ 
Sub-Saharan, 
2=White, 3=Asian, 
4=Other
Drop down: Black/ 
African-Caribbean/ 
Sub-Saharan, White, 
Asian, Other
1=Black/ African-
Caribbean/ Sub-
Saharan, 2=White, 
3=Asian, 4=Other
Only one option 
possible
Sort ID sortid Number nnn Only one option 
possible
TABLE: Baseline data
ANTHROPOMETRY Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
Height height Number nnn cm Must be in range 130-
200
Fat mass fatmass_anthro Number nn.n kg Must be in range 0-100
Weight (Tanita) weight Number nn.n kg Must be in range 0-200
Must be in range 0-130
(~70% of weight)
ERICA DATABASE SPECIFICATION DOCUMENT
BASELINE AND FOLLOW UP QUESTIONNAIRES
Fat free mass: fatfreemas_antr Number nn.n kg
236
Body fat (Tanita) bodyfat Number nn.n % Must be in range 0-100
Total body water totalbodywater Number nn.n kg Must be in range 0-130 
(~70% of weight)
Impedance, whole impedence Number nnn Ω Must be in range 0-
1500
Date of anthropometry anthrdate Date dd/mm/yyyy Should be ≥ visitdate
TABLE: Baseline data
SPIROMETRY Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
Spirometry undertaken 
at this visit?
spirothisvisit Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Date of spirometry spirodate Date dd/mm/yyyy Should be ≥ visitdate
Previous spirometry 
undertaken?
prevspirometry Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Previous FEV1 prevfev1 Number nn L Must be <3.5
Previous FEV1/FVC 
ratio
prevfevfvcratio Number n.n % Must be <0.7
Date of previous 
spirometry
prevdatespir Date dd/mm/yyyy Should be < spirodate
FVC fvc Number n.nn L Must be <4.5
FVC percentage fvcpercent Number nn %predicted Must be in range 5-160
FEV1 fev1 Number n.nn L Must be in range 0-4
FEV1 percentage fev1percent Number nn %predicted Must be ≤80%
FEV1/FVC ratio fev_fvcratio Number n.nn % Must be <0.7
ECG undertaken? ecgundertaken Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Date of ECG ecgdate Date dd/mm/yyyy Should be ≥ visitdate
ECG signed by a 
clinician?
ecgsignci Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
TABLE: Baseline data
SHORT PHYSICAL PERFORMANCE BATTERY (SPPB) Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
SPPB undertaken? sppbdone Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Date of SPPB sppbdate Date dd/mm/yyyy Should be ≥ visitdate
Balance side-by-side, 
time
sidebysidetime Number n.n sec. Must be ≤10
Correction - Balance 
side-by-side, time
re_sidebysidetime Number n.n sec. Must be ≤10
Balance side-by-side, 
points
balancesidepts Number n Must be in range 0-1
Correction - Balance 
side-by-side, points
re_balancesidepts Number n Must be in range 0-1
Balance side-by-side, 
not done
spsidbyside_nd Number: 1=?, 2=? Drop down: ?, ? 1=?, 0=? Only one option 
possible
Correction - Balance 
side-by-side, not done
re_spsidbyside_nd Number: 1=?, 2=? Drop down: ?, ? 1=?, 0=? Only one option 
possible
Balance semi-tandem, 
time
balasemitantime Number n.n sec. Must be ≤10. Variable 
sidebysidetime must 
be ≥10
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Correction - Balance 
semi-tandem, time
re_balasemitantime Number n.n sec. Must be ≤10. Variable 
sidebysidetime must 
be ≥10
Balance semi-tandem, 
points
balasemitandpts Number n Must be in range 0-1
Correction - Balance 
semi-tandem, points
re_balasemitandpts Number n Must be in range 0-1
Balance semi-tandem, 
not done
spsemitand_nd Number: 1=?, 2=? Drop down: ?, ? 1=?, 0=? Only one option 
possible
Correction - Balance 
semi-tandem, not done
re_spsemitand_nd Number: 1=?, 2=? Drop down: ?, ? 1=?, 0=? Only one option 
possible
Balance tandem, time baltandemtime Number n.n sec. Must be ≤10. Variables 
sidebysidetime and  
balasemitantime must 
be ≥10
Correction - Balance 
tandem, time
re_baltandemtime Number n.n sec. Must be ≤10. Variables 
sidebysidetime and  
balasemitantime must 
be ≥10
Balance tandem, 
points
baltandempts Number n Must be in range 0-2. 
One additional point if 
3-9.99 seconds. Zero 
points if <3 seconds.
Correction - Balance 
tandem, points
re_baltandempts Number n Must be in range 0-2. 
One additional point if 
3-9.99 seconds. Zero 
points if <3 seconds.
Balance tandem, not 
done
spbaltand_nd Number: 1=?, 2=? Drop down: ?, ? 1=?, 0=? Only one option 
possible
Correction - Balance 
tandem, not done
re_spbaltand_nd Number: 1=?, 2=? Drop down: ?, ? 1=?, 0=? Only one option 
possible
Sum points of balance sumbalancepts Number n Must be in range 0-4
Correction - Sum 
points of balance
re_sumbalancepts Number n Must be in range 0-4
Effort 1 of 4m gait 
speed test
gaitspedef1time Number n.n sec. Must be in range 0-60
Effort 2 of 4m gait 
speed test
gaitspedef2time Number n.n sec. Must be in range 0-60
Best time of effort 1 
and 2 of 4m gait speed 
test
re_gaitsped_besttime Number n.n sec. Must be in range 0-60
Converted points 4m 
gait speed test
bestgaitspeed Number n Must be in range 0-4. 
One point if > 8.70 
sec.; two points if 6.21-
8.70 sec.; three points 
if 4.82-6.20 sec.; four 
points if <4.82 sec.
Correction - 
Converted points 4m 
gait speed test
re_bestgaitspeedpts Number n Must be in range 0-4. 
One point if > 8.70 
sec.; two points if 6.21-
8.70 sec.; three points 
if 4.82-6.20 sec.; four 
points if <4.82 sec.
Gait speed test, not 
done
sp_gaitspeednd Number: 1=?, 2=? Drop down: ?, ? 1=?, 0=? Only one option 
possible
Correction - Gait 
speed test, not done
re_sp_gaitspeednd Number: 1=?, 2=? Drop down: ?, ? 1=?, 0=? Only one option 
possible
Chair stand, time chairstandtime Number n.n sec. Must be in range 0-120
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Correction - Chair 
stand, time
re_chairstandtime Number n.n sec. Must be in range 0-120
Chair stand, points chairstandpts Number n Must be in range 0-4. 
One point if 16.70-60 
sec.; two points if 
13.70-16.69 sec.; three 
points if 11.20-13.69 
sec.; four points if 
<11.20 sec.
Correction - Chair 
stand, points
re_chairstandpts Number n Must be in range 0-4. 
One point if 16.70-60 
sec.; two points if 
13.70-16.69 sec.; three 
points if 11.20-13.69 
sec.; four points if 
<11.20 sec.
Chair stand test, not 
done
sp_chairstandnd Number: 1=?, 2=? Drop down: ?, ? 1=?, 0=? Only one option 
possible
Correction - Chair 
stand test, not done
re_sp_chairstandnd Number: 1=?, 2=? Drop down: ?, ? 1=?, 0=? Only one option 
possible
Total sum of SPPB totalsumsppb Number n Must be in range 0-12. 
Summation of 
variables 
sumbalancepts , 
bestgaitspeed and  
chairstandpts
Correction - Total sum 
of SPPB
re_totalsumsppb Number n Must be in range 0-12. 
Summation of 
variables 
sumbalancepts , 
bestgaitspeed and  
chairstandpts
All 3 SPPB 
components 
completed?
re_all_3_sppb_comps Text: Yes, No Drop down: Yes, No Yes, No Only one option 
possible
TABLE: Baseline data
6 MINUTE WALK TEST (6MWT) Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
6MWT undertaken? walktestdone Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Date of 6MWT walktestdate Date dd/mm/yyyy Should be ≥ visitdate
Distance walked distancewalked Number nnn metres Must be in range 0-999
Pre-walk O2 
saturations
prewalk02satur Number nn % Must be in range 50-
100
Post-walk O2 
saturations
postwalk02satur Number nn % Must be in range 50-
100
Pre-walk borg rating prewalkborgrate Number nn Must be in range 0-10
Post-walk borg rating postwalkborgrat Number nn Must be in range 0-10
Did the patient require 
O2 supplementation?
o2supplerecd Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Did the patient require 
O2 supplementation?
o2requiredlts Number n L Must be in range 0-10
TABLE: Baseline data
VENEPUNCTURE/URINE SAMPLE Home
CRF field name short field name Field type Description Format Validation rules 
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(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
Blood sample taken? bloodsmpletaken Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Date of blood sample 
taken
bloodsmpledate Date dd/mm/yyyy Should be ≥ visitdate
Sodium sodium Number nnn mEq/L Must be in range 115-
146
Potassium potassium Number n.n  mEq/L Must be in range 2.9-
6.0
Creatinine creatinine Number nn  mg/dL Must be in range 50-
700
Glucose glucose Number n.n mmol/L Must be in range 3.0-
9.0
Glycated haemoglobin 
(HBA1c)
hba1c Number nn mmol/mol Must be in range 30-
100
Correction - Glycated 
haemoglobin (HBA1c)
re_hba1c Number nn mmol/mol Must be in range 30-
100
Glomerular filtration 
rate
gfr Number nn.nn Must be in range 0-130
Fibrinogen fibrinogen Number n.n g/dL Must be in range 1.0-
7.0
High-sensitivity c-
reactive protein 
(HSCRP)
hscrp Number n.nn mg/L Must be in range 0-200
White blood cell count wbc Number n.n mcL Must be in range 3-
20x109
Haemoglobin haemoglobin Number nnn g/L Must be in range 6-20
Correction - 
Haemoglobin 
re_haemoglobin Number nnn g/L Must be in range 6-20
Platelets platelets Number nnn mcL Must be in range 0-
800x109
Neutrophils neutrophils Number n.n mm3 Must be in range 1-
15x109
Total cholesterol totalcholestrol Number n.n mmol/L Must be <10.0
LDL cholesterol ldlcholestrol Number n.n mmol/L Must be <5.0
HDL cholesterol hdlcholestrol Number n.n mmol/L Must be <5.0
Triglycerides triglycerides Number n.n mg/dL Must be <5.0
Urine sample 
collected?
urinesmpletaken Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Date of urine sample 
collected
urinesmpledate Date dd/mm/yyyy Should be ≥ visitdate
Serum stored serumstoredone Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
TABLE: Baseline data
BLOOD PRESSURE AND ARTERIAL STIFFNESS Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
Date of blood pressure 
and arterial stiffness 
bpartstifdat Date dd/mm/yyyy Should be ≥ visitdate
Seated brachial blood 
pressure (systolic)
seatedsysbp Number nnn mmHg Must be in range 50-
250
Seated brachial blood 
pressure (diastolic)
seateddiabp1 Number nn mmHg Must be in range 40-
150
Seated central blood 
pressure (systolic)
seatcentsysbp Number nnn mmHg Must be in range 50-
250
Seated central blood 
pressure (diastolic)
seatcentbpdia Number nn mmHg Must be in range 40-
150
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Seated heart rate 
(SphygmoCor)
seathr Number nn bpm Must be in range 40-
200
Seated mean arterial 
pressure
seatedmap Number nn mmHg Must be in range 40-
200
Seated augmentation 
index
seatedaugindex Number nn % Must be in range -10-
60
Supine pulse wave 
velocity – notch-
carotid (proximal)
notchcarotidp Number nn mm Must be in range 30-
200
Supine pulse wave 
velocity – notch-
femoral (distal)
notchfemorald Number nnn mm Must be in range 300-
1000
Supine blood pressure 
(systolic)
supinesysbp Number nn mmHg Must be in range 50-
250
Supine blood pressure 
(diastolic)
supinediabp1 Number nn mmHg Must be in range 40-
150
Pulse wave velocity pwv1 Number n.n m/sec Must be in range 4-20
Supine heart rate 
(SphygmoCor)
suphr Number nn bpm Must be in range 40-
200
TABLE: Baseline data
CAROTID INTIMA-MEDIA THICKNESS (CIMT) Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
CIMT done imtdone Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Date of CIMT imtdate Date dd/mm/yyyy Should be ≥ visitdate
Right CIMT diameter imt_diam_r Number n.nn mm Must be in range 3.0-
15
Left CIMT diameter imt_diam_l Number n.nn mm Must be in range 3.0-
15
Right CIMT test imt_cimt_r Number n.nn mm Must be in range 0.0-
2.0
Left CIMT test imt_cimt_l Number n.nn mm Must be in range 0.0-
2.0
TABLE: Baseline data
SNIFF NASAL INSPIRATORY PRESSURE (SNIP) Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
SNIP undertaken? snipdone Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Date of SNIP snipdate Date dd/mm/yyyy Should be ≥ visitdate
SNIP right nostril 
(highest value)
rightnostsnip Number nn cmH2O Must be in range 0-200
TABLE: Baseline data
QUADRICEPS MAXIMAL VOLUNTARY CONTRACTION (QMVC) Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
QMVC undertaken? qmvcdone Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Date of QMVC qmvcdate Date dd/mm/yyyy Should be ≥ visitdate
Highest/best effort 
QMVC
besteffort_qmvc Number nn.n kg Must be in range 0-100
TABLE: ERICA PARTICPIANT’S QUESTIONNAIRE
GENERIC Home
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CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
ERICA questionnaire 
completion date
ericquescompdat Date dd/mm/yyyy Should be ≥ visitdate
Age derived agederied Number nn yrs Must be ≥40
Birth weight birthweight Number n.n kg Must be in range 0.2-7
Are you employed? employ Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Have you had any jobs 
involving work with 
any of these?
job Number: 0=No, 
1=Coal, 2=Asbestos, 
3= Chemicals, 4=Dust
Drop down: No, Coal, 
Asbestos, Chemicals, 
Dust
0=No, 1=Coal, 
2=Asbestos, 3= 
Chemicals, 4=Dust
Multiple options 
possible
Have you had any jobs 
involving work with 
any of these?
jobyn Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Multiple options 
possible
If yes, please specify 
approximately how 
long for 
joblong Number nn Must be in range 0-999
If yes, please specify 
approximately how 
long for 
jobunit Number: 1=Days, 2= 
Weeks, 3=Months, 
4=Years
Drop down: Days, 
Weeks, Months, Years
1=Days, 2= Weeks, 
3=Months, 4=Years
Multiple options 
possible
Are you married or 
cohabiting?
marr Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If not married/ co-
habiting, are you:  
ntmarr Number: 1=Single / 
never married, 
2=Widowed, 
3=Divorced, 
4=Separated
Drop down: Single / 
never married, 
Widowed, Divorced, 
Separated
1=Single / never 
married, 2=Widowed, 
3=Divorced, 
4=Separated
Only one option 
possible
If widowed/ divorced 
or separated, what 
year?
marryr Date yyyy Should be ≤ visitdate
TABLE: ERICA PARTICPIANT’S QUESTIONNAIRE
LUNG HEALTH Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
Do you get short of 
breath?
srtbreath Number: 0=No, 1=All 
the time, 2=Worse at 
certain times of the 
day, 3=With exercise 
only, 4=Night only
Drop down: No, All the 
time, Worse at certain 
times of the day, With 
exercise only, Night 
only
0=No, 1=All the time, 
2=Worse at certain 
times of the day, 
3=With exercise only, 
4=Night only
Only one option 
possible
Do you cough? eqcough Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If you cough, do you 
produce phlegm 
(sputum)?
eqphlegm Number: 0=Never, 
1=Yes, most 
mornings, 2=At least 
three months per year, 
3=Only with 
exacerbations, 
4=Occasionally
Drop down: Never, 
Yes, most mornings, 
At least three months 
per year, Only with 
exacerbations, 
Occasionally
0=Never, 1=Yes, most 
mornings, 2=At least 
three months per year, 
3=Only with 
exacerbations, 
4=Occasionally
Only one option 
possible
When were you 
diagnosed with 
COPD?
copdage Number nn yrs Must be in range 30-
100
When were you 
diagnosed with 
COPD?
copddiayear Date yyyy Should be ≤ visitdate
Can you climb a flight 
of stairs without 
stopping?
eqstairs Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
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Which statement best 
describes your 
breathlessness? 
descbreath Number: 1=I only get 
breathless with 
strenuous exercise, 
2=I get short of breath 
when hurrying on the 
level or walking up a 
slight hill, 3=I walk 
slower than people on 
the level/stop for 
breath when walking at 
own pace, 4=I stop for 
breath after walking 
about 100 yards or 
after a few minutes on 
the level, 5=I am too 
breathless to leave the 
house or I am 
breathless when 
dressing
Drop down: I only get 
breathless with 
strenuous exercise, I 
get short of breath 
when hurrying on the 
level or walking up a 
slight hill, I walk 
slower than people on 
the level/stop for 
breath when walking at 
own pace, I stop for 
breath after walking 
about 100 yards or 
after a few minutes on 
the level, I am too 
breathless to leave the 
house or I am 
breathless when 
dressing
1=I only get breathless 
with strenuous 
exercise, 2=I get short 
of breath when 
hurrying on the level or 
walking up a slight hill, 
3=I walk slower than 
people on the 
level/stop for breath 
when walking at own 
pace, 4=I stop for 
breath after walking 
about 100 yards or 
after a few minutes on 
the level, 5=I am too 
breathless to leave the 
house or I am 
breathless when 
dressing
Only one option 
possible
Have you ever 
smoked cigarettes? 
smoked Number: 0=No, 1= 
Yes - I currently 
smoke, 2= Yes - but I 
have given up
Drop down: No, Yes - I 
currently smoke, Yes - 
but I have given up
0=No, 1= Yes - I 
currently smoke, 2= 
Yes - but I have given 
up
Only one option 
possible
If you smoke or have 
smoked, how many 
cigarettes did you 
smoke each day? 
smokenum Number n per day Must be in range 1-999
If you smoke or have 
smoked, how many 
years was this for? 
smokeyrs Number n yrs Must be in range 1-100
What age did you start 
smoking?
smokeage Number n yrs old Must be in range 7-100
If you have given up, 
how many years ago?
smokegiven Number n yrs ago Must be in range 0-100
Have you been a cigar 
smoker?
cigar Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, how many cigarnum Number n per day Must be in range 1-999
How many years have 
you smoked cigars? 
cigaryrs Number n yrs Must be in range 0-100
Have you ever 
regularly smoked 
social drugs, for e.g. 
cannabis? 
drug Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Total pack years totalpackyears Number nn yrs Must be ≥10
Have you ever 
required steroids?
steroids Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Have you ever 
required antibiotics for 
your chest?
antibi Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, how many 
courses of steroids 
have you required in 
the last 12 months? 
stcourse Number n coure(s) Must be in range 0-999
If yes, how many 
courses of antibiotics 
have you required in 
the last 12 months? 
abcourse Number n course(s) Must be in range 0-999
When was your last 
course of steroids/ 
antibiotics? 
lascousestds Number n wks ago Must be in range 0-999
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Do you have oxygen at 
home?
oxygen Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, how many 
hours a day, have you 
been advised to use it? 
oxyhrs Number n hrs/day Must be in range 0-24
Do you snore? snore Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Do you have sleep 
apnoea (OSA)?
apnoea Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
How likely are you to 
doze off or fall asleep 
in the following 
situations in contrast to 
just feeling tired?
doze Number: 1=Sitting and 
reading, 2=Watching 
TV, 3=Sitting inactive 
in a public place, 4=As 
passenger in a car for 
an hour without break, 
5=Lying down to rest 
during the day when 
circumstances permit, 
6=Sitting and talking to 
someone, 7=Sitting 
quietly after lunch 
without alcohol, 8=In a 
car, while stopped for 
a few minutes in traffic
Drop down: Sitting and 
reading, Watching TV, 
Sitting inactive in a 
public place, As 
passenger in a car for 
an hour without break, 
Lying down to rest 
during the day when 
circumstances permit, 
Sitting and talking to 
someone, Sitting 
quietly after lunch 
without alcohol, In a 
car, while stopped for 
a few minutes in traffic
1=Sitting and reading, 
2=Watching TV, 
3=Sitting inactive in a 
public place, 4=As 
passenger in a car for 
an hour without break, 
5=Lying down to rest 
during the day when 
circumstances permit, 
6=Sitting and talking to 
someone, 7=Sitting 
quietly after lunch 
without alcohol, 8=In a 
car, while stopped for 
a few minutes in traffic
Chance of dozing dozescale Number: 0=Would 
never doze, 1=Slight 
chance of dozing, 
2=Moderate chance of 
dozing, 3=High chance 
of dozing
Drop down: Would 
never doze, Slight 
chance of dozing, 
Moderate chance of 
dozing, High chance of 
dozing
0=Would never doze, 
1=Slight chance of 
dozing, 2=Moderate 
chance of dozing, 
3=High chance of 
dozing
Only one option 
possible
Have you ever done 
pulmonary 
rehabilitation?
pulrehab Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, did you 
complete the whole 
course?
pulrehabcomp Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
How long ago was the 
course? 
pulrehabyrs Number n yrs Must be in range 0-100
What limits your 
walking? 
pulrehablim Number: 
0=Breathlessness, 
1=Legs, 
2=Nothing/other 
Drop down: 
Breathlessness, Legs, 
Nothing/other
0=Breathlessness, 
1=Legs, 
2=Nothing/other
Only one option 
possible
Have you lost or 
gained any weight in 
the last 12 months?
eqweight Number: 0=Stayed 
about same, 1=Lost 
weight, 2=Gained 
weight
Drop down: Stayed 
about same, Lost 
weight, Gained weight
0=Stayed about same, 
1=Lost weight, 
2=Gained weight
Only one option 
possible
TABLE: ERICA PARTICPIANT’S QUESTIONNAIRE
ACTIVITIES Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
How often do you take 
part in sport or 
activities that are 
mildly energetic, 
moderately energetic 
or vigorous?
sport Number: 1=Mildly 
energetic, 
2=Moderately 
energetic, 3=Vigorous
Drop down: Mildly 
energetic, Moderately 
energetic, Vigorous
1=Mildly energetic, 
2=Moderately 
energetic, 3=Vigorous
Multiple options 
possible
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How often do you take 
part in sport or 
activities that are 
mildly energetic, 
moderately energetic 
or vigorous?
sportscale Number: 0=Never/ 
hardly ever, 1=Three 
times a week, 2=Once 
or twice a week, 
3=About once or three 
times a month
Drop down: Never/ 
hardly ever, Three 
times a week, Once or 
twice a week, About 
once or three times a 
month
0=Never/ hardly ever, 
1=Three times a 
week, 2=Once or 
twice a week, 3=About 
once or three times a 
month
Multiple options 
possible
Please give the 
average number of 
hours per week that 
you spend in such 
activities
sportav Number: 1=Mildly 
energetic, 
2=Moderately 
energetic, 3=Vigorous
Drop down: Mildly 
energetic, Moderately 
energetic, Vigorous
1=Mildly energetic, 
2=Moderately 
energetic, 3=Vigorous
Multiple options 
possible
Please give the 
average number of 
hours per week that 
you spend in such 
activities
sporthrs Number n hrs/week Must be in range 0-140
In the past week, on 
average, for how long 
did you walk outside 
your home/workplace 
on each weekday?
walkweekdayeq1 Text nn.nn.nn hrs/min Must be in range 0-24
In the past week, on 
average, for how long 
did you walk outside 
your home/workplace 
on each weekend day?
walkweekendeq1 Text nn.nn.nn hrs/min Must be in range 0-24
Walking, not recorded walknoeq1 Number: 1=Yes Drop down: Yes 1=Yes Only one option 
possible
In the past, on average, 
for how long did you 
cycle on each 
weekday?
cycleweekdayeq1 Text nn.nn.nn hrs/min Must be in range 0-24
In the past, on average, 
for how long did you 
cycle on each 
weekend day?
cycleweekendeq1 Text nn.nn.nn hrs/min Must be in range 0-24
Cycling, not recorded cyclenoeq1 Number: 1=Yes Drop down: Yes 1=Yes Only one option 
possible
How would you 
describe your usual 
walking pace?
walkpace Number: 1=Slow pace 
(<3mph), 2=Steady 
average pace, 3=Brisk 
pace, 4=Fast pace 
(>4mph)
Drop down: Slow pace 
(<3mph), Steady 
average pace, Brisk 
pace, Fast pace 
(>4mph)
1=Slow pace 
(<3mph), 2=Steady 
average pace, 3=Brisk 
pace, 4=Fast pace 
(>4mph)
Only one option 
possible
TABLE: ERICA PARTICPIANT’S QUESTIONNAIRE
PAST MEDICAL HISTORY Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
Have you ever been 
told by your doctor that 
you have high blood 
pressure?
highbp Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If high blood pressure, 
in what year?
highbpyr Date yyyy Should be ≤ visitdate
If high blood pressure, 
are you on therapy for 
it?
bpther Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
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If high blood pressure 
therapy, in what year?
bptheryr Date yyyy Should be ≤ visitdate
Please specify the 
drug name.
bpdrug Max characters 50 Free text
Have you ever been 
told by your doctor that 
you have high 
cholesterol?
highchol Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If high cholesterol, in 
what year?
highcholyr Date yyyy Should be ≤ visitdate
If high cholesterol, are 
you on therapy for it?
cholther Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If high cholesterol 
therapy, in what year?
choltheryr Date yyyy Should be ≤ visitdate
Please specify the 
drug name.
choldrug Max characters 50 Free text
Have you ever been 
told by your doctor that 
you have peripheral 
vascular disease?
pvd Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If peripheral vascular 
disease, in what year?
pvdyr Date yyyy Should be ≤ visitdate
If peripheral vascular 
disease, are you on 
therapy for it?
pvdther Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If peripheral vascular 
disease therapy, in 
what year?
pvdtheryr Date yyyy Should be ≤ visitdate
Please specify the 
drug name.
pvddrug Max characters 50 Free text
Have you ever been 
told by your doctor that 
you have atrial 
fibrillation?
afib Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If atrial fibrillation, in 
what year?
afibyr Date yyyy Should be ≤ visitdate
If atrial fibrillation, are 
you on therapy for it?
afibther Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If atrial fibrillation 
therapy, in what year?
afibtheryr Date yyyy Should be ≤ visitdate
Please specify the 
drug name.
afibdrug Max characters 50 Free text
Have you ever been 
told by your doctor that 
you have diabetes?
diab Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If diabetes, in what 
year?
diabyr Date yyyy Should be ≤ visitdate
If diabetes, which 
type?
diabtype Number: 0=Don’t 
know, 1=Type I, 
2=Type II
Drop down: Don’t 
know, Type I, Type II
0=Don’t know, 1=Type 
I, 2=Type II
Only one option 
possible
Has a doctor told you 
that you have had 
angina?
angina_eq1 Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If angina, in what year? anginayear Date yyyy Should be ≤ visitdate
Has a doctor told you 
that you have had a 
heart attack?
heartattack_eq1 Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If heart attack, in what 
year?
heartattackyear Date yyyy Should be ≤ visitdate
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Has a doctor told you 
that you have had a 
stroke or transient 
attack?
stroke_eq1 Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If stroke or TIA, in 
what year?
strokeyear Date yyyy Should be ≤ visitdate
If stroke or TIA what 
type?
stroketype_eq1 Number: 1=Stroke, 
2=TIA, 3=Other, 
specify
Drop down: Stroke, 
TIA, Other, specify
1=Stroke, 2=TIA, 
3=Other, specify
Only one option 
possible
If other, please 
specify? 
otherstroke Max characters 50 Free text
Any other heart trouble 
suspected or 
confirmed?
eq_hrtrouble Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If any other heart 
trouble, please specify
eq_hrtrobother Max characters 50 Free text
TABLE: ERICA PARTICPIANT’S QUESTIONNAIRE
FAMILY HISTORY Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
Was your father ever 
diagnosed with high 
blood pressure?
fatherhighbp Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If father high blood 
pressure, younger than 
60 when diagnosed?
fathyoung60bp Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your father ever 
diagnosed with 
angina?
fatheangina Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If father angina, 
younger than 60 when 
diagnosed?
fathyng60angna Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your father ever 
diagnosed with a heart 
attack?
fatherheartatk Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If father heart attack, 
younger than 60 when 
diagnosed?
dadyng60hrtatk Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your father ever 
diagnosed with a 
stroke?
fatherstroke Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If father stroke, 
younger than 60 when 
diagnosed?
fathyng60stroke Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your father ever 
diagnosed with 
peripheral vascular 
disease?
fatherpvd Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If father peripheral 
vascular disease, 
younger than 60 when 
diagnosed?
fathyng60pvd Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your father ever 
diagnosed with 
diabetes?
fatherdiabetes Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If father diabetes, 
younger than 60 when 
diagnosed?
fathyoung60diab Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
247
Was your father ever 
diagnosed with 
asthma?
fatherasthma Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If father asthma, 
younger than 60 when 
diagnosed?
fathyng60asthma Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your father ever 
diagnosed with 
COPD?
fathercopd Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If father COPD, 
younger than 60 when 
diagnosed?
fathyng60copd Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your mother ever 
diagnosed with high 
blood pressure?
motherhighbp Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If mother high blood 
pressure, younger than 
60 when diagnosed?
mumyoung60bp Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your mother ever 
diagnosed with 
angina?
motherangina Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If mother angina, 
younger than 60 when 
diagnosed?
mumyng60angina Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your mother ever 
diagnosed with a heart 
attack?
mumheartattack Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If mother heart attack, 
younger than 60 when 
diagnosed?
mumyng60hrtatk Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your mother ever 
diagnosed with a 
stroke?
motherstroke Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If mother stroke, 
younger than 60 when 
diagnosed?
mumyng60stroke Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your mother ever 
diagnosed with 
peripheral vascular 
disease?
motherpvd Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If mother peripheral 
vascular disease, 
younger than 60 when 
diagnosed?
mumyng60pvd Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your mother ever 
diagnosed with 
diabetes?
motherdiabetes Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If mother diabetes, 
younger than 60 when 
diagnosed?
mumyng60diabe Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your mother ever 
diagnosed with 
asthma?
motherasthma Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If mother asthma, 
younger than 60 when 
diagnosed?
mumyng60asthma Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Was your mother ever 
diagnosed with 
COPD?
mothercopd Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If mother COPD, 
younger than 60 when 
diagnosed?
mumyng60copd Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
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Do you have any 
sibling?
anysibling Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Were your 
brother(s)/sister(s) 
ever diagnosed with 
high blood pressure?
siblinghighbp Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If brother(s)/sister(s) 
high blood pressure, 
younger than 60 when 
diagnosed?
siblingyng60bp Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Were your 
brother(s)/sister(s) 
ever diagnosed with 
angina?
siblingangina Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If brother(s)/sister(s) 
angina, younger than 
60 when diagnosed?
sibyng60angina Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Were your 
brother(s)/sister(s) 
ever diagnosed with a 
heart attack?
siblinghrtattk Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If brother(s)/sister(s) 
heart attack, younger 
than 60 when 
diagnosed?
sibyng60hrtatk Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Were your 
brother(s)/sister(s) 
ever diagnosed with a 
stroke?
siblingstroke Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If brother(s)/sister(s) 
stroke, younger than 
60 when diagnosed?
sibyng60stroke Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Were your 
brother(s)/sister(s) 
ever diagnosed with 
peripheral vascular 
disease?
siblingpvd Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If brother(s)/sister(s) 
peripheral vascular 
disease, younger than 
60 when diagnosed?
sibyng60pvd Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Were your 
brother(s)/sister(s) 
ever diagnosed with 
diabetes?
siblingdiabetes Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If brother(s)/sister(s) 
diabetes, younger than 
60 when diagnosed?
sibyng60diabe Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Were your 
brother(s)/sister(s) 
ever diagnosed with 
asthma?
siblingasthma Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If brother(s)/sister(s) 
asthma, younger than 
60 when diagnosed?
sibyng60asthma Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Were your 
brother(s)/sister(s) 
ever diagnosed with 
COPD?
siblingcopd Number: 0=No, 
1=Yes, 2=Don’t know
Drop down: No, Yes, 
Don’t know
0=No, 1=Yes, 2=Don’t 
know
Only one option 
possible
If brother(s)/sister(s) 
COPD, younger than 
60 when diagnosed?
sibyng60copd Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
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TABLE: ERICA PARTICPIANT’S QUESTIONNAIRE
MEDICATION Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
Inhaler medications inhoth Max characters 50 Free text
How many times per 
day?
inhaler Number n Must be in range 0-20
Do you have a 
nebuliser?
nebyn Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If so, please let us 
know what drugs you 
regularly use in your 
nebuliser
neboth Max characters 50 Free text
How many times per 
day?
nebuliser Number n Must be in range 0-20
Are there any other 
medications you have 
not mentioned to us in 
question 17 or above?
othdrugyn Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Name other 
medications
othermedname Max characters 50 Free text
How many times per 
day?
othermedtype Number n Must be in range 0-20
Other medications otherdrg1 Max characters 50 Free text
Other medications otherdrg2 Max characters 50 Free text
Other medications otherdrg3 Max characters 50 Free text
Other medications otherdrg4 Max characters 50 Free text
TABLE: ERICA PARTICPIANT’S QUESTIONNAIRE
OTHER INFORMATION Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
On average, how 
much alcohol do you 
consume in a week?
alcohol Number n units Must be in range 0-999
TABLE: ERICA PARTICPIANT’S QUESTIONNAIRE
COPD ASSESSMENT TEST (CAT) Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
Date of CAT catdate Date dd/mm/yyyy Should be ≥ visitdate
Q1 – cough cough Number: 0-5 Only one option 
possible
Q2 – phlegm phlegm Number: 0-5 Only one option 
possible
Q3 – chest chest Number: 0-5 Only one option 
possible
Q4 – stairs stairs Number: 0-5 Only one option 
possible
Q5 – activity activity Number: 0-5 Only one option 
possible
Q6 – confident confident Number: 0-5 Only one option 
possible
Q7 – sleep sleep Number: 0-5 Only one option 
possible
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Q8 – energy energy Number: 0-5 Only one option 
possible
Must be in range 0-40
Summation of 
variables cough, 
phlegm, chest, stairs, 
activity, confident, 
sleep and energy
TABLE: ERICA PARTICPIANT’S QUESTIONNAIRE
ST. GEORGE’S RESPIRATORY QUESTIONNAIRE FOR COPD PATIENTS (SGRQ-C) Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
Date of SGRQ-C sgdate Date dd/mm/yyyy Should be ≥ visitdate
Only one option 
possible
Derived from variable 
sgcough 
Q2: phlegm sgphlegm Number: 1=Most days 
a week, 2=Several 
days a week, 3=Only 
with chest infections, 
4=Not at all
Drop down: Most days 
a week, Several days 
a week, Only with 
chest infections, Not at 
all
1=Most days a week, 
2=Several days a 
week, 3=Only with 
chest infections, 4=Not 
at all
Only one option 
possible
Only one option 
possible
Derived from variable 
sgphlegm 
Only one option 
possible
Derived from variable 
sgbreath 
Q4: attacks of 
wheezing
sgwheez Number: 1=Most days 
a week, 2=Several 
days a week, 3=A few 
days a month, 4=Only 
with chest infections, 
5=Not at all
Drop down: Most days 
a week, Several days 
a week, A few days a 
month, Only with chest 
infections, Not at all
1=Most days a week, 
2=Several days a 
week, 3=A few days a 
month, 4=Only with 
chest infections, 5=Not 
at all
Only one option 
possible
Q3: shortness of 
breath
Number 0, 30.2, 47, 76.8
Q3: shortness of 
breath – score 
sgbreathscore
Total score of CAT totscore Number
Q1 – cough sgcough Number: 1=Most days 
a week, 2=Several 
days a week, 3=Only 
with chest infections, 
4=Not at all
Drop down: Most days 
a week, Several days 
a week, Only with 
chest infections, Not at 
all
1=Most days a week, 
2=Several days a 
week, 3=Only with 
chest infections, 4=Not 
at all
Only one option 
possible
Please select one box 
to show how you 
describe your current 
health
curhealth Number: 0=Very good, 
1=Good, 2=Fair, 
3=Poor, 4=Very poor
Drop down: Very good, 
Good, Fair, Poor, Very 
poor
0=Very good, 1=Good, 
2=Fair, 3=Poor, 
4=Very poor
Only one option 
possible
Q1: cough – score sgcoughscore Number 0, 28.1, 46.3, 80.6
Number 0, 50.3, 87.2
sgbreath Number: 1=Most days 
a week, 2=Several 
days a week, 3=Not at 
all
Drop down: Most days 
a week, Several days 
a week, Not at all
1=Most days a week, 
2=Several days a 
week, 3=Not at all
Only one option 
possible
Q2: phlegm – score sgphlegmscore
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Only one option 
possible
Derived from variable 
sgwheez 
Q5: How many attacks 
of chest trouble did you 
have during the last 
year?
sgattack Number: 1=Three or 
more attacks, 2=One 
or two attacks, 
3=None
Drop down: Three or 
more attacks, One or 
two attacks, None
1=Three or more 
attacks, 2=One or two 
attacks, 3=None
Only one option 
possible
Only one option 
possible
Derived from variable 
sgattack 
Only one option 
possible
Derived from variable 
sggood 
Q7: If you have a 
wheeze, is it worse in 
the morning?
sgmorning Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Only one option 
possible
Derived from variable 
sgmorning
Q8: How would you 
describe your chest 
condition?
sgchest Number: 1=Causes 
me a lot of problems 
or is the most 
important problem I 
have, 2=Causes me a 
few problems, 
3=Causes no problem
Drop down: Causes 
me a lot of problems 
or is the most 
important problem I 
have, Causes me a 
few problems, Causes 
no problem
1=Causes me a lot of 
problems or is the 
most important 
problem I have, 
2=Causes me a few 
problems, 3=Causes 
no problem
Only one option 
possible
Only one option 
possible
Derived from variable 
sgchest
Q9: Getting washed or 
dressed 
sgwash Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgwash
Q9: Walking around 
the home
sghome Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sghome
Q9: Walking outside 
on the level
sgwalklev Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Q8: How would you 
describe your chest 
condition? – score 
sgqchestconscor Number 0, 34.6, 82.9
Q9: Getting washed or 
dressed – score 
sgwashscore Number 0, 82.8
Q9: Walking around 
the home – score 
sghomescore Number 0, 80.2
Q9: Walking outside 
on the level – score 
sgwalklevscore Number 0, 81.4
Only one option 
possible
Q6: How often do you 
have good days (with 
little chest trouble)? – 
score
sggoodscore Number 0, 38.5, 76.7, 93.3
Q5: How many attacks 
of chest trouble did you 
have during the last 
year? – score 
sgattackscore Number 0, 52.3, 80.1
Q6: How often do you 
have good days (with 
little chest trouble)? 
sggood Number: 1=No good 
days, 2=A few good 
days, 3=Most days are 
good, 4=Every day is 
good
Drop down: No good 
days, A few good days, 
Most days are good, 
Every day is good
1=No good days, 2=A 
few good days, 
3=Most days are good, 
4=Every day is good
Q7: If you have a 
wheeze, is it worse in 
the morning? – score 
sgmorningscore Number 0, 62
Q4: attacks of 
wheezing – score
sgwheezscore Number 0, 36.4, 45.6, 71, 86.2
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Derived from variable 
sgwalklev
Q9: Walking up a flight 
of stairs 
sgwlkst Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgwlkst
Q9: Walking up hills sgwlkhill Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgwlkhill
Q10: My cough hurts sgchurts Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgchurts
Q10: My cough makes 
me tired 
sgctired Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgctired
Q10: I am breathless 
when I talk 
sgbrtlk Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgbrtlk
Q10: I am breathless 
when I bend over 
sgbrbend Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgbrbend
Q10: My cough or 
breathing disturbs my 
sleep 
sgcsleep Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgcsleep
Q10: I get exhausted 
easily
sgexhaus Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgexhaus
Q11: My cough or 
breathing is 
embarrassing in public 
sgcembarras Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgcembarras
Q11: My chest trouble 
is a nuisance to my 
family, friends or 
neighbours 
sgfamily Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Q11: My cough or 
breathing is 
embarrassing in public 
– score 
sgcembarrscore Number 0, 74.1
Q10: I am breathless 
when I talk – score 
sgbrtlkscore Number 0, 84.5
Q10: I am breathless 
when I bend over – 
score 
sgbrbendscore Number 0, 76.8
Q10: My cough or 
breathing disturbs my 
sleep – score 
sgcsleepscore Number 0, 87.9
Q10: I get exhausted 
easily – score 
sgexhausscore Number 0, 84
Q9: Walking up a flight 
of stairs – score 
sgwlkstscore Number 0, 76.1
Q9: Walking up hills – 
score 
sgwlkhillscore Number 0, 75.1
Q10: My cough hurts – 
score 
sgchurtsscore Number 0, 81.1
Q10: My cough makes 
me tired – score 
sgctiredscore Number 0, 79.1
Q9: Walking outside 
on the level – score 
sgwalklevscore Number 0, 81.4
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Only one option 
possible
Derived from variable 
sgfamily
Q11: I get afraid or 
panic when I cannot 
get my breath 
sgpanic Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgpanic
Q11: I feel that I am not 
in control of my chest 
problem 
sgcontrol Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgcontrol
Q11: I have become 
frail or an invalid 
because of my chest 
sgfrail Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgfrail
Q11: Exercise is not 
safe for me 
sgexsafe Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgexsafe
Q11: Everything 
seems too much of an 
effort 
sgeffort Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgeffort
Q12: I take a long time 
to get washed or 
dressed
sgwashtime Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgwashtime
Q12: I cannot take a 
bath or shower, or I 
take a long time 
sgbath Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgbath
Q12: I walk slower 
than other people, or I 
stop for rests
sgwlkslow Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgwlkslow
Q12: I cannot take a 
bath or shower, or I 
take a long time – 
score 
sgbathscore Number 0, 81
Q12: I walk slower 
than other people, or I 
stop for rests – score 
sgwlkslowscore Number 0, 71.7
Q11: I have become 
frail or an invalid 
because of my chest – 
score 
sgfrailscore Number 0, 89.9
Q11: Exercise is not 
safe for me – score 
sgexsafescore Number 0, 75.7
Q11: Everything 
seems too much of an 
effort – score 
sgeffortscore Number 0, 84.5
Q12: I take a long time 
to get washed or 
dressed – score 
sgwashtimescore Number 0, 74.2
Q11: My chest trouble 
is a nuisance to my 
family, friends or 
neighbours – score 
sgfamilyscore Number 0, 79.1
Q11: I get afraid or 
panic when I cannot 
get my breath – score 
sgpanicscore Number 0, 87.7
Q11: I feel that I am not 
in control of my chest 
problem – score 
sgcontrolscore Number 0, 90.1
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Q12: Jobs such as 
housework take a long 
time, or I have to stop 
for rests
sgjobs Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgjobs
Q12: If I walk up one 
flight of stairs, I have to 
go slowly or stop
sgstslow Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgstslow
Q12: If I hurry or walk 
fast, I have to stop or 
slow down
sghurry Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sghurry
Q12: My breathing 
makes it difficult to do 
things such as walk up 
hills, etc.
sgdiffgolf Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgdiffgolf
Q12: My breathing 
makes it difficult to do 
things such as carry 
heavy loads, etc.
sgdiffswim Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgdiffswim
Q13: I cannot play 
sports or games 
sgsports Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgsports
Q13: I cannot go out for 
entertainment or 
recreation 
sgenter Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgenter
Q13: I cannot go out of 
the house to do the 
shopping 
sgshop Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgshop
Q13: I cannot do 
housework
sghousework Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Q13: I cannot go out for 
entertainment or 
recreation – score 
sgenterscore Number 0, 79.8
Q13: I cannot go out of 
the house to do the 
shopping – score 
sgshopscore Number 0, 81
Q12: If I hurry or walk 
fast, I have to stop or 
slow down – score 
sghurryscore Number 0, 72.3
Q12: My breathing 
makes it difficult to do 
things such as walk up 
hills, etc. – score 
sgdiffgolfscore Number 0, 74.5
Q12: My breathing 
makes it difficult to do 
things such as carry 
heavy loads, etc. – 
score 
sgdiffswimscore Number 0, 71.4
Q13: I cannot play 
sports or games – 
score 
sgsportsscore Number 0, 64.8
Q12: Jobs such as 
housework take a long 
time, or I have to stop 
for rests – score 
sgjobsscore Number 0, 70.6
Q12: If I walk up one 
flight of stairs, I have to 
go slowly or stop – 
score 
sgstslowscore Number 0, 71.6
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Only one option 
possible
Derived from variable 
sghousework
Q13: I cannot move far 
from my bed or chair 
sgbed Number: 1=True, 
0=False
Drop down: True, 
False
1=True, 0=False Only one option 
possible
Only one option 
possible
Derived from variable 
sgbed
Q14: How does your 
chest trouble affect 
you? 
sgaffect Number: 0=It does not 
stop me doing anything 
I would like to do, 1=It 
stops me doing one or 
two things I would like 
to do, 2=It stops me 
doing most of the 
things I would like to 
do, 3=It stops me 
doing everything I 
would like to do
Drop down: It does not 
stop me doing anything 
I would like to do, It 
stops me doing one or 
two things I would like 
to do, It stops me doing 
most of the things I 
would like to do, It 
stops me doing 
everything I would like 
to do
0=It does not stop me 
doing anything I would 
like to do, 1=It stops 
me doing one or two 
things I would like to 
do, 2=It stops me 
doing most of the 
things I would like to 
do, 3=It stops me 
doing everything I 
would like to do
Only one option 
possible
Only one option 
possible
Derived from variable 
sgaffect
TABLE: Follow Up Questionnaire –  6, 12, 18, 24 and 32 months
CARDIAC HEALTH Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
fupvisitdate Date
fupvisitdate1
fupvisitdate2 999=missing
fupvisitdate3
fupvisitdate4
fupangina
fupangina1
fupangina2 
fupangina3
fupangina4
anghosp
anghosp1
anghosp2 
anghosp3
anghosp4
angover
angover1
angover2 
angover3
angover4
angaddate
angaddate1
angaddate2 
angaddate3
angaddate4
fuphattack
fuphattack1
fuphattack2 
fuphattack3
fuphattack4
If you did go to 
hospital, did you stay 
overnight? 
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Angina – date of 
admission
Date dd/mm/yyyy Should be ≥ visitdate
Since we last saw you, 
has a doctor told you 
that you have had a 
heart attack? 
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Q14: How does your 
chest trouble affect 
you? – score 
sgaffectscore Number 0, 42, 84.2, 96.7
Follow up date dd/mm/yyyy Should be ≥ visitdate
Since we last saw you, 
has a doctor told you 
that you have had 
angina? 
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, did you go to 
hospital?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Q13: I cannot do 
housework – score 
sghseworkscore Number 0, 79.1
Q13: I cannot move far 
from my bed or chair – 
score 
sgbedscore Number 0, 94
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hattackwhn
hattackwhn1
hattackwhn2 
hattackwhn3
hattackwhn4
hattackhosp
hattackhosp1
hattackhosp2 
hattackhosp3
hattackhosp4
hattackover
hattackover1
hattackover2 
hattackover3
hattackover4
fuphyperten
fuphyperten1
fuphyperten2 
fuphyperten3
fuphyperten4
hypertendiag
hypertendiag1
hypertendiag2 
hypertendiag3
hypertendiag4
fuphyperchol
fuphyperchol1
fuphyperchol2 
fuphyperchol3
fuphyperchol4
hypercholdiag
hypercholdiag1
hypercholdiag2 
hypercholdiag3
hypercholdiag4
fupstroke
fupstroke1
fupstroke2 
fupstroke3
fupstroke4
stroketype
stroketype1
stroketype2 
stroketype3
stroketype4
stroketypeoth
stroketypeoth1
stroketypeoth2 
stroketypeoth3
stroketypeoth4
strokewhen
strokewhen1
strokewhen2 
strokewhen3
strokewhen4
strokehosp
strokehosp1
strokehosp2 
strokehosp3
strokehosp4
strokeover
strokeover1
If other, specify Max characters 50 Free text
If yes, when? Date dd/mm/yyyy Should be ≥ visitdate
If yes, did you go to 
hospital? 
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If you did go to 
hospital, did you stay 
overnight?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Since we last saw you, 
have you been told by 
a doctor that you have 
high cholesterol?
Number: 0=No, 1=Yes 
new diagnosis, 2=Was 
already diagnosed
Drop down: No, Yes 
new diagnosis, Was 
already diagnosed
0=No, 1=Yes, new 
diagnosis, 2=Was 
already diagnosed
Only one option 
possible
If you have been newly 
diagnosed, are you on 
treatment, if so which
Max characters 50 Free text
Since we last saw you, 
have you been told by 
a doctor that you have 
had a stroke or 
transient attack?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, which type? Number: 1=Stroke, 
2=Transient Ischemic 
Attack, 999=Other
Drop down: Stroke, 
Transient Ischemic 
Attack, Other
1=Stroke, 2=Transient 
Ischemic Attack, 
999=Other
Only one option 
possible
If yes, did you go to 
hospital?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If you did go to 
hospital, did you stay 
overnight? 
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Since we last saw you, 
have you been told by 
a doctor that you have 
high blood pressure?
Number: 0=No, 1=Yes 
new diagnosis, 2=Was 
already diagnosed
Drop down: No, Yes 
new diagnosis, Was 
already diagnosed
0=No, 1=Yes, new 
diagnosis, 2=Was 
already diagnosed
Only one option 
possible
If you have been newly 
diagnosed, are you on 
treatment, if so which
Max characters 50 Free text
If yes, when Date dd/mm/yyyy Should be ≥ visitdate
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strokeover2 
strokeover3
strokeover4
fupdiab
fupdiab1
fupdiab2 
fupdiab3
fupdiab4
diabtreat
diabtreat1
diabtreat2 
diabtreat3
diabtreat4
chestpain
chestpain1
chestpain2 
chestpain3
chestpain4
walkhurry
walkhurry1
walkhurry2 
walkhurry3
walkhurry4
walkord
walkord1
walkord2 
walkord3
walkord4
pain 
pain1
pain2 
pain3
pain4
standstill
standstill1
standstill2 
standstill3
standstill4
howsoon
howsoon1
howsoon2 
howsoon3
howsoon4
painsite
painsite1
painsite2 
painsite3
painsite4
sevpain
sevpain1
sevpain2 
sevpain3
sevpain4
talkdoc 
talkdoc1
talkdoc2 
talkdoc3
talkdoc4
doccom
doccom1
doccom2 
doccom3
Where do you get this 
pain or discomfort?
Max characters 50 Free text
Since we saw you last, 
have you had a severe 
pain across the front of 
your chest lasting half 
an hour or more?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, did you talk to a 
doctor about it?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
What did he/she say 
about it?
Max characters 50 Free text
If yes, do you get it 
when you walk at an 
ordinary pace on the 
level?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, when you get 
any pain or discomfort 
in your chest, what do 
you do?
Number: 0=Stop, 
1=Slow down, 
2=Continue at the 
same pace
Drop down: Stop, Slow 
down, Continue at the 
same pace
0=Stop, 1=Slow down, 
2=Continue at the 
same pace
Only one option 
possible
If yes, does it go away 
when you stand still?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, how soon? Number: 0=In ten 
minutes or less, 
1=More than ten 
minutes
Drop down: In ten 
minutes or less, More 
than ten minutes
0=In ten minutes or 
less, 1=More than ten 
minutes
Only one option 
possible
Since we last saw you, 
have you been told by 
a doctor that you have 
diabetes?
Number: 0=No, 1=Yes 
new diagnosis, 2=Was 
already diagnosed
Drop down: No, Yes 
new diagnosis, Was 
already diagnosed
0=No, 1=Yes, new 
diagnosis, 2=Was 
already diagnosed
Only one option 
possible
If you have been newly 
diagnosed, are you on 
treatment, if so which
Max characters 50 Free text
Since we saw you last, 
have you had any pain 
or discomfort in your 
chest?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, do you get pain 
or discomfort when 
you walk uphill or 
hurry?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If you did go to 
hospital, did you stay 
overnight?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
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doccom4
attacknum
attacknum1
attacknum2 
attacknum3
attacknum4
nightbreath
nightbreath1
nightbreath2 
nightbreath3
nightbreath4
ankswell
ankswell1
ankswell2 
ankswell3
ankswell4
legpain
legpain1
legpain2 
legpain3
legpain4
TABLE: Follow Up Questionnaire – 6, 12, 18, 24 and 32 months
RESPIRATORY HEALTH AND COPD Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
fuppulrehab 
fuppulrehab1
fuppulrehab2 
fuppulrehab3
fuppulrehab4
rehabcomp 
rehabcomp1
rehabcomp2 
rehabcomp3
rehabcomp4
smokehab
smokehab1
smokehab2 
smokehab3
smokehab4
fupsmkhabstop
fupsmkhabstop1
fupsmkhabstop2 
fupsmkhabstop3
fupsmkhabstop4
fupskhabstpwhen
fupskhabstpwhen1
fupskhabstpwhen2
fupskhabstpwhen3
fupskhabstpwhen4
fupsmkhabstart
fupsmkhabstart1
fupsmkhabstart2 
fupsmkhabstart3
fupsmkhabstart4
fupshabstarnu
fupshabstarnu1
fupshabstarnu2 
fupshabstarnu3
fupshabstarnu4
When? Number n months ago Must be in range 0-250
Started Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
How many / day? Number n per day Must be in range 0-999
Since we last saw you, 
have you been on a 
pulmonary 
rehabilitation course?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, did you 
complete it?
Number: 0=No, 
1=Yes, 2=Ongoing
Drop down: No, Yes, 
Ongoing
0=No, 1=Yes, 
2=Ongoing
Only one option 
possible
Since we last saw you, 
have you changed your 
smoking habit?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Stopped Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
How many of these 
attacks have you had?
Number n Must be in range 0-999
Have you at any time 
since we last saw you 
been awoken at night 
by an attack of 
breathlessness?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Have you ever had 
noticeable swelling of 
your ankles for at least 
one week?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Do you get pain in 
either leg on walking?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
What did he/she say 
about it?
Max characters 50 Free text
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fupskhbrestart
fupskhbrestart1
fupskhbrestart2 
fupskhbrestart3
fupskhbrestart4
fupskhbchngeamt
fupskhbchngeamt1
fupskhbchngeamt2
fupskhbchngeamt3
fupskhbchngeamt4
fupshbchgeamt
fupshbchgeamt1
fupshbchgeamt2 
fupshbchgeamt3
fupshbchgeamt4
fupsmkhabothers
fupsmkhabothers1
fupsmkhabothers2 
fupsmkhabothers3
fupsmkhabothers4
fupdescbreath
fupdescbreath1
fupdescbreath2 
fupdescbreath3
breathyn
breathyn1
breathyn2 
breathyn3
breathyn4
sterbreath
sterbreath1
sterbreath2 
sterbreath3
sterbreath4
sterbreyn
sterbreyn1
sterbreyn2 
sterbreyn3
sterbreyn4
antibreath
antibreath1
antibreath2 
antibreath3
antibreath4
antibreynIf yes, how many 
courses
Number n courses Must be in range 0-999
Which statement best 
describes your 
breathlessness? – 
MRC dyspnea score
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Have you had any 
courses of steroids 
since we last saw you 
for your breathing?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, how many 
courses
Number n courses Must be in range 0-999
Have you had any 
courses of antibiotics 
since we last saw you 
for your breathing?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Changed amount Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
How many / day? Number n per day Must be in range 0-999
Other – e.g. cigars Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
Which statement best 
describes your 
breathlessness? – 
MRC dyspnea score
Number: 1=I only get 
breathless with 
strenuous exercise, 
2=I get short of breath 
when hurrying on the 
level or walking up a 
slight hill, 3=I walk 
slower than people of 
the same age on the 
level because of 
breathlessness or 
have to stop for breath 
when walking at my 
own pace on the level, 
4=I stop for breath 
after walking about 100 
yards or after a few 
minutes on the level, 
5=I am too breathless 
to leave the house or I 
am breathless when 
dressing
Drop down: I only get 
breathless with 
strenuous exercise, I 
get short of breath 
when hurrying on the 
level or walking up a 
slight hill, I walk 
slower than people of 
the same age on the 
level because of 
breathlessness or 
have to stop for breath 
when walking at my 
own pace on the level, 
I stop for breath after 
walking about 100 
yards or after a few 
minutes on the level, I 
am too breathless to 
leave the house or I 
am breathless when 
dressing
1=I only get breathless 
with strenuous 
exercise, 2=I get short 
of breath when 
hurrying on the level or 
walking up a slight hill, 
3=I walk slower than 
people of the same age 
on the level because 
of breathlessness or 
have to stop for breath 
when walking at my 
own pace on the level, 
4=I stop for breath 
after walking about 100 
yards or after a few 
minutes on the level, 
5=I am too breathless 
to leave the house or I 
am breathless when 
dressing
Only one option 
possible
Tried to stop but 
restarted
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
fupdescbreath4
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antibreyn1
antibreyn2 
antibreyn3
antibreyn4
TABLE: Follow Up Questionnaire – 6, 12, 18, 24 and 32 months
GENERAL HEALTH Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
gp
gp1
gp2 
gp3
gp4
fuphealth
fuphealth1
fuphealth2 
fuphealth3
fuphealth4
weightch
weightch1
weightch2 
weightch3
weightch4
alchunit Must be in range 0-999
alchunit1
alchunit2 
alchunit3
alchunit4
TABLE: Follow Up Questionnaire – 6, 12, 18, 24 and 32 months
HOSPITAL ADMISSION Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
copdhosp
copdhosp1
copdhosp2 
copdhosp3
copdhosp4
copdnum
copdnum1
copdnum2 
copdnum3
copdnum4
copdinten
copdinten1
copdinten2 
copdinten3
copdinten4
hospreaHave you been 
admitted to hospital 
(including A&E, day 
case or admitted) for 
any other reason since 
we last saw you?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
On average, how 
much alcohol do you 
consume in a week? 
Number n units
For your breathing or 
COPD, have you been 
admitted to hospital 
(including A&E or 
admitted) since we 
last saw you?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, please specify 
the number of times in 
the last 6 months
Number n Must be in range 1-999
If yes, did you need to 
go to intensive care?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, how many 
courses
Number n courses Must be in range 0-999
How many times have 
you consulted your GP 
since we last saw 
you?
Number n Must be in range 0-999
Compared to 6 months 
ago, how would you 
rate your health in 
general now?
Number: 1=Much 
better now than six 
months ago, 
2=Somewhat better 
than six months ago, 
3=About the same as 
six months ago, 
4=Somewhat worse 
than six months ago, 
5=Much worse than 
Drop down: Much 
better now than six 
months ago, 
Somewhat better than 
six months ago, About 
the same as six 
months ago, 
Somewhat worse than 
six months ago, Much 
worse than six months 
1=Much better now 
than six months ago, 
2=Somewhat better 
than six months ago, 
3=About the same as 
six months ago, 
4=Somewhat worse 
than six months ago, 
5=Much worse than 
six months ago
Only one option 
possible
Since we last saw you, 
have you noticed that 
your weight has 
changed?
Number: 0=No 
change, 1=Lost weight 
intentionally, 2=Lost 
weight unintentionally, 
3=Gained weight
Drop down: No 
change, Lost weight 
intentionally, Lost 
weight unintentionally, 
Gained weight
0= No change, 1=Lost 
weight intentionally, 
2=Lost weight 
unintentionally, 
3=Gained weight
Only one option 
possible
1 unit = 1 small glass 
of wine (125mL) = 1⁄2 
pint of beer/ lager/ 
cider = 25 ml pub 
measure of spirit
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hosprea1
hosprea2 
hosprea3
hosprea4
hospnum
hospnum1
hospnum2 
hospnum3
hospnum4
cause
cause1
cause2 
cause3
cause4
causemonth
causemonth1
causemonth2 
causemonth3
causemonth4
causeyear
causeyear1
causeyear2 
causeyear3
causeyear4
TABLE: Follow Up Questionnaire – 6, 12, 18, 24 and 32 months
MEDICATION Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
meds
meds1
meds2 
meds3
meds4
newpres
newpres1
newpres2 
newpres3
newpres4
TABLE: Follow Up Questionnaire – 6, 12, 18, 24 and 32 months
ACTIVITIES Home
CRF field name short field name Field type Description Format Validation rules 
(something 
meaningful relating to 
what’s on CRF)
(name used in 
database)
(text, numerical, drop 
down with options, 
date etc)
(Y/N, drop down menu 
with options, free text 
etc)
(for stats purposes – 
used for variable 
labelling in STATA)
(Details of ALL 
validation)
sportdr
sportdr1
sportdr2 
sportdr3
sportdr4
sportscaledr
sportscaledr1
sportscaledr2 
sportscaledr3
sportscaledr4
weekwalkhr Must be in range 0-24
Please specify the 
dates (year)
Date yyyy Should be ≤ visitdate
Please list below your 
medication
Max characters 50 Free text
On average, for how 
long did you walk 
outside your 
home/workplace on 
each weekday? 
Number n hrs
Is this a new 
prescription since we 
last saw you?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Multiple responses 
possible
How often do you take 
part in sports or 
activities that are 
mildly energetic, 
moderately energetic 
or vigorous?
Number: 0=Never/ 
hardly ever, 1=Three 
times a week, 2=Once 
or twice a week, 
3=About once or three 
times a month
Drop down: Never/ 
hardly ever, Three 
times a week, Once or 
twice a week, About 
once or three times a 
month
0=Never/ hardly ever, 
1=Three times a 
week, 2=Once or 
twice a week, 3=About 
once or three times a 
month
Multiple options 
possible
How often do you take 
part in sports or 
activities that are 
mildly energetic, 
moderately energetic 
or vigorous?
Number: 1=Mildly 
energetic, 
2=Moderately 
energetic, 3=Vigorous
Drop down: Mildly 
energetic, Moderately 
energetic, Vigorous
1=Mildly energetic, 
2=Moderately 
energetic, 3=Vigorous
Multiple options 
possible
Have you been 
admitted to hospital 
(including A&E, day 
case or admitted) for 
any other reason since 
we last saw you?
Number: 1=Yes, 0=No Drop down: Yes, No 1=Yes, 0=No Only one option 
possible
If yes, please specify 
the number of times
Number n Must be in range 1-999
Please specify the 
reason for 
hospitalization(s)
Max characters 50 Free text
Please specify the 
dates (month)
Date mm Should be ≤ visitdate
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weekwalkhr1
weekwalkhr2 
weekwalkhr3
weekwalkhr4
weekwalkmin Must be in range 0-60
weekwalkmin1
weekwalkmin2 
weekwalkmin3
weekwalkmin4
wnkdwalkhr Must be in range 0-24
wnkdwalkhr1
wnkdwalkhr2 
wnkdwalkhr3
wnkdwalkhr4
wnkdwalkmin Must be in range 0-60
wnkdwalkmin1
wnkdwalkmin2 
wnkdwalkmin3
wnkdwalkmin4
On average, for how 
long did you walk 
outside your 
home/workplace on 
each weekend day? 
Number n hrs
If not walked, enter ‘00’
On average, for how 
long did you walk 
outside your 
home/workplace on 
each weekend day? 
Number
On average, for how 
long did you walk 
outside your 
home/workplace on 
each weekday? 
Number n hrs
If not walked, enter ‘00’
On average, for how 
long did you walk 
outside your 
home/workplace on 
each weekday? 
Number n min
If not walked, enter ‘00’
n min
If not walked, enter ‘00’
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Appendix E: causes of death
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